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Abstract 
The regulation of metabolic gene expression is fundamental to maintaining energy 
balance. Changes in substrate availability can alter metabolic gene expression, in 
order to modify the utilisation of nutrients appropriately. Metabolic gene expression 
can also be dysregulated in disease states. The work in this thesis examines several 
situations in which energy balance or metabolic substrate supply was altered, and 
investigates how metabolic gene expression adapted and contributed to the 
phenotypes observed following these interventions. All experiments in this work 
looked at metabolic regulation from a human perspective; with either biopsy material 
or cells cultured from biopsy. These experiments included; 
1. The influence of postprandial fat-oxidising capacity during a calorie restricted 
diet of either high- or low-fat content in obese subjects. 
2. Transcriptional profiling of adipose tissue in obese subjects with high- or low-
postprandial fat oxidising capacity  
3. High-glucose treatment of primary human myotubes (as a model of 
hyperglycaemia). 
4. Increased PDC activation and hence carbohydrate oxidation in vivo, through 
administration of dichloroacetate. 
 
Postprandial fat-oxidising capacity did not affect weight-loss during a calorie 
restricted diet, and there was no affect of diet composition. However, changes in 
metabolic gene expression were observed between groups over the course of the 10-
week intervention. The groups which showed the greatest changes in gene expression 
were the low fat-oxidisers on a high fat diet and the high fat-oxidisers on a low fat diet, 
possibly due to a mismatch between diets and fat oxidising capacity, which required 
greater adaptation. Covariate analysis revealed interactions between gene expression 
and other phenotypic parameters. SREBP-1c showed a relationship with FFA 
concentrations and insulin-resistance, whilst HSL and apM1 were associated with FFA 
concentrations and Insulin resistance respectively, which underlines the importance of 
looking for underlying structures in data. 
Transcriptional profiling of adipose tissue in obese subjects with high- or low-
postprandial fat oxidising capacity, revealed significant differences in the expression of 
metabolic genes, and highlighted the importance of several transcripts; including 
RXRA, SREBP-1c and GLUT4 in determining the phenotype of adipose tissue. The 
major differences observed in gene expression between high and low fat oxidizers 
indicated that genes involved glucose metabolism and lipogenesis rather than beta-
oxidation were the major processes that differed between the two groups. Genomic 
data indicated that the expression of these genes was not influenced to a major 
degree by polymorphisms within the population. 
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High-glucose treatment of primary myotubes, demonstrated the significance of 
ChREBP and some of its targets, in inducing the expression of lipogenic enzymes, 
which may be linked to the accumulation of intramyocellular triglyceride. However, 
these data also indicated the potential for the cell to initiate protective mechanisms, of 
substrate handling and lipid clearance, in response to carbohydrate oversupply. 
Conversely, increasing PDC activity and hence carbohydrate oxidation without altering 
substrate availability via infusion of dichloroacetate, did not alter the expression of 
metabolic genes in skeletal muscle. This reflects a capacity to deal with acute 
changes in the activity in metabolic genes without altering their expression. 
In conclusion, the studies from this thesis show that important differences in 
metabolic gene expression can be observed during situations where energy balance 
and substrate availability are altered. However, flexibility within the metabolic networks 
means that acute changes can be countered without the need for induction or 
suppression of metabolic genes, and that during chronic alterations in nutrient supply, 
rapid adaptations and protective mechanisms are activated. 
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1.0 Introduction 
Metabolic rate in humans is tightly regulated - with the control of flux through 
metabolic pathways being essential as cells adapt rapidly to fluctuations in energy 
intake and expenditure, and also to changes in substrate availability. There are many 
ways in which this can be accomplished, but systems biology sets out to examine how 
the various components can work in concert to give both stability and adaptability in a 
constantly changing environment and to also to look at the pathogenesis of diseased 
states (Figure 1.0.3) (Kitano, 2002). 
Humans are evolutionarily adaSWHG IRU D µORZ-HQHUJ\ HQYLURQPHQW¶ LQ ZKLFK
the availability of nutrients was limited by what could be hunted or scavenged. The 
advent of technology and industrialisation has changed our landscape and habitat far 
more rapidly than the evolutionary processes governing metabolism are capable of 
(Prentice et al., 2008). In evolutionary terms this has been a success, since the human 
population has undergone exponential growth during the last few hundred years. 
However, in the last 40 years, metabolic diseases associated with excess calorie 
intake have become more prevalent (Figure 1.0.1;Figure 1.0.2) (Popkin & Doak, 1998; 
Kopelman, 2000).  
Until the middle of the 20th century the main health issues affecting humans 
on a global scale were those of starvation through famine, and infectious disease. 
Whilst these issues are certainly still the main focus of WHO initiatives, another 
adversary arrived in the late 20th and early 21st century ± obesity. Obesity in both 
developed and developing countries has grown at an unprecedented rate in recent 
decades. This has brought with it, a legion of associated disorders such as; type 2 
diabetes mellitus, cardiovascular disease, osteoarthritis, steatohepatitis and cancer 
(Calle et al., 2003; Kahn et al., 2006; Van Gaal et al., 2006; Teichtahl et al., 2008).  
Worldwide there are, according to WHO estimates, 1.6 billion overweight and 400 
million obese adults (WHO, 2006b). In the UK alone this costs the NHS £500 million, 
with further indirect costs to the economy of £2 billion annually (Vlad, 2003). 
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Figure 1.0.1 Global map of obesity in adult males. (% of adult population with BMI >30) per 
country. Data from IOTF 2008 (Lokal_Profil, 2009).  
 
 
Figure 1.0.2 The increasing prevalence of obesity in England 1993-2001. Obesity in adults (16 
years +), source Health Survey for England (2003). (Department of Health) 
 
The completion of the human genome project gave rise to the possibility for 
scientists to understand, on a genome wide scale, how genetic differences can 
LQIOXHQFH DQ LQGLYLGXDO¶V DELOLW\ WR UHJXODWH WKHLU PHWDEROLF rate when challenged by 
their environment, and also how it might affect ones propensity for disease (Jimenez-
Sanchez et al., 2001; Kaput & Rodriguez, 2004). There have been notable successes 
in linking individual genes to disease states, but these cases often apply to rare 
variants or small ethnic groups (Lyon & Hirschhorn, 2005). Diseases such as obesity 
and diabetes have a complex pathogenesis, involving many proteins, tissues and 
organs.  It is also understood that metabolic networks are far more complicated than 
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simply the DNA database which comprises the genome (Janssens & van Duijn, 2008). 
In the short-term i.e. during high-intensity exercise, the activity of metabolic enzymes 
can be rapidly increased via phosphorylation and signalling cascades, which provides 
the required immediate response. Over the course a day it is more usual to see 
changes in the concentration of hormones such as insulin and glucagon, which 
provide changes in gene and subsequently protein expression alongside their action 
via phosphorylation cascades. Furthermore, it is now recognised that  even prenatal 
dietary events in which may alter the methylation status and subsequently the level of 
expression of genes can affect the phenotype of offspring over generations (Ling & 
Groop, 2009; Tobi et al., 2009). These various layers of biological interaction are all 
part of the metabolic response to changes in diet and energy balance.  
The expression of metabolic genes is altered in response to the type of dietary 
substrate consumed, which affects the abundance of proteins and enzymes 
participating in metabolic pathways and also their activity through ligand binding or via 
third-party intracellular signalling events (Clarke, 1999). It is through these nutrient-
gene interactions that the basis of metabolic diseases can be understood. The 
emerging field of nutrigenomics (studying the interaction between genes and 
nutrients), will aid the development of novel pharmaceutical agents for metabolic 
diseases, and help public health authorities in diagnosing and prescribing drugs 
effectively, combined with the dissemination of improved dietary advice (Muller & 
Kersten, 2003).  
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Figure 1.0.3 Different approaches to physiology. Reductionism (left) looks at the way individual 
components cause a particular phenotype, which can be successful in characterising 
monogenic disease states. Systems biology, (right) looks at the relationships between 
molecules, pathways and organs to understand disease progression within the entire organism, 
and its surrounding environment (Ahn et al., 2006). 
 
1.1 Energy balance 
Energy balance is a term which describes equilibrium between energy intake 
and energy expenditure. During a normal 24-hour period, humans engage in various 
states of activity, rest and sleep, which alter energy expenditure greatly. Further to 
this, energy intake is confined to short periods, often 3 times per day when meals are 
consumed. The human body is capable of adapting to these fluctuations in energy 
intake and expenditure, both during the short-term and also over longer periods, such 
DV ZHHNV DQG HYHQ \HDUV 7KLV LV WKH FRQFHSW RI µHQHUJ\-EDODQFH¶ RU PHWDEROLF
homeostasis. Disturbances to energy balance can have serious health consequences, 
which are discussed in more detail later in this chapter.  
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Effective control of energy balance requires the coordination of many tissues 
and organs. The main peripheral tissues responsible for energy balance are muscle 
(chiefly skeletal muscle), the liver and adipose tissue, all of which respond to changes 
in substrate availability, as well as through the action of endocrine and neural stimuli. 
The central nervous system (CNS) is vital in integrating the response of these organs 
when energy balance is disturbed. The CNS largely controls energy intake (although 
not independently), and through both conscious physical activity and non-volitional 
activity such as shivering and maintaining body posture, controls energy expenditure 
beyond the resting-metabolic rate (RMR). Within the CNS, the hypothalamus is the 
site where signals from the periphery are processed, with the pituitary gland 
(responsible for much of the hypothalamic endocrine secretion) and arcuate nucleus 
being two of the most important structures in neuro-metabolic interaction. However, 
regions of the brain are highly interconnected, and interdependent, with other areas 
such as the pineal gland, which regulates circadian rhythms, and mesolimbic 
pathways also being involved in the control of appetite. Other endocrine tissues 
involved in the regulation of energy metabolism include; the thyroid gland, which 
regulates basal metabolic rate; the adrenal glands, from which catecholamines and 
corticosteroids are released, and the testis and ovaries which produce sex hormones.  
The pancreas is essential for the control of blood glucose concentrations, 
affecting its responses through the release of insulin and glucagon ± and to a lesser 
extent somatostatin and pancreatic polypeptide - from the islet cells. It affects glucose 
uptake and oxidation, but also plays a major role in regulating lipid storage and the 
balance between protein synthesis and breakdown. 
Skeletal muscle is the site where most energy expenditure occurs. It accounts 
for 40-45% of body mass (Janssen et al., 2000), and even at rest ~20% of energy 
consumption is via these tissues (Owen et al., 1978; Zurlo et al., 1990). It is the main 
site for insulin-stimulated glucose disposal and fat oxidation, but also contains stores 
of glycogen and intramyocellular triglycerides, which can be mobilised during exercise. 
Skeletal muscle is not typically considered as an endocrine organ, although it does 
release interleukin-6 (IL-6), which activates AMPK (Al-Khalili et al., 2006; Glund et al., 
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2007). IL-6 has also been implicated in the development of obesity (Bastard et al., 
2000). Adipose tissue is on the opposite side of the energy balance equation to 
skeletal muscle, being the main site of energy storage, particularly lipid in the form of 
triacylglycerol (TAG) with reserves that account for between 8 and 21% of body 
composition in healthy weight individuals depending on gender and activity levels. 
Adipose tissue is also involved in the regulation of energy balance through its function 
as an endocrine organ, releasing adipokines ± such as adipoQHFWLQ71)ĮOHSWLQDQG
resistin. Leptin first came to prominence when it was its role in regulating the weight of 
ob/ob mice was discovered. Subsequent research has revealed that leptin acts as a 
sensor of nutritional status, and the secretion of leptin is proportional to fat mass. 
Leptin suppresses appetite, although it may be more accurate to state that reduced 
concentrations of circulating leptin promote appetite, since elevated leptin 
concentrations in obese subjects clearly do not reduce food intake. (Friedman & 
Halaas, 1998). Adiponectin is thought to be involved in insulin sensitization, is highly 
expressed in adipose tissue (Maeda et al., 1996); the deletion of the adiponectin gene 
causes insulin resistance in mice (Kubota et al., 2002; Maeda et al., 2002). Unlike the 
majority of adipokines,  adiponectin expression is reduced during obesity (Arita et al., 
1999)33$5ȖOLJDQGVLQGXFHLWVH[SUHVVLRQ(Maeda et al., 2001), suggesting one way 
LQ ZKLFK WKH UROH RI 33$5Ȗ PD\ EH LQYROYHG LQ WKH SDWKRSK\VLRORJ\ RI LQVXOLQ
resistance. The mechanism through which adiponectin exerts its action appear to 
involve the suppression of hepatic glucose production (Combs et al., 2001), and 
increasing skeletal muscle fat oxidation via activation of AMPK  and PPARD 
(Yamauchi et al., 2001; Yamauchi et al., 2002). 
Resistin is another adipokine which according to evidence from murine studies 
(Steppan et al., 2001), appears to be involved in the regulation of adiposity and insulin 
resistance (Steppan et al., 2001). These findings have not successfully been 
replicated in humans, therefore caution should be exercised in interpreting this role, 
until studies have confirmed this (Hasegawa et al., 2005; Bendich et al., 2010)71)Į
is secreted from macrophages within adipose tissue, and is relevant to the 
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development of inflammation and insulin resistance, it will be discussed in more detail 
later in this Chapter. 
The liver is a hub of substrate exchange within the periphery; it works to 
maintain the concentration of glucose in the bloodstream at around 5mM. The flux of 
metabolic pathways in the liver is closely related to the release of insulin and glucagon 
from the pancreas. In the postprandial state it stores carbohydrate as glycogen, and 
exports triglycerides for storage in adipose tissue. During the postabsorptive state this 
role is reverse through the breakdown of glycogen into glucose, which is then released 
into the blood stream.  Further to this, the liver receives substrates from other tissues, 
such as glycerol and lactate, which it can convert back into glucose for utilisation by 
peripheral tissues.  
The CNS can provide both behavioural adaptations and paracrine and 
endocrine responses to energy intake and expenditure. To do this the CNS also 
requires feedback from other organs, which is accomplished at many levels. Earlier in 
this Chapter the interaction between adipokines and satiety were described. These 
provide a long-term mechanism for controlling energy balance, however the 
gastrointestinal tract produces a range of acute responses to feeding; such as ghrelin, 
secreted from the stomach (Kojima et al., 1999; Nakazato et al., 2001; Williams & 
Cummings, 2005), and PYY and cholecystokinin (CCK) from the colon -  all of which 
affect feelings of satiety through the hypothalamus (Lieverse et al., 1995; Batterham et 
al., 2002). Another acute organ-organ interaction in response to feeding is mediated 
by incretins. Incretins such as glucagon-like-peptide-1 (GLP-1) and gastric inhibitory 
peptide (GIP) are released from the intestinal mucosa, and are part of a feed-forward 
PHFKDQLVPE\ZKLFKWKHJXWSULPHVLQVXOLQUHOHDVHIURPWKHȕ-cells of the pancreas, 
before an increase in blood glucose concentrations. They also regulate the rate of 
gastric emptying and inhibit the release of glucagon (Holst & Gromada, 2004).  
 
Aside from the large shifts in fuel use initiated by the endocrine system, more 
subtle control of fuel switching is required when substrate availability cannot meet 
demand or is depleted (e.g. during exercise or fasting), and at other times when there 
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is an excess of a particular fuel substrate. It should be stressed that these responses 
are usually complimentary, indeed part of endocrine responses and not necessarily 
distinct. 
 Many of the enzymes in carbohydrate and fat oxidation are prone to feedback 
inhibition; a notable example is the rate limiting step in glycolysis ± the conversion of 
fructose-6-phosphate to fructose 1,6-bisphosphate by phosphofructokinase which is 
inhibited by ATP (the action of which is enhanced by citrate), to self regulate flux. PFK 
is also activated by fructose 2,6,-bisphosphate, which in liver reduces the activity of 
PFK when blood glucose concentrations are low ± favouring gluconeogenesis. The 
first step in glycolysis is mediated via hexokinase, which has a low Km, (high affinity for 
glucose); however it is negatively regulated by its product G6P, which prevents the 
excessive use of cellular ATP to form G6P when glucose is not limiting.   Pyruvate 
kinase (PK), which catalyses the final step in glycolysis, is positively regulated by its 
own substrate - phosphoenolpyruvate, and fructose 1,6-bisphosphate, along with 
negative regulation by ATP and acetyl-CoA (Matthews et al., 1999). 
 The pyruvate dehydrogenase complex (PDC), catalyzes the conversion of 
pyruvate into acetyl-CoA, this reaction is a further example of (indirect) product 
inhibition. PDC activity is regulated by pyruvate dehydrogenase kinase (PDK) - which 
inactivates the PDC and pyruvate dehydrogenase phosphatise (PDP) which restores 
activity. PDK activity is enhanced by the products of the PDC, NADH and acetyl-CoA, 
and inhibited by its substrate pyruvate (Holness & Sugden, 2003)(Figure 1.1.1).  
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Figure 1.1.1 The regulation of PDC activity through reversible phosphorylation by PDK and 
PDP. PDK is activated by acetyl-CoA and NADH, which causes it to phosphorylate and inhibit 
PDC activity. PDC activity is restored through dephosphorylation by PDP. PDK1 is expressed at 
low levels in cardiac and pancreatic cells. PDK2 is expressed ubiquitously and is responsible for 
basal regulation of PDC activation. PDK3 is uniquely expressed in testis and the brain, whilst 
PDK4 is highly expressed in heart, skeletal muscle, liver, kidney and the pancreas. PDP1 is 
expressed in heart and at low levels in skeletal muscle, whereas PDP2 is found in liver and 
adipose tissue. The phosphorylation of either Site1, 2 or 3 on the E1-subunit will inactivate the 
PDC, however Site1 produces this action faster than the other sites, with Site3 being the 
slowest. All of the PDKs preferentially target Site1, but PDK2 has the highest affinity for Site1 ±
affecting acute changes in PDC activation, whilst PDK4 has the highest affinity for Site2. 
(Holness & Sugden, 2003). 
 
'XULQJWKHȕ-oxidation of fatty acids, carnitine palmitoyltransferase-1 (CPT1) - 
an enzyme found in the outer mitochondrial membrane, responsible for the movement 
of long chain fatty acids across the membrane - forms the rate limiting step. Its 
significance in fuel switching lies in the interaction with carbohydrate metabolism. 
7KHJOXFRVHIDWW\DFLGF\FOHILUVWSURSRVHGE\5DQGOHLQWKH¶V(Randle et 
al., 1963) is a relationship, which describes the interaction between glucose and fatty 
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DFLG R[LGDWLRQ ,W VWDWHV WKDW ))$ DYDLODELOLW\ LQFUHDVHV ȕ-oxidation rates, which 
generates acetyl-CoA, and therefore increases citrate concentrations ± citrate is an 
inhibitor of phosphofructokinase and hence reduces glycolysis/carbohydrate oxidation. 
$ORQJVLGH WKLV ȕ-oxidation also produces NADH/NAD+, which are inhibitors of PDC 
activity through activation of PDKs (Figure 1.1.1). The glucose-fatty acid cycle can 
also be reversed; when glucose concentrations are high, the production of malonyl-
CoA is increased, which inhibits CPT1 ± WKXVUHGXFLQJȕ-oxidation rates (Sidossis & 
Wolfe, 1996).  
Any discussion of energy balance would be incomplete without introducing the 
master regulator of cellular metabolism AMP-activated protein kinase (AMPK). AMPK 
is an enzyme which plays a central role in maintaining energy homeostasis, therefore 
LWPHULWVGLVFXVVLRQKHUH$03.LVIRUPHGIURPVXEXQLWVĮȕDQGȖ7KHȖVXEXQLW
is responsible for the binding of AMP, which allows AMPK to monitor fuel levels within 
the cell. Low levels of ATP (and therefore high levels of AMP) activate AMPK, which 
then targets ACC. This limits the production of malonyl-CoA, (an inhibitor of CPT1), 
WKXVLQFUHDVLQJ))$LPSRUWLQWRWKHFHOODORQJZLWKȕ-oxidation. GLUT4 translocation is 
increased by the action of AMPK, along with upregulation of GLUT4 gene expression. 
AMPK plays a part role in the regulation of lipolysis in adipocytes but the mechanisms 
underlying these effects have  yet to be fully determined (Hardie, 2008).  
 
1.1.1 Energy balance in the postabsorptive state 
The postabsorptive or fasting state is the situation commonly encountered 
upon waking-up in the morning. It has often been 9-11 hours since food was 
consumed, and as a result, plasma glucose and insulin concentrations are low, and 
FFA concentrations high at ~0.5mol l-1. Glucagon is being released from the pancreas, 
and glucose is produced by glycogenolysis in the liver, with an increasing proportion 
from gluconeogenesis as time progresses. Glucose released from the liver is oxidised 
in the brain and also used by red blood cells and other cells via glycolysis. Skeletal 
muscle primarily oxidises FFAs due to the operation of the glucose-fatty-acid cycle, 
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which, via the production of acetyl-CoA indirectly inhibits glycolysis as previously 
described. 
Net protein anabolism occurs in muscle, due to the low insulin concentrations. 
The amino acids released are oxidised, and the amino groups are returned to the liver 
as alanine, to undergo gluconeogenesis (Figure 1.1.2). In adipose tissue the low 
insulin concentration causes an increase in lipolysis, and the FFAs which are liberated 
into the bloodstream become the primary fuel substrate in skeletal muscle. FFAs are 
also oxidised in the liver, where the ATP produced is used for gluconeogenesis. 
Ketones produced as a by-product of FFA oxidation are used by the brain, muscle and 
adipose tissue, but do not contribute greatly as a fuel source due to the low 
concentration (Frayn, 2010). 
 
1.1.2 Energy balance in the postprandial state 
The postprandial state, describes the situation shortly after the consumption of 
a meal. After a normal meal containing a mixture of carbohydrate, fat and protein, the 
food passes through the stomach and into the intestine; at this point glucose 
absorption raises the blood glucose concentration, which causes the pancreas to 
secrete more insulin and less glucagon.  This increases glucose uptake in muscle, 
adipose tissue, via the translocation of the insulin stimulated glucose transporter, 
GLUT4 to the plasma membrane. Glucose oxidation is rapidly increased, along with 
glycogen synthesis, and lipogenesis, whilst at the same time lipolysis in adipose tissue 
is suppressed. Glycogenolysis is inhibited in the liver by the action of insulin, and 
FFAs produced by de novo lipogenesis from glucose are transported via VLDL to 
adipose tissue depots. 
Dietary fat passes from the ileum ± where it is packaged into chylomicrons- 
through the lymphatic system and into the bloodstream. Lipoprotein lipase (LPL) in 
capillary endothelial cells liberates the FFAs and glycerol from the chylomicrons; in 
adipose tissue these are stored as TAG, and in skeletal muscle they are oxidised. 
Amino-acid adsorption from the gut, in combination with insulin signalling triggers a 
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switch from net-protein breakdown to net-protein synthesis in liver and muscle (Frayn, 
2010).  
Throughout the course of the day, each successive meal reinforces the 
insulin-stimulated processes, which have the effect of increasing energy storage, in 
the forms of glycogen and TAG. Overnight the situation slowly reverses, precipitated 
by a drop in plasma insulin and a rise in glucagon concentrations. As a result 
glycogenolysis and lipolysis take a greater role in providing the fuel sources for the 
body at rest.  
 
1.1.3 High-fat diets 
Excessive consumption of dietary fat has been linked to the development of 
obesity, hyperglycaemia, insulin resistance and atherosclerosis. Since high-fat diets 
are more energy-dense, it is easier to achieve a positive energy-balance when 
consumed over long periods. Furthermore, reduced ability to utilise increased loads of 
dietary fat, are associated with the obese condition (Thomas et al., 1992; Astrup et al., 
2002). Unlike carbohydrate oxidation which is rapidly increased in response to 
carbohydrate feeding; fat oxidation rates fail to respond with increased dietary fat 
intake (Schutz et al., 1989a). Flatt proposed a two-reservoir model, which represents 
the contribution of carbohydrate, and (the much larger) fat reserves, to whole body 
substrate oxidation rates. In this model the utilisation of carbohydrate is increased to a 
much greater extent after consumption of a meal, compared to fat oxidation, since 
there is a much greater potential for lipid storage than there are glycogen reserves 
(Flatt, 1987). Under this hypothesis, adipose depots expand with a slow increase in fat 
oxidation until equilibrium is restored.  The type of dietary fat appears to affect the link 
between high fat diets and insulin resistance, with long-chain polyunsaturated omega-
3 fatty acids ameliorating the potential to develop insulin resistance (Storlien et al., 
1987). 
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1.1.4 Exercise 
Another situation to which the body must be able to adapt, is that of physical 
activity. During exercise there is a greater demand for fuel substrates, most 
importantly from skeletal muscle. If exercise is of high intensity for a short duration, 
then it is termed anaerobic. Under anaerobic conditions muscle rapidly hydrolyses 
ATP, which is buffered by phosphocreatine and replenished via glycogenolysis and 
glycolysis. This can be sustained for a short period of time, before fatigue metabolites 
such as lactic acid begin to interfere with muscle contraction.   Longer periods of lower 
LQWHQVLW\ µDHURELF¶ H[HUFLVH XWLOLVH YHU\ GLIIHUHQW mechanisms to provide a constant 
source of fuel, which is derived from sources external to the contracting muscle. The 
somatic nervous system, and muscle contraction itself cause glycogenolysis in 
muscle, but it is the sympathetic nervous system and epinephrine secretion that 
causes lipolysis and glycogenolysis around the body. Substrates are completely 
oxidised during aerobic exercise, which is both more efficient in terms of ATP 
generation and also eliminates the build up of lactic acid in the muscle fibres (Frayn, 
2010). 
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Figure 1.1.2 Glucose utilisation in peripheral tissues. Glucose is taken up by the muscle and 
adipose tissue where it is oxidised into CO2 and H2O.  Depending on the state of energy 
balance, a variable proportion of this carbon (some derived from proteolysis) is recycled to the 
liver to undergo gluconeogenesis (Herman & Kahn, 2006). 
 
 
 
1.2 Metabolic disorders 
1.2.1 Obesity 
Obesity is defined as a BMI >30 kg-1m2 (WHO, 2006b). However, there is no 
strict cut-off from the physiological perspective, and a sliding scale from a healthy BMI 
of 20, up to the morbidly obese, >35, can be observed. It is also important to 
recognise that BMI alone is a rather crude measurement of overweight/obesity, since 
it fails to take account of body composition, which in some individuals, such as 
athletes, is distorted due to a high BMI, but a low body fat percentage. However in the 
vast majority of cases an increased mass of adipose tissue accompanies the increase 
in body weight observed in the obese state. Obesity is a condition arising from the 
prolonged imbalance between energy intake and energy expenditure. Energy intake 
and expenditure are most often, finely balanced even over the long-term, due to the 
mechanisms discussed earlier in this chapter. However, situations clearly arise where 
this equilibrium is compromised, both in starvation and in obesity. Research has 
demonstrated that some groups of people are predisposed to low energy expenditure 
(Ravussin et al., 1988), and given the obvious evolutionary benefits to conserving 
energy, WKHFRQWURYHUVLDOVHDUFKIRUDµWKULIW\¶JHQHKDVEHHQJLYHQPXFKDWWHQWLRQ,WLV
clear from global trends that the increasing levels of obesity require an explanation 
which lies outside the genome alone. Reduced levels of physical activity and excess 
calorie intake are obviously the main contributors to the epidemic of obesity, but since 
not everyone becomes obese, how these factors are co-regulated is clearly more 
complex. 
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Obesity leads to a range of secondary health implications, such as 
cardiovascular disease, hypertension, osteoarthritis and various cancers. However, 
linking BMI to increased mortality has been fraught with difficulty, due to complications 
arising from the fact that lower BMI is also associated with disease states, along with 
behavioural risks which reduced life expectancy such as smoking and alcoholism. 
Despite these problems, once these factors are accounted for, obesity, especially 
central-obesity, is clearly linked with increased mortality (Solomon & Manson, 1997). 
As already discussed, obesity is linked to type 2 diabetes mellitus. However, some 
obese people are able to maintain a high BMI and increased adiposity (usually 
accompanied by hyperinsulinaemia) without developing T2DM, and are referred to as 
the fat-fit phenotype ± fit being a relative term (Ethan, 2001). In other individuals 
K\SHULQVXOLQDHPLDFDQRQO\EHVXVWDLQHGIRUDSHULRGRIWLPHEHIRUHWKHSDQFUHDWLFȕ-
cells undergo apoptosis, leading to the development of T2DM. 
Adipose tissue biology changes during the shift from lean to obese 
phenotypes, particularly with the onset of insulin resistance. The physical expansion of 
adipose tissue depots leads to changes in the vascular structure and infiltration by 
macrophages, this causes inflammation, and further dysregulation of adipokine 
production which is partially responsible progression from local to systemic insulin 
resistance and cardiovascular disease (Xu et al., 2003; Berg & Scherer, 2005) (Figure 
1.2.1). Two key adipokines linked to the development of obesity and insulin resistance 
are leptin and adiponectin, both of which are secreted from adipose tissue, and are 
often dysregulated in obesity. As previously stated, leptin is responsible for feelings of 
satiety. Interestingly experiments have shown that circulating leptin concentrations are 
very high in obese subjects, but that it fails to suppress appetite, a situation termed 
µOHSWLQ UHVLVWDQFH¶ (Enriori et al., 2006), although it may be the case that leptin 
transport across the blood brain barrier is saturable, which limits the effects of raised 
leptin concentrations. Murine studies had shown some promise for treating this with 
exogenous leptin, however studies in humans have failed to replicate this effect 
(Bowles & Kopelman, 2001). 
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Adiponectin, on the other hand, is inversely correlated with increasing fat-
mass, and since it has been observed to increase insulin sensitivity, this 
µK\SRDGLSRQHFWLQDHPLD¶ LV D FDQGLGDWH IRU FDXVLQJ LQVXOLQ UHVLVWDQFH (Weyer et al., 
2001). Hypoadiponectinaemia, was partially reversed in obese women during a 2-day 
very low calorie diet, but restored with refeeding, which indicates that adiponectin 
expression responds rapidly to dietary changes, and is influenced by insulin sensitivity 
(Liu et al., 2003). The role of ghrelin in obesity is controversial since a study in 
humans showed that circulating ghrelin concentrations were decreased in obese 
subjects ± which is surprising given that lower levels would be expect to stimulate 
feelings of satiety, via its action in the orexigenic NPY neurons in the brain (Tschöp et 
al., 2001). These findings, suggest that adipokines acting as satiety hormones are 
closely linked to the development of metabolic disease, through their ability to regulate 
appetite, and therefore energy intake.  
The discovery of uncoupling proteins generated a great deal of interest 
surrounding their role in energy expenditure. This family of proteins were first 
discovered in brown adipose tissue, where UCP- KDV WKH DELOLW\ WR µXQFRXSOH¶ $73
production from oxygen consumption by allowing protons to leak back across the inner 
mitochondrial membrane (Ricquier et al., 1991). This has the effect of releasing 
energy in the form of heat as the potential energy stored in the proton gradient is 
dissipated.  UCP-2 and -3, which are found in white adipose tissue and skeletal 
muscle respectively, were then isolated, but their function appears to be different in 
these tissues. Interestingly, there is increasing evidence that suggests UCP3 is 
instrumental in regulating lipid metabolism. Fasting and high-fat feeding in rodents, up-
regulate expression of UCP3 mRNA (Ricquier & Bouillaud, 2000). Although these two 
interventions have opposite effects on energy expenditure, they both increase the 
concentration of circulating free fatty acids (FFA's) and consequently, increase lipid 
oxidation rates. More recently it has been suggested that UCP3 might facilitate lipid 
oxidation by transporting FFA anions out of the mitochondria, or reducing limiting the 
production of reactive oxygen species (Nagy et al., 2004). UCP3 expression appears 
WR EH XSUHJXODWHG E\ 33$5Į DQG į LQ UHsponse to increased circulating FFAs in 
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skeletal muscle (Villarroya et al., 2007). Pima Indians are an ethnic group which have 
the highest known incidence of obesity and diabetes, and a lower RMR, which may 
translate into altered body composition over a number of years. Polymorphisms in the 
UCPs have been correlated with resting energy expenditure (but not obesity) in Pima 
Indians and Caucasians (Walder et al., 1998; Schrauwen et al., 1999).  
Attempts to treat obesity have traditionally relied upon advice to reduce calorie 
intake and increase levels of physical activity. This remains the most common and 
effective method of treatment in the early stages of obesity. However, once obesity or 
T2DM are sufficiently advanced, compliance with such regimes is poor, and both 
secondary disorders and physical disability compound this. 
CaloriH UHVWULFWLRQ &5 RU µGLHWLQJ¶ LV WKH FRQFHSW RI GHOLEHUDWHO\ UHGXFLQJ HQHUJ\
intake, usually to achieve weight loss. It has been promoted for many years (alongside 
exercise) as the most effective way to induce weight loss without using surgery. 
CR diets in obese subjects shift energy balance into negative territory, which when 
sustained, lead to weight loss until equilibrium is re-established and body weight is 
maintained at a lower mass. Humans have evolved to survive for considerable periods 
with reduced food intake, and the mechanisms which regulate this, also operate 
during weight loss diets. Once an individual begins a CR diet, leptin and thyroid 
hormone levels decrease which reduce energy expenditure considerably, thus 
requiring additional reductions in energy intake just to begin the process of weight loss 
± made harder by the reduced action of leptin which promotes feelings of hunger 
(ghrelin also providing an acute response). Once glycogen reserves have been 
exhausted, the adipose tissue stores will become the main fuel source. The high 
energy density of stored TAGs means that weight loss is a slow process ± especially 
since physical activity is usually reduced in obese individuals. Reduced levels of 
physical activity precipitate a drop in the expression of peroxisome proliferator-
activated receptor-Ȗ -1-Į 3*&Į ± a transcription factor which regulates genes 
involved in energy metabolism and mitochondrial biogenesis, this is a factor which 
contributes to poor oxidative capacity in skeletal muscle. Reductions in fat mass are 
eventually accompanied by loss of lean mass, which requires the dieter to make 
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further reductions to their energy intake to maintain weight loss. These difficulties 
outline why CR diets are in some individuals so unsuccessful. The effects of dietary 
composition during CR are still being examined, with long-term success rates and 
compliance obfuscating the issue. A large multi-centre study by Viguerie et al appears 
to show that CR is of greater importance than dietary composition, in promoting weight 
loss and reducing insulin resistance (Viguerie et al., 2005). Very-low carbohydrate 
diets have become popular in recent years, but concerns exist about both the side-
effects, and long term efficacy of these programmes (Astrup et al., 2004). 
During the last decade, the number of surgical interventions, as a treatment 
for obesity, has increased exponentially (Burns et al., 2010). Bariatric surgery 
produces a dramatic and permanent reduction in energy intake, but the costs and 
risks of surgery must be balanced against the necessity for this operation.  
Pharmacological attempts to induce weight loss have had some success, but 
are prone to have such adverse side effects, that treatment is either highly unpleasant, 
or even dangerous. At present only one drug, Orlistat, is prescribed on the NHS to 
promote weight loss. Orlistat, (tetrahydrolipstatin) prevents the release of pancreatic 
lipase, which reduces the uptake of dietary fat in the ileum. Sibutramine, which was 
previously prescribed, but has now been withdrawn from use, worked by increasing 
the concentration of serotonin (5-HT) in the brain, which  reduced appetite and in-turn 
calorie intake. These drugs can significantly reduce weight, but only by a small 
percentage and therefore, other mechanisms for reducing weight by pharmacological 
intervention are being sought (Davidson et al., 1999; Arterburn et al., 2004). 
Rimonabant, a CB1 antagonist, was a promising pharmaceutical agent developed to 
target the CB1 receptor, which helps in the regulation of appetite. It was dropped from 
development after psychological disturbances were observed during trials, however 
recent research has shown that genotyping of patients could eliminate this risk (Topol 
et al.). Mutations in the melanocortin receptor (MC4R) have been linked with obesity, 
and therefore agonists are being actively developed by pharmaceutical companies. 
MC4R is a second order target for leptin, the effects of which are mediated through 
the inhibitory NPY/AgRP and stimulatory POMC/CART neurons in the Arcuate 
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nucleus. However, a range of side-effects have stifled efforts thus far (Adan et al., 
2006).  
The progression to Type 2 Diabetes Mellitus is often associated (in 80% of 
cases in the UK), with overweight and obese conditions, however, despite this fact, 
the causes of diabetes at the molecular level are still not fully understood. When 
diabetes is present in the overweight/obese condition, it is often referred to as 
metabolic syndrome (Alberti et al., 2006). 
 
 
Figure 1.2.1 The link between overnutrition and insulin resistance. The development of 
systemic insulin resistance in response to the obese state.  
In obesity the expanding adipose tissue mass is infiltrated by macrophages, which scavenge for 
adipocytes. These macrophages release pro-LQIODPPDWRU\ F\WRNLQHV VXFK DV 71)Į DQG ,/-6. 
These signals lead to increased FFA release, and reduced production of adipokines which 
causes local insulin resistance within the adipose tissue.  The release of pro-inflammatory 
cytokines, and  concomitant disruption of adipokines, along with increased ectopic fat 
deposition, eventually lead to the development of systemic insulin resistance, hyperinsulinaemia 
and potentially T2DM (de Luca & Olefsky, 2006).  
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1.2.2 Diabetes 
Diabetes mellitus is a metabolic disease characterised by persistently high 
EORRGJOXFRVHFRQFHQWUDWLRQVPPROO(WHO, 2006a). High blood glucose, termed 
hyperglycaemia, can cause a range of secondary diseases which such as kidney 
failure, neuropathy, retinopathy and infection ± which all lead to an increased risk of 
mortality.  
 There are two main categories of diabetes. The first, Type 1 diabetes 
mellitus, (also referred to as early-onset or insulin dependent diabetes mellitus) is 
caused by auto-iPPXQH GHVWUXFWLRQ RI SDQFUHDWLF ȕ-cells, which renders the patient 
unable to produce endogenous insulin. Successful treatment of Type 1 diabetes can 
achieved through the administration of regular insulin injections, and careful 
monitoring of blood glucose concentrations. Type 1diabetes is not highly-prevalent 
with only about 0.5% of the UK population being affected. 
Type 2 diabetes mellitus (more rarely called; late-onset, or non-insulin 
dependent diabetes) has a different pathogenesis to Type 1 diabetes. Insulin secretion 
in T2DM is partially impaired, but the main cause is the failure of insulin action on 
metabolic tissues ± this is known as insulin resistance. Insulin resistance in T2DM 
occurs even at normal insulin concentrations. Due to impaired glucose uptake in 
muscle and adipose tissues (principally via GLUT4) blood glucose concentrations 
remain high even in the fasting state. Raised levels of glucagon are also observed in 
diabetes, as a result of increased sympatho-adrenal activity, which promotes 
glycogenolysis, lipolysis, gluconeogenesis and ketogenesis, whilst inhibiting 
lipogenesis and glycolysis. The liver adapts to this situation by producing glucose via 
gluconeogenesis. If untreated this can lead to a dangerous situation termed 
ketoacidosis. Chronically high levels of insulin secretion, as a mechanism of 
FRPEDWLQJ LQVXOLQ UHVLVWDQFH DORQJ ZLWK OLSRWR[LFLW\ LQ SDQFUHDWLF ȕ-cells  causes 
apoptosis, and when this occurs insulin can no longer be endogenously produced, 
leading to a clinical diagnosis of T2DM (Unger & Zhou, 2001). 
As previously stated, the development of T2DM is often attributed to obesity, 
although in some cases it affects lean people, especially the elderly. The 
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pathogenesis of T2DM in lean cases is different to that of obese subjects -. The 
heterogeneity of T2DM suggests that it is important to differentiate between these 
groups when conducting research. 
The mechanisms surrounding the switch from the obese insulin resistant state 
WR 7'0 DUH XQFOHDU EXW WKHUH KDV EHHQ VWURQJ LPSOLFDWLRQ RI WKH UROH RI 33$5Ȗ
(Barroso et al., 1999; Kubota et al., 1999). Theories suggest that it could be due to the 
H[SDQVLRQ RI DGLSRVH WLVVXH PDVV ZKLFK H[FOXGHV ))$V IURP ELQGLQJ ZLWK 33$5Ȗ
and therefore reducing lipid storage potential through adipocyte differentiation and 
further expansion. This may then lead to ectopic fat storage, through various 
pathways, increasing the risk of systemic insulin resistance (Balasubramanyam & 
Mohan, 2000). Initially insulin resistance is compensated for by increasing insulin 
VHFUHWLRQ DQG ȕ-cell mass, however there is a point at which this is unable to keep 
pace with increases in IR, and glucose toxicity as a result of chronic hyperglycaemia, 
FRPELQHGZLWKPHWDEROLFVWUHVVOHDGVWRȕ-cell apoptosis and eventually T2DM. 
Treatment for type 2 diabetes mellitus usually begins with dietary advice, 
suggesting a weight-loss diet in those patients who are obese; insulin injection may be 
used in some cases. Pharmaceutical treatment has utilises two main approaches; 
increasing insulin secretion and increasing insulin sensitivity. 
 6XOIRQ\OXUHDV LQFUHDVH LQVXOLQ VHFUHWLRQ IURP ȕ-cells in the pancreas, but a 
balance has to be struck between the half-life of the drug and the potential for causing 
hypoglycaemia, furthermore, poor administration can cause weight gain through 
excessive release of insulin. Incretin mimetics, such as Exenatide, bind to GLP 
receptors in the pancreas and have a similar end result to sulfonylureas, whereby 
insulin secretion is increased - although this is action is initiated via a different route.  
Metformin is another commonly prescribed anti-diabetic drug. It acts by 
suppressing endogenous glucose production (which contributes up to 20% of the 
raised blood glucose concentrations in T2DM) through activation of AMPK, and 
through increasing insulin sensitivity in peripheral tissues ± which further reduces 
hyperglycaemia  Thiazolidinediones, which also increase insulin sensitivity, have been 
prescribed since the 1990s, but many have been withdrawn due to adverse 
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cardiovascular side-effects. The two main prescription drugs in this class are 
rosiglitazone, and pioglitazone, which increase insulin sensitivity through binding to 
WKH33$5VKDYLQJJUHDWHVWDIILQLW\IRU33$5Ȗ7KHDJRQLVPRI33$5ȖLVEHOLHYHGWR
improve lipid storage by adipose tissue, thus reducing the substrate competition in 
skeletal muscle. This allows increased glucose utilisation, alleviating the effects of 
hyperglycaemia, although it does come with the drawback of increasing adiposity. 
Recently there have been calls for Rosiglitazone to be withdrawn, due to some 
evidence that it may also increase the risk of myocardial infarction (Cohen, 2010).  
 
1.3 Transcriptional regulation in metabolism 
The regulation of gene expression is carried out in many ways, with 
interactions between ligands, transcription factors and the promoters of target genes. 
In addition to these transcriptional mechanisms; translation and post-translational 
modification also play an important role. In reality, the concept of pathways ± which 
have been very successful used in the study of enzyme-metabolite-enzyme 
interactions ± cannot be readily applied to gene expression. However, studies have 
consistently shown a set of transcription factors to be involved in the control of 
metabolic gene expression. The list below is not exhaustive, but provides and 
introduction to the major regulators of metabolic gene expression, particularly in the 
context of carbohydrate and fat oxidation. 
 
1.3.1 Sterol Response Element Binding Protein (SREBP) 
Sterol regulatory element binding proteins (SREBP) are transcription factors 
belonging to the class containing basic-helix-loop-helix-leucine-zipper (bHLH/LZ) 
domains (Kim et al., 1995). To date, three variants of SREBP have been described: 
SREBP-1a and SREBP-1c are splice variants of the same gene (SREBF1), 
transcribed via alternate promoters. SREBP-2 is transcribed from a separate locus 
(SREBF2) and only shares 50% homology with SREBP1, but is expressed 
ubiquitously (Hua et al., 1993). SREBP-1a is expressed in most tissues at a low level, 
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but at more significant levels in cell lines and the intestine. SREBP-1c is expressed at 
higher levels in skeletal muscle, adipose tissue, liver, the adrenal medulla and the 
brain (Shimomura et al., 1997).  
The SREBP-1 isoforms are primarily responsible for regulating fatty acid 
biosynthetic genes, whereas SREBP-2 controls cholesterol biosynthesis (Horton et al., 
2002). SREBP-1c has a slightly shorter transactivation domain than SREBP-1a, which 
gives it a lower affinity for the promoters of target genes (Shimano et al., 1997).  
The mechanism which regulates the activity of SREBPs is known as 
µ5HJXODWHG LQWUDPHPEUDQH SURWHRO\VLV 5LS (Brown et al., 2000). In this system, 
SREBPs are translated from mRNA into 125 kDa precursor proteins which are then 
localized to the endoplasmic reticulum (ER). In the ER SREBPs associate with two 
proteins; SREBP-cleavage activating protein (SCAP), and insulin-induced gene 
(INSIG) (Nohturfft et al., 1998). SREBPs are retained in the ER, and only translocate 
to the Golgi apparatus for activation after being released through one of two 
mechanisms. In the first case, if sterol levels are reduced, SCAP no longer binds to 
INSIG, this applies to SREBP-2 and SREBP-1a (Brown & Goldstein, 1999). In the 
second case a rise in insulin concentrations causes INSIG to release the SREBP-
1c:SCAP complex (Hegarty et al., 2005). In both situations the SREBPs are then free 
to translocate to the Golgi apparatus via COPII vesicles (Sun et al., 2005). Once they 
arrive in the Golgi apparatus, they are cleaved by two proteases; Site-1 protease 
(S1P) and Site-2 protease (S2P), into a transcriptionally active 68 kDa proteins. The 
mature SREBP is then free to bind with SREs in the nucleus, where it can initiate 
transcription of target genes (Wang et al., 1994; Sakai et al., 1998) (Figure 1.3.1).  
 Aside from their mechanical role, INSIG proteins refine the regulation of 
SREBPs, through alternative splicing. Three variants of INSIG; -1, -2a and -2b are 
recognised (-2a and -2b are splice variants of the same gene). Both INSIG-1 and -2 
are required for sterol mediated retention of SREBP:SCAP in the ER (Yabe et al., 
2002; Engelking et al., 2004). INSIG-1 is readily degraded by the ubiquitin-proteasome 
pathway, but INSIG-2 has a comparatively longer half-life (Gong et al., 2006). INSIG-1 
uniquely requires nuclear SREBPs for its expression. Whilst INSIG-2 binds SCAP only 
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in the presence of sterols preventing release from the ER (Yabe et al., 2002). In liver, 
INSIG-1 is induced by insulin, but INSIG-2a (the more prevalent hepatic isotype of 
INSIG-2) is suppressed (Yabe et al., 2003). More recent experiments show that 
SREBP-1c:SCAP associates selectively with INSIG-2a, and that insulin promotes 
degradation of INSIG-2a, which enhances the export of SREBP-1c to the Golgi 
apparatus, where it matures (Yellaturu et al., 2009; Sato, 2010). 
 
Figure 1.3.1 SREBP activation pathway. SREBP associates with SCAP via the C-termini, and 
SREBP:SCAP then binds to INSIG, which is retained in the endoplasmic reticulum (ER). When 
sterol levels decrease, or insulin signalling increases, INSIG and SCAP dissociate and 
SREBP:SCAP  translocates to the Golgi apparatus, where proteolytic cleavage by S1P and S2P 
releases the mature SREBP protein, which is then able to bind to SREs in the nucleus 
(Rawson, 2009). 
 
Each of the SREBPs can activate all of their target genes, but with varying 
affinities and differing effects on transcription. SREBP1 is involved in the lipogenic 
program, whereas SREBP2 targets genes involved in cholesterol biosynthetic 
pathways. 
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Unlike SREBP-2 and 1-a, the expression of SREBP-1c is not regulated by cholesterol 
(Sheng et al., 1995). SREBP-1c is expression is induced by insulin (Shimomura et al., 
1999). This effect on SREBP-1c expression appears to be mediated via the PI3K-
signalling pathway. Akt and PKC have both been shown to play a role in this action 
(Fleischmann & Iynedjian, 2000; Matsumoto et al., 2003). SREBP-1c expression is 
also induced by Liver X Receptor-Į /;5Į (Repa et al., 2000; Yoshikawa et al., 
2001b). LXR is activated by cholesterol derivatives, and the function of its binding with 
SREBP-1c may be to induce lipogenesis to create cholesterol esters, which would be 
capable of buffering high cholesterol concentrations (Tontonoz & Mangelsdorf, 2003). 
PUFAs can inhibit transcription of SREBP-1c by antagonising ligand dependent 
activation of LXR (Ou et al., 2001; Yoshikawa et al., 2001b). Interestingly dietary 
saturated fatty acids appear to have the opposite effect, whereby short-term high fat 
feeding in mice, induces hepatic SREBP-1c  expression along with genes involved in 
the lipogenic programme, which Lin et al believe is effected through the coactivational 
properties of PGC-ȕ65(%3ELQGVZLWK3*&-ȕDWDGRPDLQQRWSUHVHQWLQ3*&-Į
(Lin et al., 2005). This may be one mechanism by which high-fat feeding could 
stimulate hyperlipidemia. Inhibition of RIP by PUFAs is a further factor in reducing the 
abundance of SREBP1c in the nucleus, possibly accounting for the decrease in 
acetyl-CoA carboxylase (ACC), fatty-acid synthase (FAS), pyruvate kinase (PK) and 
glucokinase (GK), in hepatocytes (Nakamura et al., 2004; Jump et al., 2005b).  
  As stated earlier, SREBP-1c is principally involved in regulating the lipogenic 
program in cells. It does this in concert with various coactivators and with different 
responses depending on the tissue type and nutritional status. 
SREBP-1c induces expression of fatty-acid synthase (FASN); an enzyme responsible 
for the production of lipids (de novo lipogenesis)  by conversion of  acetyl-CoA and 
malonyl-CoA into palmitate in adipose tissue (Kim et al., 1998), liver (Foretz et al., 
1999) and skeletal muscle (Ducluzeau et al., 2001). SREBP-1c targets hexokinase II 
(HKII) in adipose tissue and skeletal muscle, where its pattern of expression during 
fasting and refeeding is similar to that of FASN (Gosmain et al., 2005). HKII catalyzes 
the phosphorylation of glucose into glucose-6-phosphate (G6P). Deletion of the SRE 
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site in the HKII promoter, abolishes the inducing effect of insulin on HKII expression in 
cultured human myotubes (Gosmain et al., 2004). SREBP-1c has been found to 
increases the flux of the pentose phosphate pathway, through induction of glucose-6-
phosphate dehydrogenase (G6PDH) in mouse liver (Shimomura et al., 1998). G6PDH 
converts glucose-6-phosphate into 6-phosphogluconic acid lactone. This step may 
have consequences for the activation of carbohydrate response element binding 
protein (ChREBP), since 6-phosphogluconic acid lactone is later converted into 
xylulose 5-phosphate (Xu 5-P). Xu 5-P is a substrate for the production of NADPH, 
and also activates protein phosphatise (PP2A), allowing ChREBP to enter the 
nucleus. In hepatocytes, SREBP-1c mediates the pro-transcriptional effects of insulin 
on glucokinase (GK) expression (Bécard et al., 2001; Ferre et al., 2001). SREBP-1c 
has also been shown to regulate the expression of ACC, and steroyl-CoA desaturase 
1 (SCD). Adipose tissue SREBP-1c expression is lower in the obese state, compared 
with lean controls, but increases with weight loss, possibly due to improved insulin 
sensitivity. (Kolehmainen et al., 2001; Sewter et al., 2002) Similar decreases in 
SREBP-1c expression have been observed in the skeletal muscle of diabetic patients, 
but the picture is more mixed regarding obesity (Sewter et al., 2002) Fasting 
decreases the abundance of SREBP-1c in mRNA in rat skeletal muscle, and refeeding 
restores iWEXWWKLVLVQRWOLQNHGWRWKHDFWLRQRILQVXOLQ,W¶VWDUJHWV+.,,DQG)$6ZHUH
also correlated with changes in SREBP-1c expression in this study (Commerford et 
al., 2004). 
 
1.3.2 Carbohydrate Response Element Binding Protein (ChREBP) 
ChREBP is another transcription factor belonging to the basic-helix-loop-helix-
leucine zipper (bHLH/LZ) family. It binds to carbohydrate response element (ChRE) 
sequences, which aUHFRPSULVHGRIWZRƍ-CACGTG type E-box motifs separated by 
5  base pairs (Yamashita et al., 2001). As its name indicates; ChREBP is responsible 
for affecting glucose induced changes in gene expression. ChREBP itself is expressed 
in many tissues, but most highly in metabolically active tissues such as; liver, white 
and brown adipose and skeletal muscle (Yamashita et al., 2001; Iizuka et al., 2004). 
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ChREBP is positively regulated by glucose, independently of insulin, in a process 
whereby, increased glucose is metabolised via the pentose phosphate pathway 
(PPP). One product of the PPP is xylulose 5-phosphate (Xu 5-P), a metabolite which 
increases the activity of a protein phosphatase, (PP2A) (Doiron et al., 1996).  PP2A, 
activation allows ChREBP to translocate to the nucleus where it can induce lipogenic 
gene expression (Kabashima et al., 2003). When blood glucose concentrations are 
low, ChREBP is localised in the cytosol, but it rapidly translocates to the nucleus when 
blood glucose concentrations rise. This is the result of dephosphorylation of serine 
and threonine residues. Ser196 - the target for PKA is dephosphorylated, which 
permits entry of ChREBP into the nucleus. Ser565 and Thr666 are then 
dephosphorylated by PP2A, which allows it to bind with DNA and initiate transcription 
of target genes. ChREBP is negatively regulated by glucagon via cAMP and PKA 
(Burke et al., 2009), which through phosphorylation prevent DNA binding. PUFAs 
have an inhibitory effect on ChREBP especially during the consumption of a high fat 
diet (Uyeda et al., 2002). ChREBP works in partnership with SREBP to regulate 
lipogenesis; with some targets having binding sites for both TFs (Koo et al., 2001; 
Rufo et al., 2001). This relationship allows a lipid storage program to be initiated only 
when both insulin and glucose signalling is coordinated, providing an integrated 
response (Towle, 2001). Studies using metformin support the idea of synergy, 
showing that AMPK inhibits the activity of both SREBP and ChREBP (Zhou et al., 
2001). ChREBP does not work alone, instead it forms a heterodimer with Max-like 
protein X (Mlx) to mediate glucose induced gene expression in liver (Ma et al., 2006) 
Mlx acts to distinguish between E-boxes which are glucose responsive and those 
which are not (Stoeckman et al., 2004; Dentin et al., 2005b). L-type pyruvate kinase 
(L-PK) and lipogenic genes such as, ACC and FASN are targeted by ChREBP, to 
promote fat storage through de novo lipogenesis and glycolysis (Dentin et al., 2005b). 
High fat diets are also capable of suppressing the expression of L-PK and FAS, by 
expediting the degradation of ChREBP, possibly by the action of  PUFAs (Dentin et 
al., 2005a). 
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1.3.3 The Peroxisome-Proliferator-Activated-Receptors (PPARs) 
The Peroxisome-Proliferator-Activated-Receptors are members of the nuclear 
receptor superfamily. They have a wide range of targets involved in metabolic 
UHJXODWLRQ $W SUHVHQW WKUHH 33$5 LVRW\SHV ĮȖį (Table 1.3.1)  have been 
discovered, and in common with all ligand activated receptors, they have a ligand 
binding domain (LBD), activating-function domains (AF) and a DNA binding domain 
(DBD). After ligand binding occurs, the PPARs form obligate heterodimers with RXR, 
without which they are unable to bind to DNA. Co-repressor proteins such as SMRT 
and N-CoR are then released (Yu et al., 2005), and potential co-DFWLYDWRUVOLNH3*&Į
or CREB are recruited. The endogenous ligands for the PPARs are fatty acids and 
their derivatives; eicosanoids and prostaglandins (Forman et al., 1997; Kliewer et al., 
1997). Elevated levels of FFAs activate PPARs and depending on the isoform, the 
response is different.  In PPARs, the DBD binds to a PPAR-response-element (PPRE) 
in the promoter of the target gene, and transcriptional activation is initiated. The 
activity of PPARs can also be increased through insulin and AMPK induced 
phosphorylation (Diradourian et al., 2005). 
33$5Į LV H[SUHVVHG LQ OLYHU KHDUW NLGQH\ LQWHVWLQH SDQFUHDV VNHOHWDO
muscle and brown adipose tissue where it induces the expression of genes involved in 
WKH WUDQVSRUW DQG ȕ-oxidation of fatty acids and glucose oxidation. It is a molecular 
sensor of F$¶VDQGWKHLUGHULYDWLYHV - its natural ligands include polyunsaturated fatty 
acids. Its action is achieved through its multiple target genes, with it being strongly 
correlated with increasing the expression of CPT-D WKH UDWH OLPLWLQJ HQ]\PH LQ ȕ-
oxidation. It is also a regulator of CD36, Lipoprotein lipase (LPL), UCP-3 and 
potentially PDK4 (Zhang et al., 2004)+XPDQ33$5ĮPD\WDUJHW75%H[SUHVVLRQLQ
liver) which forms an important part of the insulin signalling chain, TRB3 is an inhibitor 
of Akt, which positively regulates the cell response to insulin (Koo et al., 2004). 
)LEUDWHV DUH D FODVV RI GUXJV ZKLFK WDUJHW WKH 33$5Į UHFHSWRU WR UHGXFH HOHYDWHG
levels of TAGs and cholesterol, this occurs due WR LQFUHDVHGȕ-oxidation and LPL. It 
KDVEHHQVXJJHVWHGWKDWVLQFH33$5ĮLQFUHDVHVIDWW\DFLGR[LGDWLRQQRWRQO\LQOLYHU
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and muscle, but also in the pancreas where it may prevent lipotoxicity, and therefore 
the progression from insulin resistance to type 2 diabetes (Ravnskjaer et al., 2005). 
33$5į LV H[SUHVVHG XELTXLWRXVO\ 0XFK OLNH 33$5Į LW¶V DFWLYDWHG E\ 38)$V DQG
HLFRVDQRLGV DQG DOVR LQGXFHV WKH H[SUHVVLRQ RI JHQHV ZKLFK UHJXODWH IDWW\ DFLG ȕ-
oxidation, mitochondrial respiration and oxidative metabolism. It also plays a role in 
the regulation of HDL concentrations. Research suggests that it is also capable of 
ILOOLQJ WKH UROH RI 33$5Į LQ 33$5Į-/- PLFH 6LPLODUO\ WR 33$5Į LW LV XSUHJXODWHG LQ
UHVSRQVH WR IDVWLQJ DQG H[HUFLVH 33$5į LV SUHVHQW DW KLJKHU OHYHOV LQ JO\FRO\WLF
myofibers. Post-translational modifications resulting from signalling proteins such as 
SURWHLQNLQDVH$DQG0$3.PD\SKRVSKRU\ODWH33$5įWRLQFUHDVHLWVDFWLYLW\(Barish 
et al., 2006).  
33$5ȖKDVWKUHHPDLQVSOLFHYDULDQWV± PPAR-Ȗb expressed ubiquitously at 
low levels, PPAR-Ȗ ZKLFK LV H[SUHVVHG XQLTXHO\ LQ DGLSRVH WLVVXH DQG 33$5-Ȗ
found in macrophages, the small intestine and adipose tissue. PPARJ is most highly 
expressed as the PPARJ2 isoform in white adipose tissue, where it exerts greatest 
influence. Its main roles are in adipocyte differentiation, fatty acid transport and 
storage, and glucose metabolism. Its natural ligands are thought to be long-chain 
PUFAs, prostaglandins and possibly some phospholipids, and it induces the 
expression of genes including UCP2 & -3, LPL, FATP, FABP, ACS, GK and GLUT4. 
9DULDQWV LQ WKHVHTXHQFHRI WKH33$5ȖJHQHDUHQRWFRPPRQEXW LQD IHZVWXGLHV
SNPs have been linked to obesity, diabetes and hypertension (Meirhaeghe & 
Amouyel, 2004) 33$5Ȗ H[SUHVVLRQ LV GHFUHDVHG GXULQJ VWDUYDWLRQ LQ URGHQWV EXW
increases in response to refeeding. It also appears to play a significant role in the 
GHYHORSPHQW RI GLDEHWHV DV GLVFXVVHG HDUOLHU LQ WKLV FKDSWHU  33$5Ȗ-/- knockouts 
are XVXDOO\ OHWKDO KRZHYHUKHWHUR]\JRXV33$5ȖGHILFLHQWPLFHDUHSURWHFWHG IURP
high-fat diet induced obesity, and insulin resistance (Kubota et al., 1999), through 
decreases in hepatic an skeletal muscle TG content as a result of increased leptin 
expression, increased fatty-acid oxidation and decreased lipogenesis. Conversely, 
DJRQLVWV RI 33$5Ȗ VXFK DV 7='V KDYH VXFFHVVIXOO\ WUHDWHG K\SHUOLSLGDHPLD DQG
hyperglycaemia, by improving lipid storage in white adipose tissue (and reducing 
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storage in liver and skeletal muscle) ± with the side effect of weight gain (Yki-Jarvinen, 
2004). A recent study has shown that obesity induced by high fat feeding in mice, 
DFWLYDWHV F\FOLQ GHSHQGHQW NLQDVH  &'. ZKLFK SKRVSKRU\ODWHV 33$5Ȗ DQG
dysregulates the expression of target genes ± including the insulin sensitising 
adipokine, adiponectin (Choi et al., 2010).  
 
 
Table 1.3.1 PPAR isotypes. PPAR isotypes, with their corresponding tissue distribution, ligands 
metabolic function, target genes and potential disease interactions. 
 
 
1.3.4 Peroxisome-proliferator-activated-receptor-Ȗ&o-activator-Į3*&Į 
Peroxisome-proliferator-activated-receptor-Ȗ &R-activator-Į LV D
transcriptional coactivator which, despite its name, is a coactivator of all three PPARs. 
Its main function is to regulate mitochondrial biogenesis, and hence it is more 
abundant in the metabolically active tissues, such as skeletal and cardiac muscle and 
brown adipose tissue, with lower levels found in liver and white adipose tissue. It is 
LQGXFHG E\ FROG H[SRVXUH YLD WKH ȕ-adrenergic/cAMP pathway. PPAR Gamma co-
activator 1-Į3*&-ĮLVSDUWRIDIDPLO\RIWUDQVFULSWLRQDOFR-activators which induce 
the expression of genes involved in a number of metabolic processes. These include; 
adaptive thermogenesis, carbohydrate and fatty acid oxidation and mitochondrial 
biogenesis. Roles have also been suggested for PGC-Į LQYROYHPHQW LQ KHSDWLF
gluconeogenesis and glucose uptake in skeletal muscle through its interaction with 
FOXO1 (Oberkofler et al., 2003; Puigserver et al., 2003). Coactivators such as PGC-
ĮGRQRWELQG WR'1$EXWDIIHFW WKHLU WDUJHWVYLD LQWHUDFWLRQVZLWKQXFOHDU UHFHSWRUV
Isotype Active state Primary Tissues Ligands Function Targets Related disease process
PPARɲ Post absorptive Liver, muscle, heart FFAs. Fibrates Fat oxidation FATP, acyl-CoA oxidase, 
cytochrome P450, CPT1
Dyslipidemia, Diabetic 
cardiomyopathy
PPAR ɶ Postprandial Adipose, muscle, heart, 
macrophages
FFAs. TZDs Fat storage
CD36, LPL,GLUT4, PEPCK, 
acyl-CoA synthase
Insulin resistance, 
obesity, NAFLD, LVH
PPARɷ Movement (Ubiquitous), muscle, 
adipose
FFAs, 
prostaglandins
Energy balance MCAD, CPT1,UCP3 Dyslipidemia, obesity
Peroxisome-Proliferator-Activated Receptors (PPARS)
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VXFKDV33$56ĮįDQGȖE\LQFUHDVLQJWKHLUDELOLW\WRLQLWLDWHWUDQVFULSWLRQ3*&VFDQ
act by docking to specific receptors alone, but can also recruit more co-activators such 
as CBP/p300 and p160/SRC-1 (Puigserver & Spiegelman, 2003). PGC-ĮKDVEHHQ
demonstrated to upregulate PDK4 expression in C2C12 myotubes. Gel shift assays 
revealed that it was bound to the estrogen-UHODWHGUHFHSWRUĮ(55Į(Wende et al., 
2005) 3*&Į LQGXFHV 3'. DQG 3'. LQ UDW KHSDWRF\WHV SRWHQWLDOO\ GHFUHDVLQJ
PDC flux, reducing the conversion of pyruvate into acetyl-CoA and into oxaloacetate 
and gluconeogenesis instead (Ma et al., 2005). 
 
1.3.5 The Retinoid X Receptors (RXR) 
The Retinoid X Receptor (RXR) also forms part of the nuclear receptor 
superfamily of transcription-factors which are ligand-activated. The three receptor 
sXEW\SHVDUHNQRZQDVĮȕ	Ȗ7KHLVRW\SHVDUHHQFRGHGE\GLIIHUHQWJHQHVZKLFK
WKURXJKDOWHUQDWLYHVSOLFLQJSURGXFHD WZR LVRIRUPVHDFK ĮĮHWF$V WKHQDPHV
suggests, of 9-cis retinoic acid (RA) coactivates RXR.  They were first discovered to 
bind heterodimerically with the thyroid receptor (TR) and RARs, and later discovered 
to dimerize with pregnane X receptor, farnesoid X receptor, liver X receptor, 
constitutively activated receptors (CAR) and PPARs (Szanto et al., 2004). Evidence 
exists that shows RXR to be capable of activating PPAR targets as a homodimer 
binding to PPRE sites in gene promoters (IJpenberg et al., 2004)5;5ĮLV IRXQGLQ
OLYHU NLGQH\ HSLGHUPLV DQG LQWHVWLQH 5;5ȕ LV IRXQG XELTXLWRXVO\ EXW 5;5Ȗ LV
restricted to skeletal muscle, and the pituitary gland (Mangelsdorf et al., 1992). As 
Germain et al have suggested, the fact that RXR is an obligate heterodimer for many 
nuclear receptors, the number of targets which they regulate at the  transcriptional 
level is vast (Germain et al., 2006). As a result of the myriad binding targets, most 
research has focussed on the binding partners of RXR. 
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1.3.6 Liver X Receptors (LXR) 
LXRs are another class of nuclear receptors related to RXRs and PPARs. 
7KHUHDUH WZR/;5JHQHVĮDQGȕ WUDQVFULEHG IURPGLIIHUHQW ORFL/;5Į LV IRXQG LQ
liver, adipose WLVVXH PDFURSKDJHV ERQH LQWHVWLQH DQG VSOHHQ ZKLOVW /;5ȕ LV
expressed ubiquitously. LXRs bind to the LXR response element (LXRE) which has 
the consensus sequence TGGTCACTCAAGTTCA. LXRs are activated by oxysterols, 
and are involved in cholesterol homeostasis, in conjunction with SREBP1. It regulates 
a range of metabolic genes, due in part to its promiscuous nature and ability to 
dimerize with other receptors including RXR. These targets include FAS, LPL, 
CYP7A1, APOE, ABCs, SREBP-1c and LXR (Repa et al., 2000; Chiang et al., 2001; 
Laffitte et al., 2001; Yoshikawa et al., 2001a; Zhang et al., 2001; Joseph et al., 2002a). 
Activation of LXR with the synthetic ligand GW3965 improves glucose tolerance in 
murine models of obesity and insulin resistance, with reduced gluconeogenesis, and 
improved glucose uptake ± SULQFLSDOO\E\WKHVXSSUHVVLRQRIKHSDWLF3*&ĮJOXFRse-
6-phosphatase and PEPCK. In adipose tissue it increases the expression of GLUT4 
(Laffitte et al., 2003). 
Mitro et al reported that D-glucose and D-G6P were direct agonists of LXR in 
the liver, which activated a programmer of hepatic lipogenesis and reduced 
gluconeogenesis (Mitro et al., 2007). This has been challenged more recently, by 
experiments in mice showing that ChREBP but not LXR are required for the induction 
of glucose regulated genes in mouse liver (Denechaud et al., 2008). PPARs suppress 
SREBP-1c expression by inhibiting the binding of RXR:LXR to the SREBP-1c 
promoter (Yoshikawa et al., 2003). It may be that the ratio of available RXR binding 
ZLWK HLWKHU 33$5V RU /;5 GHWHUPLQHV WKH SURJUDP RI OLSRJHQHVLV RU ȕ-oxidation, 
however these findings are yet to be replicated in vivo. 
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1.4 Aim of thesis 
The field of nutrigenomics has developed to investigate the questions 
surrounding how metabolic gene expression adapts to the changing environment, and 
how its dysregulation may contribute to disease states. As this introduction has 
shown, the diverse regulatory mechanisms compliment and compete with one another 
to achieve energy balance. Transcription is a major regulator of energy balance and 
peripheral substrate flux. Experimental observation of metabolic gene expression 
coupled with pathway analysis offers a powerful way of understanding how these 
systems operate. 
This aim of this thesis is to investigate how fuel substrates interact with gene 
expression to generate a particular phenotype and how gene expression adapts to 
alterations in substrate availability. The major themes of this thesis are; 
1.  Changes in metabolic gene expression during a 10-week low-energy diet of 
varying fat content in obese subjects with high or low postprandial fat oxidising 
capacity. 
2. Differences in the global gene expression profiles of obese subjects with high- 
or low-postprandial fat oxidation rates. 
3. Acute hyperglycaemia induces the expression of lipogenic genes in human 
primary myotubes. 
4. Increasing PDC flux, independently of insulin signalling does not affect gene 
expression in human skeletal muscle. 
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Molecular Biology: Materials & Methods 
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2.0 Molecular Biology Materials and Methods 
2.1 Human study design and protocol 
The human studies described in this thesis (section 2.1.1 ± 2.1.4) the author 
was provided with total RNA for subsequent quantification by RT-QPCR and total 
protein extracts for quantification of protein expression by Western blotting, and 
therefore acknowledges the assistance of the following in performing the human 
studies. 
 
2.1.1 Fat oxidising capacity influences gene expression changes during 10-week low-
fat or high-fat low energy diets in obese subjects (Tantip Boonsong, Professor Ian 
Macdonald, Dr Andrew Bennett, NUGENOB) (See Chapter 3). 
 
2.1.2 Transcriptional Profiling of Adipose Tissue in Obese Subjects with High- or Low-
Postprandial Fat Oxidising Capacity (Hui Shi, Christopher Medway, Kevin Morgan, 
Professor Ian Macdonald, Dr Andrew Bennett, NUGENOB) (See Chapter 4). 
 
 2.1.3 Effects of high-glucose treatment on metabolic gene expression in Human 
primary myotubes. (Roya Jadidi-Babaei, Dr Kostas Tsintzas, Professor Ian 
Macdonald, Dr Andrew Bennett)  (See Chapter 5). 
 
2.1.4 Skeletal muscle metabolic gene expression is not affected by dichloroacetate 
mediated modulation of substrate utilisation (Dr Andrew Bennett, Dr Kostas Tsintzas, 
Professor Ian Macdonald, Dr Nandini Seevaratnam) (See Chapter 6). 
 
 
 
 
Detailed study protocols and methods are  included in individual chapters 
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2.2 Molecular Biology  
2.2.1 Isolation of RNA 
Total RNA was extracted from human muscle tissue (stored under liquid 
nitrogen) by placing ~50 mg into cryovial tubes, to which 800 µL TRIzol® (Invitrogen) 
and 20 µL glycogen (10µg/µL) were added. This was homogenised (Polytron, USA) at 
speed 2.5 for 30 seconds. After incubation at room temperature for 5 minutes the 
solution was transferred to a 1.5 ml RNase-free Eppendorf tube. Following this 156.8 
µL of Chloroform and 3.2 µL of Isoamyl alcohol were added and the tube was briefly 
vortexed and incubated at room temperature for 2 minutes. The sample was 
centrifuged at 12, 000g at 4°C for 15 minutes and the aqueous phase (approx 500 µL) 
transferred to a clean 1.5 ml Eppendorf tube. 400 µL isopropanol was added and the 
sample placed at -20°C overnight or for a minimum of 4 hours. Subsequently the 
samples were centrifuged at 12,000g at 4°C for 15 minutes. The supernatant was then 
removed and the RNA pellet air dried for 5 minutes. The pellet was washed with 800 
µL 75% EtOH by vortexing, and then centrifuged at 10,000g for 10 minutes. The 
supernatant was then removed, and the pellet air dried for 5 minutes. The RNA pellet 
was finally re-dissolved in 30 µL of RNase-free water and stored at -80°C. 
 
2.2.2 Reagents  
Glyoxal reaction mixture 
1x BPTE buffer 
1M deionised glyoxal 
4.8% (v/v) glycerol 
60% (v/v) DMSO 
20% (w/v) ethidium bromide 
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BPTE electrophoresis buffer 
1mM EDTA, pH 8.0 
10mM PIPES (piperazine-1,4-bis[2-ethanesulphonic acid], pH 6.5 
30mM Bis-Tris (bis [2-hydroxyethyl] iminotris [hydroxymethyl] methane) 
 
TBE (Tris Borate EDTA) buffer 
0.09M Tris-HCl, pH 7.5 
0.09M Boric acid 
0.01mM EDTA, pH 7.5 
 
2.2.3  Agarose gel electrophoresis of total RNA (Glyoxal/DMSO method) 
To assess RNA integrity, RNA samples (1-2 µg) were mixed with 10 µL of 
glyoxal reaction mixture, and then incubated at 55°C for 1 hour and placed on ice for 
10 minutes. 2µL of loading dye was added to the sample, which was then loaded into 
the wells of a 1.5% agarose gel (w/v) made up in BPTE buffer. The gel was run at 90 
V (5 V/cm). The RNA 18S and 28S bands were visualised with a UV transilluminator, 
and the photograph recorded using Genesnap software. 
 
2.2.4 Agarose gel electrophoresis of cDNA (Ethidium Bromide method) 
A 1% (w/v) agarose gel was produced using 0.5g of agarose in 50 ml of TBE 
(heated in microwave until dissolved) after allowing it to cool to 60°C, 1 µL of ethidium 
bromide (10mg/mL) was added to the solution and mixed by gently swirling the flask. 
The combs were inserted into the tank and the gel was poured slowly, following which 
the gel was left at room temperature for 40 minutes. Once set TBE buffer was poured 
into the tank until the gel was submerged by 4mm depth. 10 µL of the PCR product 
was mixed with 2 µL 6x Loading dye prior to being pipetted into the wells.  The gel 
was run at 100V (5V/cm). Once the gel had finished running it was placed under UV 
light and photographed using GeneSnap software. 
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2.2.5 Reverse Transcription (RT) 1. 
cDNA was produced from human tissues by the reverse transcription of total 
RNA in (section 2.1.4). RNA samples were firstly quantified using a Nanodrop ND-
1000 (Thermo Fisher Scientific, Delaware, USA), and then diluted to a concentration 
of 50 ng/µL in RNase-free water. 10 µL of RNA and random primers (Invitrogen) at 
J/FRQFHQWUDWLRQZHUHDGGHG WRPO3&5 WXEHVDORQJZLWK/RIG173¶V
(Invitrogen) at a concentration of 10 mM. 1 µL of RNase-free water was added to give 
a total volume of 13 µL. The tubes were briefly vortexed and centrifuged before being 
placed into a thermocycler with a heated lid at 65°C for 5 minutes then placed on ice 
for at least 2 minutes. Whilst on ice 4 µL of 5 X First-strand buffer (Invitrogen), 1 µL of 
RNase-inhibitor (40u/µL), 1 µL of SupHUVFULSW,,,57X/,QYLWURJHQDQG/
of 0.1M DTT were added to the primer:RNA mix. The tubes were then incubated at 
25°C for 5 minutes, 50°C for 1 hour, 70°C for 15 minutes and then cooled to 4°C. 
cDNA was stored at -20°C until RT-QPCR analysis.  
 
2.2.6 Reverse Transcription (RT) 2. 
7KH 6XSHUVFULSW ,,, )LUVW-Strand Synthesis SuperMix for qRT-PCR 
(Invitrogen) kit was used to produce cDNA in sections 2.1.1-2.1.3. 1 µg of RNA was 
added to a thin-walled 0.2 ml PCR tube along with 10 µL 2X RT Reaction Mix, 2 µL 
RT Enzyme Mix and RNase-free water to 20 µL. The tube was gently mixed and then 
incubated at 25°C for 10 minutes, 50°C for 30 minutes and 85°C for 5 minutes before 
cooling to 4°C and storing at -20°C. Thermocycling was carried out on a Geneamp 
PCR System 9700 with a heated lid. 
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2.2.7 Polymerase Chain Reaction (PCR) 
To give a total volume in of 25 µL in a single PCR reaction; 
 
Reagents                 Volume 
cDNA         5 µL 
5 x PCR Buffer (Promega)      2.5 µL 
Forward Primer (10 µM)       0.75 µL 
Reverse Primer (10µM)       0.75 µL 
dNTPs (10mmol)                  0.5 µL 
Taq Polymerase (Promega)       0.25 µL 
H2O         15.25 µL 
 
The tubes were flick mixed and briefly centrifuged. They were then placed on 
a thermocycler (with heated lid) at 95°C for 50 minutes, 40 X (95°C for 1 minute, 60°C 
for 1 minute, 72°C for 2 minutes) and finally 72°C for 5 minutes.  The product size and 
specificity were assessed by using agarose gel electrophoresis and ethidium bromide 
staining. 
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2.2.8 Analysis of mRNA expression by TaqMan® (Applied Biosystems, Foster 
City, CA USA) real-time quantitative PCR 
Reaction set up 
Each reaction was in a final volume of 25uL (see below) but a series of master 
mixes were made up to ensure reproducibility. 
 
Reagents    Volume per reaction Final concentration 
 
TaqMan® Universal PCR Mastermix   12.5uL         - 
Forward primer (10 µM)     0.75uL  0.3uM 
Reverse primer (10 µM)     0.75uL  0.3uM 
Probe (dual labelled) (10 µM)    0.5uL  0.2uM 
cDNA        5uL       - 
Water (molecular grade)    5.5uL       - 
Total volume      25 uL  
 
The reactions were carried out using; ABI PRISM 7000 sequence detection 
system, ABI PRISM 7700 sequence detection system and an ABI StepOne Plus 
(Applied Biosystems, UK). 5µL of RNase-free water was used as a negative/No 
Template Control (NTC). Thermo-cycling parameters were 50°C for 2 minutes, 95°C 
for 10 minutes followed by 40 x (95°C for 15 seconds, 60°C for 1 minute). Once the 
reaction had been completed, the mRNA was quantified using the standard curve 
method. The standard curve consisted of two-fold serial dilutions of cDNA reverse 
transcribed from a known quantity of RNA. All standards, samples and negative 
controls were assayed in triplicate to ensure accurate results. The threshold cycle (Ct 
Value) is the point at which fluorescence rises to a point considered statistically 
significant above the baseline values. A standard curve was then constructed by 
plotting Ct values versus the logarithm of the serial cDNA dilutions. The efficiency (E) 
of the reaction was calculated with the equation.  
E= 10(-1/slope)-1 
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Any assay which did not have a standard curve with a slope between -3.0 and -3.6 
(90-100% efficient) was rejected as were any results where the values for the 
triplicates had a range greater than 0.5 Ct. The control genes used during experiments 
were Hydroxymethylbilane Synthase (HMBS), and 18S. All values were normalised by 
dividing through these genes. 
 
Table 2.2.1 Oligonucleotide sequences for probes and primers 
Gene 6HTXHQFHV¶-Æ ¶ 
Ampli
con 
size 
(bp) 
Gen Bank 
Accession 
No. 
Origin 
18S FWD CGGCTACCACATCCAAGGAA PROBE TGCTGGCACCAGACTTGCCCTC 
REV GCTGGAATTACCGCGGCT 
188 M10098 Dr A Bennett 
Į-ACTIN FWD GAGCGTGGCTACTCCTTCGT PROBEACCACAGCTGAGCGCGAGATCGT 
REVGTAGCACAGCTTCTCCTTGATGTC 
72 NM_001100 Dr K Tsintzas 
ACC2 FWD CACACTCTGCCCAAGACACC PROBE CCCCAAAGATGCCGGTCGGC 
REV TTCTGGTGGGAGGGTGGTAG 
101 U89344 Dr T Boonsong 
apM1 
FWD TGCAGTCTGTGGTTCTGATTCC 
PROBE GGCTCAGGATGCTGTTGCTGGGA 
REV TTGAGTCGTGGTTTCCTGGTC 
109 NM_004797 Dr T Boonsong 
ATGL FWD CCAACACCAGCATCCAGTTC PROBE CTCTTCCCGCCGGAGCCCCT 
REV TATCCCTGCTTGCACATCTCTC 
103 NT_035113 Dr T Boonsong 
CPT1 FWD TTTGGCCCTGTAGCAGATGAT PROBE TCGTGTTCTCGCCTGCAATCATGT 
REV ACTTGCTGGAGATGTGGAAGAAG 
85 Y08683 Dr K Jewell 
HKII 
FWD AAGTTCTTGTCTCAGATTGAGAGTGACT 
PROBE CTGCAACACTTAGGGCTTGAGAGCACCTG 
REV CAGTGCACACCTCCTTAACAATG 
121 NM_000189 Dr T Boonsong 
HMBS FWD            ---- PROBE        ---- 
REV             ---- 
-- 
-- 
Applied 
Biosystems, UK 
HSL FWD GATGCTTCTATGGCCGCTG PROBE TTCCAGTTCACGCCTGCCATCCG 
REV GACACCAGCCCAATGGAGA 
85 BC070041 Dr T Boonsong 
MCAD FWD GCCGTGACCCGTGTATTATTG PROBE TTCGGGCGATGCTGCAGGGT 
REV CGATTGGCTTTTGTATGC TGTG 
133 MN_000016 T Boonsong 
PDK2 
FWD CATCATGAAAGAGATCAACCTGCTT 
PROBE CCGACCGAGTGCTGAGCACACCC 
REV CAGGAGGCTCTGGACATACCA 
109 NM_002611 Dr K Tsintzas 
PDK4 
FWD CAAGGATGCTCTGTGATCAGTATTATTT 
PROBE CATCTCCAGAATTAAAGCTTACACAAGTGAATGGA 
REV TGTGAATTGGTTGGTCTGGAAA 
90 NM_002612 Dr K Tsintzas 
PGC-Į FWD GGTGCAGTGACCAATCAGAAATAA PROBE ATCCAATCAGTACAACAATGAGCCTTCAAACATAT 
REV TTGCCTCATTCTCTTCATCTATCTT 
90 NM_013261 Dr K Tsintzas 
33$5Į FWD GCTTCCTGCTTCATAGATAAGAGCTT PROBE AGCTCGGCGGCACAACCAGCA 
REV CACCATCGCGACCAGATG 
 
NM_005036 Dr K Tsintzas 
33$5į FWD TGCGGCCATCATTCTGTGT PROBE ACCGGCCAGGCCTCATGAACG 
REV CAGGATGGTGTCCTGGATAGC 
 
NM_006238 Dr K Tsintzas 
SREBP-
1C 
FWD GGAGGGGTAGGGCCAAC 
PROBE CGCGGAGCCATGGATTGCAC 
REV GTCAAATAGGCCAGGGAAGTC 
150 NM_004176 Dr T Boonsong 
UCP2 FWD CGTCTCCCACCCATTTTCTATG PROBE CCAAGGGGATCGGGCCATGA 
REV GGAATCCGGCTTTGTAAG GTCT 
135 BC011737 Dr T Boonsong 
UCP3 FWD CTGGACTACCACCTGCTCACT PROBE AGGATCCCAAACGCAAAAAGGAGG 
REV AGGTTACGAACATCACCACGT 
 
NM_003356 Dr K Tsintzas 
SREBP1a FWD GCGAGCCGTGCGATCT PROBE CGCTGCTGACCGACATCGAAGACA 
REV CTGTCTTGGTTGTTGATAAGCTGAA 
 
NM_0010052
91 
P Tisdale 
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2.2.10 Reduction of ribosomal RNA by Invitrogen Ribominus module 
5LER0LQXV7UDQVFULSWRPH,VRODWLRQ.LW+XPDQ0RXVH9HUVLRQ& 
 
2.2.11 Affymetrix HuEx 1.0 ST Array 
GeneChip® Whole Transcript (WT) Sense Target Labeling Assay Manual Version 4 
 
2.3 Primary cell culture (Human myotubes) 
Human muscle biopsy material was washed 3 times in 10ml of PBS, and then 
SURFHVVHG LQWRD µWLVVXHPDVK¶ XVLQJDVFDOSHO QREODGH7KHVDPSOH ZDV WKHQ
WUDQVIHUUHGWRDXQLYHUVDOWXEHFRQWDLQLQJDµIOHD¶DQGPORI[WU\SVLQIRULQFXEDWLRQDW
37ºC for 15 minutes.  The supernatant was transferred to a universal tube and 
QHXWUDOLVHGXVLQJPORIPHGLD+DP¶V)-10, streptomycin, penicillin and foetal bovine 
serum), then centrifuged at 1700 rpm for 5 minutes. The supernatant was removed 
and satellite cells were resuspended in 1-2 ml of media, by gentle aspiration with a 
pasteur pipette.  1ml of satellite cells was pipetted into each gelatinised flask (washed 
with PBS after 24 hours) and grown at 37ºC and 5% CO2. Media was changed every 
2 days for ~5weeks until the cells had differentiated into a dense multinucleated 
myotube network, at which point they were treated. 
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2.4 Protein gel electrophoresis and Western blotting 
2.4.1 Reagents 
 
10% Ammonium persulfate 
0.1g of Ammonium persulfate was dissolved in 1ml of distilled water immediately prior 
to use.  
 
SDS-PAGE gel solutions (for 2 gels) 
 
10% Separating gel        (20ml) 
30% Acrylamide/bisacrylamide (Severn Biotech Ltd.)   6.68 ml  
2M Tris HCl (pH 8.8)       3.76 ml  
10% SDS (w/v)         0.2 ml  
TEMED         20 µL  
Distilled water        9.18 ml  
10% Ammonium Persulfate      160 µL  
 
5 % Stacking gel       (10ml) 
30% Acrylamide/bisacrylamide (Severn Biotech Ltd.)   1.7 ml 
1M Tris HCl (pH 6.8)       1.26 ml  
10% SDS (20g/200ml)        100 µL  
TEMED         10 µL  
Distilled water        6.84 ml  
10% Ammonium Persulfate      100 µL  
 
SDS-PAGE running buffer 
1.92 M Glycine 
0.25 M Tris base 
10% (w/v) SDS 
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Transfer buffer (for western blotting) 
1.92 M Glycine 
0.25 M Tris 
20% (v/v) Methanol 
 
Ponceau Red 
0.1% (w/v) Ponceau S (3-hydroxy-4[2-sulpho-4-(4-sulphophenylazo)-phenyl-azo]-2,7-
napthalenedisulphoric acid) in 5% (v/v) acetic acid. 
 
TBS 
1.2g Tris Base 
8.75g NaCl 
pH adjusted to 7.5 and made up to 1 L with distilled H2O 
 
TBS-T 
TBS 
YY7ZHHQ 
 
Blocking buffer 
TBS-T 
5% (w/v) non-fat dry milk (Marvel) 
 
Stripping buffer 
Biorad, UK 
 
Protein extraction from human tissue 
Trizol reagent (Invitrogen, UK) 
 
 
 
                                                          The regulation of metabolic gene expression in Humans 
 
Paul Tisdale                                                                                                                                                  46 
 
 
2x Protein sample loading buffer 
1 M Tris (pH 6.8) 
20% (v/v) Glycerol 
4% (w/v) SDS 
100 mM DTT 
Bromophenolblue (0.01% w/v) 
 
Protein solubilisation buffer 
9M Urea 
50 mM Tris 
4% SDS 
 
Protein quantification 
Protein concentration was determined using the BCA Protein Assay Kit (Pierce, 
Rockford, IL). 
 
2.4.2 SDS-PAGE 
The separating gels were mixed as described in 2.4.1. The separating gel was 
then cast in a Bio-Rad (Hercules, CA) miniature slab gel apparatus (Mini-Protean) and 
overlaid with water-saturated butanol and allowed to polymerise fully for 30 minutes. 
After the gel had set, the butanol was removed and the gel surface rinsed with distilled 
water. 3M filter paper was used to remove any excess water. The stacking gel was 
mixed and then poured on-top of the separating gel, after which the comb was 
inserted between the plates. A further 30 minutes were allowed for polymerisation of 
the stacking gel. 50 µg of protein was mixed with 2x protein loading buffer to a total 
volume of 50 µL and then boiled for 4 minutes. The protein samples were then loaded 
into the wells of the stacking gel, with 10 µL of SeeBlue® Plus2 Pre-stained Standard 
(Invitrogen) molecular weight markers loaded at either end of the gel. The proteins 
were separated using the Bio-Rad Mini-Protean tanks filled with SDS-PAGE running 
buffer. The samples were run at 40mA for 120 minutes. 
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2.4.3 Electrotransfer  
The samples were transferred to Hydrophobic polyvinylidene difluoride 
(PVDF) membrane (GE Healthcare) (pre-soaked in 100% methanol for 15 seconds 
and then distilled water for 2 minutes). 3M filter paper and sponges were pre-soaked 
in transfer buffer. Electrotransfer was carried out in the Bio-Rad mini-protean, with ice 
filled inserts at 200 mA for 120 minutes. Protein bands were visualised using Ponceau 
S and subsequently destained by rinsing with distilled water. Non-specific protein 
binding was reduced by incubating the membrane in 5% blocking buffer on a shaker 
for 1 hr at room temperature. Primary antibodies were diluted in 1% blocking buffer, 
and then applied to the membrane and incubated overnight at 4°C on a roller. After 
the incubation was completed, the membrane was washed with 2 x 10 minute washes 
in TBS-T and 2 X 10 minute washes in 1% blocking buffer. The membrane was then 
incubated with horseradish peroxidise-conjugated (HRP) secondary antibody diluted 
at a 1:2000 ratio with 1% blocking buffer for 1 hr at room temperature. The membrane 
was then washed for 5 x 10 minutes in TBS-T, and rinsed with distilled water. The 
antigen:antibody complexes were then visualised by soaking the membrane with 
HLWKHU (&/ RU (&/ 3OXV *( KHDOWhcare), and placing it into a cassette and 
exposing it to Amersham Hyperfilm ECL (GE Healthcare). Band intensities were 
quantified by optical densitometry using Bio-rad, Quantity One software (Bio-Rad, 
Hercules, CA). 
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Table 2.4.1 List of antibodies 
 
Protein Primary  
Antibody 
Secondary antibody Tissue Amount of 
protein loaded 
per well  (µg) 
Į$FWLQ Rabbit  anti- Į$FWLQ
antibody. Diluted at 
1:2000 with 1% 
blocking buffer. 
(Sigma-Aldrich® 
#A2066) 
Swine polyclonal anti-
rabbit Ig. Conjugated 
with HRP. Diluted at 
1:2000 with 1% 
blocking buffer. (Dako 
#P0217) 
Skeletal 
muscle 
50 
Akt Rabbit polyclonal 
antibody. Anti Akt. 
Diluted at 1:1000 with 
1% blocking buffer. 
(Cell signalling 
TECHNOLOGY® 
#9272) 
Swine polyclonal anti-
rabbit Ig. Conjugated 
with HRP. Diluted at 
1:2000 with 1% 
blocking buffer. (Dako 
#P0217) 
Skeletal 
muscle 
50 
Phospho-Akt Mouse monoclonal 
IgG2b antibody. Anti-
phospho(Ser473) Akt. 
Diluted at 1:1000 with 
1% blocking buffer. 
(Cell signalling 
TECHNOLOGY® 
#4051) 
Goat polyclonal anti-
mouse Ig. Conjugated 
with HRP. Diluted at 
1:2000 with 1% 
blocking buffer. (Dako 
#P0447) 
Skeletal 
muscle 
50 
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Chapter 3 
 
Fat oxidising capacity influences gene 
expression changes during 10-week low-
fat or high-fat low energy diets in obese 
subjects 
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3.0 Fat oxidising capacity influences gene expression changes during 10-week 
low-fat or high-fat low energy diets in obese subjects 
3.1 Introduction 
Metabolic disorders such as obesity, type-2 diabetes and atherosclerosis have 
become much more prevalent in the global population during recent decades. As a 
result there has been extensive research into how various diet regimes can influence 
weight loss in obese individuals (McManus et al., 2001; Astrup et al., 2002; Schoeller 
& Buchholz, 2005), and yet whilst there is widespread agreement between clinicians 
and researchers that reduced energy intake is beneficial in reducing body-mass index 
(BMI) (Labib, 2003) there remains considerable debate as to what constitutes the 
most effective and safe dietary composition, including among other aspects the ratio 
of carbohydrate to fat (Acheson, 2010). Both genes and the environment influence 
metabolic disorders, such as obesity. Differences between individuals at the 
transcriptomic level, most likely as a result of interaction between the genes and the 
environmental influences are increasingly being recognised as key elements in 
maintaining energy balance. Therefore further investigation, into the transcripts where 
these effects are produced, is warranted.  
Hypo-energetic diets are known to influence the transcription of metabolic 
genes. Previous studies using subjects from the NUGENOB trial (3) have examined 
how different diets affected changes in gene expression (Petersen et al., 2005; 
Viguerie et al., 2005; Jocken et al., 2007; Capel et al., 2008; Corpeleijn et al., 2009), 
but none looked at this within the context of fat oxidising capacity. The differences in 
fat oxidation rates between individuals may be an important factor in determining 
weight-loss during energy-restricted diets of varying carbohydrate and fat content. 
Examining how fat oxidising capacity is related to variations in adipose tissue gene 
expression, and whether this might be altered by dietary composition would provide a 
more comprehensive understanding of nutrient-gene interactions, which could in turn 
relate to differences in weight loss and phenotypic characteristics. 
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Here we performed a study on obese subjects with different baseline 
postprandial fat-oxidising capacities, and different dietary composition during weight 
loss. A candidate gene approach was utilised, with transcripts chosen on a functional 
basis (some of which had been assessed in previous NUGENOB studies (Sørensen et 
al., 2006; Jocken et al., 2007)). The genes studied represented lipolysis; adipose 
tissue triglyceride lipase (ATGL) and hormone sensitive lipase (HSL), lipogenesis; 
sterol-regulatory-element-binding protein-1c (SREBP-1c), fatty acid oxidation; 
medium-chain acyl-coenzymeA dehydrogenase (MCAD), energy expenditure; 
uncoupling protein-2 (UCP2) and glucose regulation/fatty acid catabolism; adiponectin 
(apM1). Our analysis utilised Real-time quantitative PCR (RT-qPCR), combined with a 
general linear model univariate analysis to see how differences in baseline fat-
oxidising capacity between obese individuals might reflect disparities in adipose tissue 
gene expression, weight loss and other metabolic parameters when consuming low 
energy diets of varying fat content. 
3.2 Materials and methods 
Study protocol and selection of individuals 
771 obese Caucasian Europeans (579 women) (age 20- \U %0,  
kg/m2) participated in the NUGENOB study, funded by the European Union, which is 
described by Petersen et al. (Petersen et al., 2005). Subjects in this study were 
randomly assigned to either a high-fat, low carbohydrate (HF) or low-fat, high 
carbohydrate (LF), 10-week hypoenergetic diet (600 kcal less than their estimated 
daily requirement). The diet contained 40±45% or 20±25% fat, and 40±45% or 60±
65% carbohydrate in the HF and LF diets respectively, with the remainder being 
derived from protein.  
For the purposes of this study, 200 individuals were drawn from an original 
group of 648 individuals who completed the diet. They were chosen on the basis of 
their respiratory quotient (RQ) after a high-fat test meal during the pre-weight loss 
clinical evaluation. The postprandial fat oxidation data (iAUC) was used to rank them 
into two distinct and non-overlapping groups, with the top 100 referred to as the high 
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(HX) and the bottom 100 the low (LX) ±fat oxidising groups, respectively. The subjects 
were then divided into two further groups; those on HF diet and those on LF diet. This 
gave four groups (n=50 in each); high postprandial fat oxidisers on a high-fat diet 
(HXHF), high postprandial fat oxidisers on a low-fat diet (HXLF), low postprandial fat 
oxidisers on a high-fat diet (LXHF), and low postprandial fat oxidisers on a low-fat diet 
(LXLF). Half of the subjects in each fat ox/diet group were then randomly assigned to 
either a preliminary study (see below), or to the main/present experiment. 
 
Figure 3.2.1 Weight loss during the 10-week diets. Mean values are shown in each histogram, 
GLVSOD\LQJǻPDVVDQGǻIDWPDVV)0(UURUEDUVDUH6( HX, high fat oxidising; HF, high-fat 
diet; LX, low fat oxidising; LF, low-fat diet. 
 
Preliminary analysis 
A preliminary (unpublished) study with 100 subjects (25 in each of the 4 
groups), also drawn from the NUGENOB cohort, using identical criteria to the present 
investigation, had revealed that SREBP-1c was significantly down regulated post-diet 
in HXLF, but there were no other changes in gene expression per se during weight 
loss. However, statistical analysis had shown associations between the expression of 
SREBP-1c and both FFA and HOMA-IR, and between HSL and energy intake, while 
ATGL expression was affected by changes in HOMA-IR.  
The present study describes the use of the second set of individuals (without 
re-use of the first set) to examine the potential relationships between phenotypic 
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(metabolic) characteristics and adipose tissue gene expression changes during weight 
loss in which we refined our experimental techniques by using improved reagents, 
adjusted dilutions, triplicate RT reactions and a more sensitive RT-qPCR machine (as 
described in the methods below), to investigate these relationships in the remaining 
subjects.  
Anthropometry and metabolic rate 
Body mass was measured using calibrated scales. Waist circumference was 
measured with the participant wearing only non-restrictive underwear. Body height 
was measured using a calibrated stadiometer. Fat mass and fat-free mass were 
assessed by multifrequency bioimpedance (Bodystat®; QuadScan 4000, Isle of Man, 
British Isles). Resting metabolic rate and substrate oxidation were measured via a 
ventilated hood system (Petersen et al., 2005; Blaak et al., 2006). 
Biochemical analyses 
Venous blood samples were drawn after an overnight fast of 12 h, following a 
3-day period when subjects had been instructed to avoid excessive physical activity or 
alcohol consumption. Subjects rested in the supine position for 15 min prior to the 
procedure. Blood metabolites were assayed using techniques previously described 
(Petersen et al., 2005; Viguerie et al., 2005). 
 
RNA isolation 
After an overnight fast adipose tissue biopsies were taken from subcutaneous 
abdominal fat (~1 g), both before and after the dietary intervention (Petersen et al., 
2005). The adipose tissue specimens were stored in RNA Later solution, at -80°C. 
RNA was extracted using the RNeasy total RNA Mini kit (Qiagen, Courtaboeuf, 
France) at the INSERM laboratory in Toulouse. The quality of the RNA was assayed 
using a 2100 Bioanalyser (Agilent Technologies, Massy, France). 
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mRNA quantification by Real Time ± Quantitative PCR (RT-qPCR) 
cDNA was synthesized from 1µg of RNA (after DNase treatment), using 
Superscript III Supermix for qRT-PCR (Invitrogen) in accordance with the protocol; the 
reaction was carried out on a GeneAmp PCR System 9700. Probes and primers for 
TaqMan® RT-qPCR were designed using Primer Express V2.0 software (Applied 
Biosystems, UK) and manufactured by MWG (Germany). The reaction was carried out 
in a 96-well Micro-amp plate, utilising both an ABI Prism 7700 Sequence Detection 
System and an ABI StepOne Plus (Applied Biosystems, UK). Probes and primers 
were used at a final concentration of 10µM in a reaction volume of 25µL, containing 
5µL of cDNA. Assays were performed in triplicate with the average threshold cycle 
(Ct) values normalised using 18S. The Ct values for 18S did not change significantly 
between time-points, nor was there any bias between machines. The slope of the 
standard curve was maintained between -3.1 and -3.6.  
 
Statistical Analysis 
Statistical analyses were performed using SPSS V. 15 (SPSS, Chicago, IL). 
Due to missing samples only 89 subjects were assessed. Changes in phenotypic 
SDUDPHWHUVDQGP51$H[SUHVVLRQ OHYHOVZHUHFRPSDUHGXVLQJDSDLUHG6WXGHQW¶V t-
test and ANOVA. General linear model univariate analysis was used to study the 
effect of changes in phenotypic parameters on gene expression, for each of the 
dietary/fat-oxidising groups.  Values given are means ± S.D. 
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3.3 Results 
Phenotypic measurements 
All groups showed a significant reduction in body weight; HXHF 6.08 ± 3.33 
kg (n=19), HXLF 5.32 ± 2.96 kg (n=23), LXHF 6.69 ± 3.03 kg (n=27) and LXLF 5.29 ± 
2.75 kg (n=20), with no significant difference between groups (Figure 3.2.1).  This 
mass was mainly lost from body fat (HXHF 4.83 ± 2.42 kg, HXLF 4.03 ± 2.51 kg, 
LXHF 5.29 ± 2.39 kg and LXLF 3.65 ± 2.17 kg). Significant reductions for all groups 
were seen in fat-free mass, waist circumference, energy intake and leptin 
concentrations. Serum insulin concentration fell over the dietary intervention period by 
2.24 ± 4.91 µU ml-1 in HXLF and 2.84 ± 3.69 µU ml-1 in LXLF, but was unchanged with 
the high-fat diets. Cortisol increased significantly in LX, and showed a trend for 
increasing in HXHF. IGF fell in HXHF (P<0.05) but was unchanged in other groups. A 
significantly lower value for HOMA-IR was observed after the dietary intervention in 
LXLF, indicating improved insulin sensitivity, but the smaller decreases in the other 
groups were not significant - although there was a trend in HFLX.  FFA showed a 
trend for decreasing in HXLF p=0.054. (Table 3.3.1) 
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                                      High postprandial fat oxidisers -1                                                                    Low postprandial fat oxidisers - 2
          High fat diet (n=19)                            Low fat diet (n=23)                     High fat diet (n=27)                     Low fat diet (n=20)
Before After P Before After P Before After P Before After P
Weight (kg) 103.52 ± 25.50 97.43 ± 27.69 <0.001 96.76 ± 12.51 91.44 ± 13.25 <0.001 98.08 ± 17.25 91.40 ± 17.06 <0.001 95.61 ± 12.83 90.33 ± 12.51 <0.001
Waist (cm) 106.6 ± 17.35 100.03 ± 29.83 <0.001 100.70 ± 10.21 91.44 ± 13.25 <0.001 103.41 ± 12.05 96.96 ± 12.15 <0.001 104.26 ± 26.83 98.34 ± 24.61 <0.001
FFM (kg) 54.37 ± 6.79 53.12 ± 7.12 0.003 54.07 ± 5.17 52.80 ± 5.52 0.009 54.00 ± 5.77 52.59 ± 5.66 <0.001 53.59 ± 5.19 51.98 ± 4.88 <0.001
FM (kg) 49.15 ± 20.00 44.32 ± 21.64 <0.001 42.67 ± 9.08 38.64 ± 9.38 <0.001 44.10 ± 12.73 38.81 ± 12.68 <0.001 42.00 ± 11.13 38.35 ± 10.38 <0.001
Energy Intake (kcal/day) 1806.75 ± 505.24 1479.31 ± 173.90 0.008 2010.39 ± 564.04 1504.82 ± 162.79 <0.001 1958.91 ± 628.07 1446.71 ± 285.48 <0.001 2022.68 ± 451.94 1552.17 ± 266.11 <0.001
FFA (uM) 543.03 ± 128.96 557 ± 139.08 0.667 563.59 ± 159.75 463.89 ± 155.39 0.054 500.20 ± 119.78 534.89 ± 181.30 0.303 504.48 ± 171.54 466.90 ± 138.85 0.434
Glucose (uM) 5.17 ± 0.43 5.14 ± 0.38 0.591 5.23 ± 0.62 5.13 ± 1.23 0.216 5.19 ± 0.48 5.17 ± 0.53 0.774 5.31 ± 0.50 5.22 ± 0.47 0.314
Insulin (uU/ml) 11.37 ± 7.22 10.77 ± 7.12 0.858 10.44 ± 5.97 8.10 ± 7.31 0.045 7.88 ± 4.52 7.57 ± 5.12 0.595 10.50 ± 6.62 7.66 ± 4.98 0.003
Leptin (ng/ml) 38.81 ± 14.10 25.40 ±15.76 <0.001 33.70 ± 15.54 27.49 ± 13.18 0.039 32.87 ± 14.93 22.21 ± 12.44 <0.001 36.00 ±13.93 27.00 ± 14.57 <0.001
Cortisol nM) 192.68 ± 133.77 230.22 ± 148.57 0.088 213.34 ± 125.81 207.78 ± 128.69 0.756 201.50 ± 124.58 285.62 ± 156.07 <0.001 172.20 ± 84.19 259.61 ± 140.45 <0.001
IGF (ng/ml) 19.46 ± 7.82 22.09 ± 7.84 0.024 26.62 ± 14.13 27.95 ± 12.41 0.365 22.45 ± 6.41 23.42 ± 8.30 0.333 24.53 ± 6.43 25.51 ± 10.10 0.591
HOMA-IR 2.61 ± 1.70 2.47 ± 1.65 0.843 2.54 ± 1.77 1.98 ± 2.31 0.11 1.87 ± 1.23 1.81± 1.42 0.672 2.54 ± 1.70 1.82 ± 1.22 0.005
Values are means ± S.D. FFM, fat-free mass; FM, fat-mass; FFA, free fatty-acids; IGF, insulin-like grow th factor; HOMA-IR, homeostasis model assessment -insulin resistance
Table 3.3.1 Metabolic and phenotypic measurements for high- and low-postprandial fat oxidising groups, assigned to high or low fat diets for 10 weeks. Values are mean ± S.D. FFM, fat-free mass; FM, fat-mass; FFA, free 
fatty-acids; IGF, insulin-like growth factor; HOMA-IR, homeostasis model assessment -insulin resistance.
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Changes in adipose tissue gene expression 
In this study ANOVA revealed a significant (p<0.05) time effect for all genes, 
independently of postprandial fat-oxidation rates or diet group (Figure 3.3.1).  
SREBP-1c expression was unchanged in individual groups ± although there 
was a trend in LXHF (p=0.054) and LXLF (p=0.084). HSL, MCAD and ATGL were 
significantly down regulated in HXLF and LXHF. apM1 expression dropped in HXLF. 
UCP2 was reduced in HXHF and LXHF with a trend in HXLF (p=0.056) (Table 3.3.2). 
ANOVA between subjects effects showed that HSL and MCAD were significantly 
different between the LX diet groups (p<0.05). 
 
 
 
  
Figure 3.3.1 mRNA expression for metabolic genes, pre and post diet, independent of 
postprandial fat-oxidation rates or diet group. Units are A.U. according to the standard curve. 
Values are means ± S.D. SREBP-1c, sterol-regulatory-element-binding protein-1c; HSL, 
hormone sensitive lipase; apM1, adiponectin; ATGL, adipose tissue triglyceride lipase, MCAD; 
medium-chain acyl-coenzymeA dehydrogenase; UCP2, uncoupling protein-2. mRNA quantified 
using RT-qPCR.  
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                                      High postprandial fat oxidisers -1                                                                                   Low postprandial fat oxidisers - 2
           High fat diet (n=19)                              Low fat diet (n=23)                             High fat diet (n=27)                              Low fat diet (n=20)
Before After P Before After P Before After P Before After P
SREBP1c 0.698 ± 0.409 0.609 ± 0.431 0.199 1.077 ± 0.850 0.819 ± 0.625 0.109 0.899 ± 0.634 0.704 ± 0.541 0.054 1.251 ± 0.806 0.926 ± 0.550 0.084
HSL 1.037 ± 0.623 0.827 ± 0.495 0.085 1.072 ± 0.481 0.845 ± 0.323 0.007 1.061 ± 0.531 0.872 ± 0.436 0.017 1.314 ± 0.731 1.414 ± 0.912 0.540
apM1 1.139 ± 0.574 1.032 ± 0.405 0.337 1.320 ± 0.499 1.073 ± 0.353 0.017 1.205 ± 0.527 1.194 ± 0.512 0.910 1.404 ± 0.632 1.326 ± 0.585 0.593
ATGL 1.163 ± 0.626 0.937 ±  0.422 0.090 1.371 ± 0.610 1.036 ± 0.456 0.006 1.180 ± 0.680 0.973 ± 0.443 0.046 1.305 ± 0.562 1.194 ± 0.466 0.240
MCAD 1.486 ± 0.731 1.265 ± 0.740 0.176 1.398 ± 0.493 1.141 ± 0.411 0.012 1.420 ± 0.645 1.117 ± 0.425 0.018 1.659 ± 0.646 1.688 ± 1.037 0.888
UCP-2 1.513 ± 1.407 1.050 ± 0.690 0.028 1.374 ± 0.908 1.085 ± 0.560 0.056 1.556 ± 0.919 1.185 ± 0.757 0.021 1.790 ± 1.246 1.722 ± 0.876 0.713
Units are AU according to standard curve. Values are means ± S.D. SREBP-1c, sterol-regulatory-element-binding protein-1c; HSL, hormone sensitive lipase; apM1, adiponectin; ATGL, adipose tissue 
triglyceride lipase, MCAD; medium-chain acyl-coenzymeA dehydrogenase; UCP2, uncoupling protein-2. mRNA quantif ied using RT-qPCR. 
Table 3.3.2 mRNA expression quantified using RT-qPCR. SREBP-1c, sterol-regulatory-element-binding protein-1c; HSL, hormone sensitive lipase; apM1, adiponectin; ATGL, adipose
tissue triglyceride lipase; MCAD, medium-chain acyl-coenzymeA dehydrogenase; UCP-2, uncoupling protein-2.
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General linear model analysis 
General linear model analysis involved using an ANCOVA, where the effect of 
the covariate (in this case a phenotypic parameter or metabolite) is removed from the 
data-set, prior to performing an ANOVA test. This approach improves the power of the 
test by accounting for some of the variability inherent to human trials. After accounting 
for changes in phenotypic parameters or metabolites, further relationships with gene 
expression were observed.  SREBP-1c showed a significant change in expression, 
when differences in responses to plasma FFA concentrations and HOMA-IR were 
allowed for. HSL expression was associated with plasma FFA whilst apM1 was found 
to be associated with HOMA-IR (Table 3.3.3). 
 
Table 3.3.3 Covariate analysis for dietary/postprandial fat-oxidation groups. Values are A.U. 
showing mean differences between the groups. 
 
 
 
 
 
3.4 Discussion 
Low-energy diets are commonly used to reduce BMI in obese and overweight 
individuals. We have assessed the interaction between fat oxidising capacity, 
composition of a low-energy diet, and change in relevant phenotypic characteristics in 
their effects on adipose tissue gene expression. The first, preliminary study revealed 
some phenotype ± gene expression interactions, and we therefore refined our 
techniques to increase the sensitivity of our assays in the present study to see if 
differences in basic gene expression between the groups could be observed. The 
direction of change in gene expression in the first and second study was consistent in 
all transcripts. 
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The study was successful in significantly reducing body mass in both dietary 
groups. The context of fat oxidising capacity produced two distinct populations where 
gene expression was fundamentally altered, with significant reductions in four 
transcripts in HXLF and LXHF. Individually, neither fat oxidation status nor diet group 
were key determinants of gene expression. Analysis associated two of the phenotypic 
variables with the expression of three genes. The principal outcome of the study was 
the demonstration that fat oxidising capacity appears to have a dietary fat content 
dependent impact on the regulation of gene expression in adipose tissue during low-
energy diets. 
Individuals with high or low fat oxidising capacity may have developed this phenotype 
through long-term dietary preferences, inter-genomic variation ± or more likely a 
combination of these factors (Keskitalo et al., 2007; den Hoed et al., 2008).  
SREBP-1c is the master regulator of lipogenic genes, and its suppression in 
this study is small but significant (P<0.05) in the cohort as a whole. GLM analysis 
correlated SREBP-1c with FFA and HOMA-IR. Insulin induces skeletal muscle 
SREBP-1c in humans (Boonsong et al., 2007) and fasting suppresses it in rat adipose  
tissue (Gosmain et al., 2005). SREBP-1c expression also decreased ~30% in the 
adipose tissue of obese subjects post-diet (Ribot et al., 2001). Since fasting plasma 
insulin was unchanged, they proposed that reduced fat mass was responsible. 
However, Kolehmainen et al also found no link between insulin sensitivity and 
SREBP-1c expression in obese subjects (Kolehmainen et al., 2001). Therefore, it may 
be the case that in obese insulin resistant individuals, FFAs  act as the primary 
mechanism of regulation via PPARs (Pegorier et al., 2004; Jump et al., 2005a), 
whereas insulin plays a role when its signalling pathways are conserved.  
NUGENOB studies preceding this one ± albeit smaller in size, with different 
cohorts of subjects and not focussed on fat oxidation - had revealed a pronounced 
decrease in the expression of HSL and ATGL (Viguerie et al., 2005; Jocken et al., 
2007), and as a result they had suggested that there might be a co-regulatory 
pathway. Our data strongly confirm this association, seen in the group-specific 
suppression of the two lipases, with a trend in HXHF, and significant changes in HXLF 
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and LXHF. HSL and ATGL expression are suppressed by insulin, and it is possible 
that subtle improvements in insulin signalling were responsible for this (Jocken et al., 
2007)0&$'LVUHTXLUHGIRUWKHILUVWVWHSLQWKHȕ-oxidation of fatty acids; and its down 
regulation in HXLF is probably attributable to the decreased lipid handling 
requirements by the cell following energy restriction. MCAD expression in LXHF was 
similar to the other groups prior to the diet, but was significantly reduced afterwards. 
This is hard to reconcile with the requirements of the cell, and it could be that the 
phenotype is ill-DGDSWHG WR XVLQJ WKH GLHWDU\ IDW RU SHUKDSV SDUW RI D ZLGHU 33$5Ȗ
Coactivator-1a (PGC1a) - Estrogen Related Receptor (ERR) mediated response to 
underfeeding, which subsequently affects MCAD as the cell adapts to reduced energy 
intake, rather than fuel availability (Kamei et al., 2003). 
The regulation of UCP2 expression in adipose tissue is less clear. Induction 
occurs with short term fasting in both lean and obese subjects, but is not affected by 
acute insulin infusion (Millet et al., 1997). UCP2 has been shown to be suppressed in 
previous weight loss studies (Viguerie et al., 2005). However, in our study, it was more 
specifically the high fat diet groups which were affected. The suppression of UCP2 
during this long term intervention could be part of the mechanism by which lower REE 
is observed after weight loss. This is thought to be an adaptation of the human body in 
response to starvation (i.e. evolutionarily advantageous in times of famine), and, as 
Rosenbaum et al have described, this is a persistent phenotype, which may explain 
the difficulty in maintaining  post-dietary weight loss (Rosenbaum et al., 2008).  
Although FFAs are responsible for PPAR activation, and PPARs are the main 
activator of UCP induction, weight loss appears to be the determining factor.  
Adiponectin mRNA and protein expression are lower in obese individuals 
(Arita et al., 1999), contrary to what might be expected, since adiponectin is secreted 
exclusively from adipocytes (Scherer et al., 1995). However in the HXLF group, 
adiponectin was also significantly lower after the diet ± this is unusual since 
adiponectin expression typically increases with weight loss. GLM analysis associated 
adiponectin expression with HOMA-IR in all groups; this is in accordance with the 
                                                          The regulation of metabolic gene expression in Humans 
 
Paul Tisdale                                                                                                                                                  62 
 
 
observation that decreased circulating adiponectin is associated with the development 
of insulin resistance (Davis & Scherer, 2008).  
The vast majority of significant changes in gene expression are seen in the 
HXLF and LXHF groups, this is most likely due to a greater need for the cell to adapt 
to the changes in lipid availability, transport and oxidation, because of the initial 
phenotype being mismatched with the subsequent dietary fat compositions. In the 
case of HXLF, a reduced requirement for postprandial fat oxidation during the low fat 
diet, is reflected in the downregulation of gene expression. This may support a 
hypothesis that the HX phenotype results from long-term habitual high fat 
consumption. LXHF may have been unable to utilise the extra dietary fat, and have 
therefore reduced energy expenditure, alongside candidate gene expression. 
Although fat oxidation groups did reveal important differences in the changes in gene 
expression, as described above, these were part of an adaptation to the diet. Changes 
in gene expression were not a key determinant of BMI reduction during the low-energy 
diet; with reduced energy intake exerting fundamental control of metabolic gene 
expression. 
The differences observed in the transcriptome may have been stabilised over 
many years by their exposure to particular diets. Transcriptional pathway analysis and 
integration with metabolomic data would be the next step in providing a 
comprehensive assessment of which factors in metabolic gene expression are 
responsible for fat oxidation rates, and subsequent weight loss during energy 
restriction.  Future studies should also include a post-diet postprandial fat oxidation 
test to assess whether there are any changes in fat oxidising capacity during these 
diets. 
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Postprandial Fat Oxidising Capacity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          The regulation of metabolic gene expression in Humans 
 
Paul Tisdale                                                                                                                                                  64 
 
 
4.0 Transcriptional Profiling of Adipose Tissue in Obese Subjects with High- or 
Low-Postprandial Fat Oxidising Capacity 
 
4.1 Introduction 
Adipose tissue, originally considered to be metabolically inert, is now 
recognised as an important regulator of energy balance. It exerts its actions via 
adipokines and also through its energy storage and mobilisation potential (Sethi & 
Vidal-Puig, 2007). The ability to store or utilise dietary fat varies between individuals, 
but there have only been cursory investigations into how gene expression in adipose 
tissue is affected by whole-body fat oxidation rates (and vice-versa). Rising obesity 
rates are a concern for industrialised nations, and challenge to healthcare provision. In 
obese individuals, adipose tissue depots increase in size leading to changes in; insulin 
sensitivity, osteoarthritis, cardiovascular function, and predisposition to various 
cancers (Calle et al., 2003; Kahn et al., 2006; Van Gaal et al., 2006; Teichtahl et al., 
2008). 
Obesity is the result of a long-term, positive energy balance - caused by high 
energy intake and low energy expenditure. Studies have shown that energy 
expenditure appears to differ depending on the dietary fuel substrate consumed; a 
factor which may contribute to weight gain. Increased dietary carbohydrate intake  
leads to a rapid increase in carbohydrate oxidation rates (Blaak & Saris, 1996), with 
insulin dependent  downregulation of PDK4 (Lee et al., 2004; Tsintzas et al., 2007). 
Increasing dietary fat does not produce the same increase in fat-oxidation rates, with a 
slower and more blunted adaptation (Schrauwen et al., 1997) (Schutz et al., 1989b; 
Thomas et al., 1992). 
The relationship between fat oxidation and obesity is complicated. There is 
evidence that postprandial fat oxidation rates are lower in obese individuals (Blaak et 
al., 2006), and that fat oxidation rates in individuals susceptible to becoming obese 
may be lower; or alternatively as Astrup, Buemann et al have suggested, obesity could 
be viewed as an adaptation to a low fat-oxidation rate; whereby through becoming 
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obese, and consequently insulin resistant, this reduces carbohydrate oxidation and 
promotes higher-rates of fat oxidation (Astrup et al., 1994). It should also be noted that 
there is considerable variation in fat oxidation rates between individuals in obese 
populations, with a range that can also be observed in lean subjects. It remains 
unresolved as to how different postprandial fat oxidation rates are maintained.  
Understanding how fat oxidation in obese subjects is related to gene expression in 
adipose tissue, could provide more effective, dietary strategies, personalised 
treatment options and improved clinical outcomes for obese patients.  
In this investigation, the transcriptional profiles of adipose tissue in high- and 
low- postprandial-fat oxidising obese subjects were compared through microarray 
analysis. The main focus of this investigation has been to look at gene expression 
more generally, without bias, to see whether genes can be discriminated on the basis 
of postprandial fat oxidising capacity.  This study will also highlight areas where further 
research might be necessitated. Secondly, the genomic contribution to obesity, 
assessed via genome-wide association studies (GWAS) has yielded interesting 
targets such as FTO (Scuteri et al., 2007) and MC4R (Loos et al., 2008) which are 
most likely involved in the energy intake, but to-date fat oxidation has only been linked 
to a small number of genes (Hofker & Wijmenga, 2009).  The present study examines 
whether expression Quantitative Trait Loci (eQTLs) contribute to the high- and low-
postprandial fat oxidising phenotypes, and to investigate any potential genetic 
component to changes observed in the transcriptome.  
 
4.2 Materials and methods 
Subjects and study protocol 
771 Caucasian Europeans (579 pre-menopausal women) all of whom were 
obese (age 20- \U %0,   NJP2) , along with 119 lean control subjects, 
participated in the NUGENOB study, funded by the European Union, which is 
described by Petersen et al. (Petersen et al., 2005). The subjects for the present study 
(all female; non-diabetic) were selected from this population, on the basis of their 
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respiratory quotient (RQ) after a high-fat test meal. The test meal consisted of double 
cream (40g fat/100g, with butter used to standardise the fat percentage in 3 centres). 
Subjects were required to consume the meal within 10 minutes. The fat oxidation data 
was used to rank subjects, with the top and bottom 100 subjects referred to as the 
high (HX) and low (LX) ±postprandial fat-oxidising groups, respectively. Selection was 
made at random from these categories to form two distinct and non-overlapping 
groups; HX, n=17; LX, n=18 (Figure 4.2.1). All subjects were matched for HOMA-IR, 
body mass and composition. 
 
Figure 4.2.1 Postprandial fat oxidation rates (iAUC) for HX and LX groups, relative to lean 
control subjects. Bars represent means ± S.E.M. *P<0.001. 
 
Biochemical analyses 
Venous blood samples were drawn after an overnight fast of 12 h, following a 
3-day period when subjects had been instructed to avoid excessive physical activity or 
alcohol consumption. Subjects rested in the supine position for 15 min prior to the 
procedure. Blood metabolites were assayed using techniques previously 
described.(Petersen et al., 2005; Viguerie et al., 2005) 
 
RNA isolation 
Adipose tissue biopsies were taken from subcutaneous abdominal fat (~1 g). 
The adipose tissue specimens were stored in RNA Later solution, at -80°C. RNA was 
extracted using the RNeasy total RNA Mini kit (Qiagen, Courtaboeuf, France) at the 
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INSERM laboratory in Toulouse. The quality of the RNA was assayed using a 2100 
Bioanalyser (Agilent Technologies, Massy, France). 
 
Gene expression 
ȝJRI51$ZDVVXEMHFWHGWRULERVRPDO51$UHGXFWLRQXVLQJWKH5LER0LQXV
7UDQVFULSWRPH,VRODWLRQNLW +XPDQ0RXVH ,QYLWURJHQDORQJZLWK WKH0DJQD6HS
magnetic particle separator (Invitrogen), prior to cDNA synthesis. After this, the 
Affymetrix GeneChip® Whole Transcript (WT) Sense Target Sense Target labeling 
assay as described in the protocol. The ssDNA was then hybridised to Affymetrix 
GeneChip® Human Exon 1.0ST arrays, and quality control checks were performed 
using Affymetrix Expression Console software. 
 
mRNA quantification by Real Time ± Quantitative PCR (RT-qPCR) 
cDNA was synthesized from 1µg of RNA (after DNase treatment), using 
Superscript III Supermix for qRT-PCR (Invitrogen) in accordance with the protocol; the 
reaction was carried out on a GeneAmp PCR System 9700. Probes and primers for 
TaqMan® RT-qPCR were designed using Primer Express V2.0 software (Applied 
Biosystems, UK) and manufactured by MWG (Germany). The reaction was carried out 
in a 96-well Micro-amp plate, utilising both an ABI Prism 7700 Sequence Detection 
System and an ABI StepOne Plus (Applied Biosystems, UK). Probes and primers 
were used at a final concentration of 10µM in a reaction volume of 25µL, containing 
5µL of cDNA. Assays were performed in triplicate with the average threshold cycle 
(Ct) values normalised using either RPLP0 or 18S. The Ct values for RPLP0 and 18S 
did not change significantly between time-points, nor was there any bias between 
machines. The slope of the standard curve was maintained between -3.1 and -3.6.  
 
Genotyping 
Illumina Sentrix® HumanHap300 BeadChips (Illumina, San Diego, CA) were 
used for high-throughput SNP genotyping, which was carried out at Integragen (Evry, 
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France) Baseline blood samples were used for the extraction of DNA from buffy coat, 
carried out at the Steno Diabetes Centre in Copenhagen.  
 
 
Data analysis 
Affymetrix HuEx 1.0ST arrays were analysed using GeneSpring GX11. 
Normalisation was performed using the RMA16 summarization algorithm. Transcripts 
with a p-YDOXHDIWHU%HQMDPLQL- Hochberg multiple testing correction and a fold-
FKDQJHZHUHFRQVLGHUHGERWKVWDWLVWLFDOO\DQGELROogically significant. A Euclidean 
distance metric was used to define co-expression of transcripts. Alternatively spliced 
WUDQVFULSWV ZHUH GHWHFWHG E\ '$%* S DSSOLFDWLRQ RI D VSOLFLQJ $129$
SDQGDVSOLFLQJLQGH[WKUHVKROGRI§IROGdifference). PLINK (Purcell et 
al., 2007) was used for the analysis of HumanHap300 BeadChip SNP data, using the 
options; missing rate per person (mind), 0.05; missing rate per SNP (geno), 0.05; 
minor allele frequency (maf)  0.02, Hardy-Weinberg equilibrium cut-off P=0.001, to 
determine whether any SNPs were associated with the postprandial fat oxidizing 
capacity, or gene expression. 817 genes with a fold-FKDQJHZHUHXVHGIRUH47/
analysis. The genomic inflation factor was used to correct for batch effects and to 
assess genome wide significance, the threshold of which was 10-8. Geographical 
structures within the data (Figure 4.3.5) were accounted for, by allocating centre 
numbers as a covariate. Linkage disequilibrium (LD) blocks were defined using the 
Gabriel confidence rule in Haploview (Barrett et al., 2005) and the CEU population in 
HapMap. Ingenuity Pathway Analysis v11 (Ingenuity Systems, CA) was used to find 
relationships between differentially expressed genes. GLM covariate analysis of 
metabolite-gene expression relationships was performed using SPSS V. 15 (SPSS, 
Chicago, IL). 
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4.3 Results 
 
Figure 4.3.1 Principal component analysis (PCA) plot showing the distribution of subjects along 
3 eigenvectors.  
 
Gene expression 
Principal component analysis (PCA) of global gene expression profiles 
revealed two distinct populations based on postprandial fat oxidation group (Figure 
4.3.1), with eigenvalues of X =56.95, Y=23.96, Z=10.87.  Out of a total 15715 
transcripts with detectable level of expression, 179 (p<0.05) and 112 (p<0.001) were 
expressed with a folGFKDQJH$SSHQGL[,) 
RT-QPCR was used to validate changes in mRNA expression ±relative to HX 
± for; FASN (1.47), GLUT4 (1.59), RXRA (1.44) & SREBP1c (2.25) (Figure 4.3.2). 
One other transcript ± ADRA2A could not be validated due to a large S.E.M, although 
directional concordance was observed. Of the 179 transcripts exported for analysis in 
IPA, any connection between two or more entities was retained (self-regulatory motifs 
were therefore not included) (Figure 4.3.3).  
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Figure 4.3.2 mRNA expression for FASN, GLUT4, RXRA and SREBP1c. Values are mean ± 
S.E. *P<0.05. 
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Figure 4.3.3 Pathway analysis using IPA v11. Connect rule; using Human, Rat and Mouse 
data. Solid lines are direct relationships, dashed lines are indirect relationships. mRNA 
expression is shown using green and red. Green indicates higher expression in LX. All 
transcripts shown had a fold-change  >1.3, and  P<0.05. 
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Table 4.3.1 Co-expression of key metabolic transcripts. Values calculated using an Euclidean 
distance metric. 
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Alternative Splicing 
402 transcripts showed alternative splicing including; SREBF1, ADRB1, ATGL 
(PNPLA2) and PNPLA3 (Figure 4.3.4).  RT-qPCR validation of SREBF1 showed that 
there was no difference between the abundance of the -1a splice variant between 
groups, but that -1c was significantly more abundant in LX than in HX( P<0.05). 
 
Figure 4.3.4 Exon specific (each shape is one exon) mRNA expression for; A, SREBF1; B, 
ADRB1; C, PNPLA2 (ATGL); D, PNPLA3 (ADPN).   
 
eQTL assessment 
Out of the 817 transcripts assessed for eQTL status, 28 (35 SNPs) were 
found to have statistically significant values after genomic control was applied.  4 
SNPs were located on the same chromosome - although none were cis-acting (within 
1Mb of the transcript). 14 trans-acting SNPs lay within the coding regions of other 
transcripts or at splice junctions (Appendix I). For example, rs861826, which was 
associated with the expression of Early Endosome Antigen-1 (EEA1) was located 
within the LD block for both a non-synonymous-coding and Splice-site SNP (Appendix 
I). 
HX    LX 
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Figure 4.3.5 PCA plot showing the geographic distribution of SNP data for centres involved in 
the NUGENOB study. Image courtesy of Tune Pers, CBS, Denmark.  
 
4.4 Discussion 
These data suggest a central role for adipose tissue GLUT4, FASN, AQP7, 
and the transcriptional regulators SREBP1c and RXR in the maintenance of 
postprandial fat-oxidation phenotypes. Low postprandial fat-oxidisers may also have 
improved lipid storage and mobilisation, which results from their decreased use of 
FFAs as a fuel substrate. 
GLUT4 is the insulin regulated transporter of glucose, and its higher 
expression in low fat oxidising subjects, along with other associated entities (Figure 
4.3.3) is indicative of an increased potential for glucose uptake into adipocytes. 
However, GLUT4 is not differentially expressed in isolation. The transcriptional 
regulators, RXRA and SREBF1 are both upregulated in the LX group, along with their 
targets; FASN, ATGL, AQP7 and ALDOC. RXRA regulates the expression of 
SREBP1c (Kamei et al., 2008), and both of these transcription factors are responsible 
for the lipogenic program in adipose tissue (Pegorier et al., 2004). The contribution of 
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de novo lipogenesis to lipid storage remains controversial (Chascione et al., 1987; 
Diraison et al., 2003), but expression of FASN is tightly correlated with lipid synthesis 
rates in adipose tissue (Wang et al., 2004). These results indicate that low 
postprandial fat-oxidisers, have better control over the storage and mobilisation of 
dietary lipids. If the ability to control TAG lipolysis more effectively is the outcome of 
these changes in gene expression, then increased AQP7 would allow the export of 
glycerol to be used as a fuel substrate (Maeda et al., 2009).  The purpose of the 
increased GLUT4 expression could be to import glucose to regenerate glycerol, 
required for the storage of FFAs as TAGs as glycerol released during lipolysis cannot 
be reutilised in TG synthesis.  GLUT4 expression was highly co-expressed with FASN 
(Table 4.3.1); almost certainly induced via RXRA. 
The cause of these differences in gene expression could be that FFA 
metabolism in LX muscle and other peripheral tissues is impaired in some way, which 
therefore forces WAT to store the lipids, and it does this by altering metabolic gene 
expression. This would concur with the idea that high fat oxidisers rapidly metabolise 
dietary fat after consumption. However, subjects in this study were matched for 
HOMA-IR, and were not insulin resistant; as a result it cannot be suggested, in this 
study, that any impairment in fat oxidation is the result of insulin resistance in muscle. 
Other transcripts which were differentially expressed include those familiar to 
vascular endothelial cells; VCAM1, ANGPT1, IFNAR1 and IFI16, which may be 
consequential to the vascular structure of WAT, perhaps by reducing blood flow to the 
tissue, and subsequently the availability of nutrients ± which could contribute to the 
changes observed in lipolytic genes. However these transcripts are also involved in 
inflammatory responses and may be a result of differences in inflammation between 
the two groups, a factor which is linked to the development of insulin resistance 
(Ferrante, 2007; Ingelsson et al., 2008). 
 The large number of alternatively spliced transcripts reveals the 
potential importance of splicing in determining the difference between the postprandial 
fat oxidising phenotypes. Alternative splicing events in SREBF1 can be ascribed to 
differences in the lipid handling requirements of the cell. The higher levels of SREBP-
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1c  mRNA observed in LX (p<0.05) would be anticipated in response to increased 
storage of FFAs (Osborne, 2000) . Varying differences in the abundance of SREBP1c  
& -1a have been reported depending on the organism and tissue type, with -1c being 
3 times more abundant than -1a in adipose tissue (Shimomura et al., 1997).  In this 
study, the expression of -1a was approximately equal in the LX and HX groups 
(Appendix I). Differences in the expression of SREBF1 can therefore be attributed to -
1c.  
PNPLA2 (ATGL) and PNPLA3 (ADPN) were both alternatively spliced 
between the two groups, with splicing events occurring in the Acyl_Trfase/lysoPlipase 
superfamily domains, which could affect catalytic efficiency (Figure 4.3.4)(Jenkins et 
al., 2004; Kim et al., 2006b). ATGL and ADPN are both lipases which have been 
linked to energy balance (Liu et al., 2004). The picture regarding these lipases is 
complicated with experimental data showing that ATGL is down regulated by insulin in 
3T3-L1 adipocytes (Kim et al., 2006a), but also decreased in the obese insulin 
resistant state (Jocken et al., 2007). Conversely, evidence suggests that ADPN is 
upregulated in (insulin sensitive) obesity, and that it may have also have a lipogenic 
role (Johansson et al., 2006). A reduction in lipolytic/lipogenic capacity, resulting from 
alternative splicing, could significantly reduce energy expenditure during weight loss 
diets, and therefore success during such programmes. 
 Alternative splicing and increased ADRB1 expression (Figures 4.3.3 & 
4.3.4) in LX could point towards an altered lipolytic response when stimulated by 
FDWHFKRODPLQHV 'HFUHDVHG H[SUHVVLRQ RI ȕ2-adrenoceptors has already been 
implicated in the development of obesity (Haffner et al., 1993; Reynisdottir et al., 
1994) with some studies associating ADRB1 polymorphisms with metabolic 
dysregulation (Lima et al., 2007). 
Since Brown Adipose Tissue (BAT), which has a high metabolic rate, is now 
recognised as being present in adult adipose tissue masses (Nedergaard et al., 2007), 
we looked for the BAT specific marker PRDM16 (Seale et al., 2008) ± which was not 
expressed, although PRDM16 has been linked to BAT depots rather than diffuse 
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brown adipocytes, which probably have a different developmental origin (Ravussin & 
Kozak, 2009). 
Integration of SNP data revealed several associations with gene expression, 
but none where the SNPs lay within the coding genes, or the surrounding LD block. 
Some of the associated SNPs lay within the coding regions of other genes, and their 
involvement may show that they are involved in the same pathways or are interacting 
through epistasis. The current understanding of the genome restricts interpretation of 
this data.  5 SNPs were associated with the expression of genes involved in GLUT4 
translocation (Appendix I), although the significance of this finding is unclear due to 
the limited knowledge of epistatic and pathway interactions. Another study from the 
NUGENOB project examined 42 SNPs in isolation using a larger number of subjects 
and associated IL-6 with postprandial fat oxidation rates, although it was reported with 
the caveat that IL6 is also released from working muscle ± which makes interpretation 
of the role in adipose difficult. They also found no association with the FTO gene, 
which was interpreted as a lack of influence of FTO on fat oxidation.  (Corpeleijn et al., 
2009). In the present study neither IL-6 or FTO were associated with eQTLs.  
Co-expression analysis of several key genes clarifies the effects of 
transcriptional regulation, with FASN and GLUT4 having very closely linked profiles 
(Table 4.3.1), which is likely due to their shared modes of induction via RXRA:LXR 
and SREBP1c  (Joseph et al., 2002b; Dalen et al., 2003). SREBF1 was also 
coexpressed with GLUT4; therefore it is possible that this synergy between two 
transcription factors (RXRA & SREBF1) drove the higher expression in LX. 
Covariate analysis (data not shown) of RXRA expression also showed an interaction 
with fasting blood glucose levels p=0.041. The physiological significance of this is 
unclear, although as previously discussed; RXRA is involved in the regulation of 
GLUT4 expression, although GLUT4 expression itself was not linked with fasting 
blood glucose (FBG) concentrations in this study. ALDOC (P=0.038) & ATGL 
(P<0.036) also presented an interaction with FBG. HSL, which is often co-expressed 
with ATGL, showed no relationship with FBG. This difference in responsiveness 
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between ATGL and HSL demonstrates the basal role that ATGL plays in lipolysis in 
adipose tissue and also its place in the glucose-fatty-acid cycle (Langin et al., 2005).  
This study has outlined differences in the transcriptional profiles of obese 
subjects with different postprandial fat-oxidising capacities. Adaptations to low 
postprandial fat-oxidation involve the use of glucose for storage and mobilisation of 
lipids, principally under the control of RXRA and SREBP1c.  Potential methods of 
increasing fat oxidation such as upregulating UCPs or modifying appetite using 
agonists for MC4R, will need to take account of differences in lipid mobilisation, and 
whether these differences in postprandial fat-oxidation have an epigenetic or genomic 
cause. 
Subsequent studies in this area should also attempt to examine the 
expression of skeletal muscle metabolic gene expression in relation to the observed 
changes in adipose tissue biology, to see whether impairment of postprandial fat 
oxidation is the cause of alterations in adipose tissue gene expression, and also 
whether decreased lipolysis might lead to an increase in IMTG storage ± potentially a 
contributing factor in peripheral insulin resistance. The sequencing of further genomes 
and methylomic analysis offer another avenue to investigate the impact of, less 
common genetic variants with large influences on energy balance, and the role of 
epigenetics in the development of these phenotypes. 
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Chapter 5 
 
Effects of high-glucose treatment on 
metabolic gene expression in Human 
primary myotubes 
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5.0 Effects of high-glucose treatment on metabolic gene expression in Human 
primary myotubes 
5.1 Introduction 
Type 2 Diabetes Mellitus (T2DM) is characterised by high fasting blood 
glucose concentrations. This situation is termed hyperglycaemia, and has a number of 
serious negative physiological effects including; retinopathy, nephropathy and 
neuropathy.   The development of hyperglycaemia (defined by the WHO as fasting 
EORRG JOXFRVH FRQFHQWUDWLRQV PPROO LV XVXDOO\ D FRQVHTXHQFH RI LQVXOLQ
resistance (WHO, 2006a).  Insulin resistance occurs when the release of normal levels 
RI LQVXOLQ IURP ȕ-cells in the pancreas fails to promote an adequate increase in 
glucose uptake from insulin-responsive cells. Since skeletal muscle is the main site of 
insulin stimulated glucose-disposal, the effects of skeletal muscle insulin resistance on 
whole-body glucose homeostasis can be severe.   
In obesity and diabetes (obesity often preceding the development of 
diabetes); ectopic fat distribution is thought to contribute to the development of 
systemic-insulin resistance.  Ectopic fat distribution in skeletal muscle is via the 
accumulation of intramyocellular triglycerides (IMTG) in response to nutrient 
oversupply ± commonly increased fat intake (Ravussin & Smith, 2002). IMTG content 
has been linked to the development of insulin resistance, but whether it is a causal 
relationship remains unclear, especially since trained athletes have high IMTG content 
in their skeletal muscle (van Loon & Goodpaster, 2006). Although IMTG accumulation 
is associated with chronically elevated blood lipid profiles; hyperglycaemia may 
contribute to the increased production of IMTG by promoting de novo lipogenesis 
(DNL) in skeletal muscle (Bandyopadhyay et al., 2006). Glucose induced insulin 
resistance has been demonstrated in several studies (Vuorinen-Markkola et al., 1992; 
Del Prato et al., 1994; Boden et al., 1996), and synthesis of IMTG in skeletal muscle, 
may link these observations. The transcriptional activation of lipogenic proteins, and 
therefore DNL, in skeletal muscle thought to be under the control of sterol-regulatory 
element binding protein-1c (SREBP-1c) and carbohydrate response element binding-
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protein (ChREBP), both having been established as the transcriptional activators of a 
number of lipogenic enzymes, most notably acetyl co-A carboxylase (ACC) and fatty 
acid synthase (FAS) (Dentin et al., 2005b). LXR may contribute to the activation of 
lipogenic gene expression, as has been demonstrated in primary myotubes using by 
modulating LXR activity (Kase et al., 2007), although more recent work has shown 
that ChREBP alone, and not LXR, induce glucose regulated genes in mouse liver 
(Denechaud et al., 2008). This action has not yet been established in skeletal muscle. 
The aims of the present study were; to establish how the expression of 
metabolic genes involved in carbohydrate oxidation and de novo lipogenesis, might be 
altered in response to hyperglycaemia ± without the influence of insulin signalling. It 
was anticipated that lipogenic gene expression such as FAS and ACC would be 
upregulated, under the control of ChREBP. This study was carried out using high-
glucose treated human primary myotubes. 45 metabolic genes including; 
transcriptional activators, cells signalling proteins, substrate transporters, lipogenic 
enzymes, and proteins catalysing glucose and fat oxidation were observed, after 
incubation in either normal ( 5mM control) or high-(18mM) glucose media for 4 and 24 
hour periods. 
 
5.2 Materials and methods 
 
Muscle biopsy 
Young (20-40 years), male non-diabetic subjects were fasted overnight, and 
rested for 30 minutes prior to muscle biopsy. Muscle biopsies were obtained from the 
vastus lateralis under local anaesthetic using percutaneous Bergstrom needles.    
 
Cell culture 
Muscle biopsy tissue was digested and the satellite cells prepared as 
described (2.3). Cells were plated into 14 gelatine-coated T25 flasks (6 control; 8 
treated), and grown until they became fully differentiated myotubes. Primary myotubes 
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were then treated with media containing either 5mM (Control) or 18mM (High) 
glucose, for 4 hours and 24 hours, before RNA extraction. 
 
RNA isolation 
Total RNA was isolated from muscle biopsies using Trizol (Invitrogen), and 
further purified using RNeasy RNA clean up columns (Qiagen). RNA concentration 
was determined using a Nanodrop ND-1000 (Thermo Fisher Scientific, Delaware, 
USA). 
 
Gene expression 
ABI StepOne+ RT-qPCR 
1 µg of RNA was reverse transcribed using Superscript III reverse 
transcriptase (Invitrogen), and quantified using an ABI StepOne Plus (Applied 
Biosystems, UK). Probes and primers were used at a final concentration of 10µM in a 
reaction volume of 25µL, containing 5µL of cDNA. Assays were performed in triplicate 
with the average threshold cycle (Ct) values normalised using RPLP0. The Ct values 
for 18S did not change significantly between time-points. The slope of the standard 
curve was maintained between -3.1 and -3.6. 
 
Taqman® Low-Density Array 
 Taqman® Low-Density Custom Array using Micro Fluidic cards (ABI Applied 
Biosystems, UK) was used for the quantification of expression of 48 key metabolic 
genes in human skeletal muscle.  Each card allowed for 8 samples to be run in 
parallel against 48 Taqman gene expression assay targets that were pre-loaded into 
each of the wells on the card.  Briefly, 50 µl of Taqman Universal PCR master mix (2x) 
(ABI Applied Biosystems, UK) was added to 250 ng RNA equivalent of cDNA into an 
eppendorf RNAse free tube.  RNAse free water was then added to make the total 
volume of the reaction mixture up to 100 µl.  The reaction mixture was then vortexed, 
centrifuged and loaded into one of the fill reservoirs of the Micro Fluidic card.  The 
cards were then centrifuged (MULTIFUGE 3 S-R, Heraeus) and run on a 7900HT Fast 
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Real-Time PCR System (ABI Applied Biosystems, UK).  The expression of 
hydroxymethylbilane synthase (HMBS) was used to normalise the data to minimize 
variations in the expression of individual housekeeping genes. Gene expression was 
measured using the 2-ǻǻCt method 
 
Statistical Analysis 
All data were analysed with 2-way ANOVA using SPSS v.16 (Chicago, IL). 
Results are presented as fold-change ± S.E.M. Statistical significance was accepted 
at P<0.05.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          The regulation of metabolic gene expression in Humans 
 
Paul Tisdale                                                                                                                                                  84 
 
 
5.3 Results 
RT-QPCR 
A preliminary study, using the same protocol as described above ± was used 
to determine whether there were changes in PDK4 expression, prior to using the low-
density custom array. Measuring only PDK4 expression using StepOne RT-qPCR, this 
study showed a significant (P<0.05) suppression of mRNA abundance at 4 hours (-
2.19-fold) in the high-glucose treated cells relative to the control. This was followed by 
a sharp and significant 7.66-fold increase at 24 hours ± which was also significantly 
higher than the control (Figure 5.3.1). 
 
 
Figure 5.3.1 PDK4 mRNA expression. Values are fold-change ± S.E.M. n=6. *P<0.05 from 
baseline. PDK4, pyruvate, dehydrogenase kinase. 
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Taqman Low-Density Array  
Table 5.3.1 Changes in metabolic gene expression, in response to 4 and 24 hours high-glucose 
treatment.   
 
Significant (P<0.05) fold-changes in gene expression between i) treatment, relative to control; 
and ii) time, relative to 4 hours. PDP2, pyruvate dehydrogenase phosphatase 2; ADFP, adipose 
differentiation-related protein/perilipin; FASN, fatty acid synthase; IRS2, insulin receptor 
substrate 2; ChREBP, carbohydrate response element binding protein, PDK4; pyruvate 
dehydrogenase kinase 4; DGKD, diacylglycerol kinase į1P0KRXUV+P0KRXUV
N24, 5mM 24 hours; H24, 18mM 24 hours. 
 
Changes in gene expression between the control and treated cells were 
limited to a suppression of PDK4 at 4 hours and the induction of ChREBP and DGKD 
at 24 hours ± no change in SREBP-1c abundance was observed. However there were 
also increases in the abundance of 5 transcripts between 4 and 24 hours in the high 
glucose treated cells, with ADFP, FASN, IRS2, CHREBP and PDK4 all being 
upregulated. There was also a 2.78-fold increase in PDP2 expression between 4 and 
24 hours in the control samples. (Table 5.3.1). 
5.4 Discussion 
These results demonstrate that ChREBP may be able to induce lipogenic 
gene expression in vitro, independently of increases in SREBP-1c mRNA abundance, 
which could contribute to raised IMTG content through de novo lipogenesis.  It was 
previously considered controversial to assume that there was any significant capacity 
for de novo lipogenesis in myocytes. However, the consensus has begun to shift in 
recent years due to in vitro studies showing that it could play a small, but important 
N4 v H4 N24 v H24 N4 v N24 H4 v H24
PDP2 2.78
ADFP 2.75
FASN 2.59
IRS2 1.72
CHREBP  +  + 
PDK4 -1.58 2.32
DGKD 2.12
Treatment Time
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role in fat balance (Aas et al., 2004).  A number of studies had previously established 
that glucose alone is capable of inducing the expression of HKII, FAS and ACC, via 
SREBP-1c, which leads to an increase in lipogenesis, and potentially IMTG 
concentrations (Guillet-Deniau et al., 2004; Meugnier et al., 2007).  
In the present study, ChREBP mRNA expression was only observed in the 
high-glucose treated cells after 24 hours (Table 5.3.1), this made the calculation of a 
fold-change value impossible, although it did confirm an effect for high-glucose 
treatment, which indicates that perhaps in the absence of insulin, only prolonged 
incubation in a high-JOXFRVH PHGLXP FDQ LQLWLDWH LWV WUDQVFULSWLRQ /;5Į LV D OLNHO\
transcriptional regulator of ChREBP in this situation, as has been described in liver 
(Cha & Repa, 2007). Clarification is stLOO UHTXLUHGDV WRZKHWKHU/;5ĮELQGVJOXFRVH
directly to activate ChREBP, but in the absence of insulin, which mediates lipogenic 
gene expression via SREBP-1c, the data in this study suggest a reliance upon 
ChREBP for the induction of lipogenic genes. SREBP-1c expression was found to be 
unchanged in this study. 
 This study also demonstrated the  induction of a ChREBP target gene, fatty 
acid synthase (FAS) (Dentin et al., 2004) between 4 and 24 hours in high-glucose 
treated cells (Table 5.3.1). Fatty-acid synthase is responsible for synthesizing long-
chain fatty acids from acetyl-CoA, malonyl-CoA and NADPH (Semenkovich, 1997). 
Oversupply of glucose, followed by an increased flux through the glycolytic pathway, 
and expansion of the TCA cycle, could increase the cytosolic concentrations of citrate. 
Citrate is a starting point for the synthesis of malonyl-&R$ZKLFK LQKLELWVȕ-oxidation 
and is also the precursor of fatty-acid synthesis, via ACC and FAS.  This sets in 
motion a process through which an increase in fatty-acyl-CoA, DG and TG 
concentrations, would lead to the accumulation of IMTG (Figure 5.4.1). This process 
would also explain the induction of adipose differentiation-related protein (ADFP) 
(Table 5.3.1), also known as perilipin, which is responsible for coating lipid droplets. Its 
increase in expression between 4 and 24 hours would help in sequestering 
intramyocellular lipids to reduce lipotoxicity (Phillips et al., 2005b). ADFPs expression 
LV XQGHU WKH FRQWURO RI 33$5Ȗ LQ DGLSRVH WLVVXH (Dalen et al., 2004), and similar 
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systems may regulate its expression in myocytes. It has also recently been 
demonstrated  that LXR agonists directly induce ADFP expression in primary 
hepatocytes, suggesting another important link between hyperglycaemia and lipid 
storage (Kotokorpi et al., 2010). ADFP is also down-regulated in the skeletal muscle of 
diabetic subjects which may be linked to the development of insulin-resistance through 
reduced lipid clearance (Phillips et al., 2005a). 
'LDF\OJO\FHURO JO\FHURO NLQDVH į '*.' ZDV VLJQLILFDQWO\ XSUHJXODWHG DW 
hours in high-glucose treated cells, compared to the 24 hour control. DGKD has been 
implicated in the development of hyperglycaemia induced insulin resistance, through 
its substrate diacylglycerol (Chibalin et al., 2008). Diacylglycerol is a precursor in the 
development of triglycerides, and prolonged increases in cellular DAG concentrations 
are associated with the accumulation of intramyocellular triglycerides, reductions in 
insulin PKC mediated signalling and insulin resistance (Timmers et al., 2008) (Itani et 
al., 2002).  DAG is also phosphorylated to produce phosphatidic acid which acts as a 
secondary messenger, in a range of metabolic pathways. DGKD is responsible for this 
phosphorylation event. DGKs are able to deplete DAG at various intracellular sites, 
and may reduce the potential for the developing insulin resistance. One study found 
that 96 hours of high-glucose (25mM) incubation downregulated  DGKD expression in 
myotubes cultured from healthy individuals (Chibalin et al., 2008). Conversely this 
study observed that 24 hours high-glucose treatment lead to a 2.12 fold induction 
(p<0.05). It could be the case that since the study by Chibalin et al used higher 
JOXFRVH FRQFHQWUDWLRQV DQG IRU D PXFK ORQJHU SHULRG WKDW D PRUH µGLDEHWLF¶
phenotype is observed in the cell, with a failure of such protective mechanisms, as 
observed in the present study.  
PDK4, which regulates the activity of the pyruvate dehydrogenase complex 
(PDC) is suppressed by insulin (Majer et al., 1998) and upregulated by glucose 
deprivation and high-fat feeding (Abbot et al., 2005) (Tsintzas et al., 2007). A number 
of pathways coordinate these changes, with the involvement of the FOXO in the 
LQVXOLQ UHVSRQVHDQG33$5Į3*&-ĮDQG (55PHGLDWLQJ WKHHIIHFWVRI IDWW\ DFLGV
(Furuyama et al., 2003) (Wende et al., 2005). In this study PDK4 was transiently 
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suppressed (-1.58 fold) in the high-glucose treated myotubes at 4 hours, which 
suggests that despite a lack of insulin stimulation/PI3K signalling, there is a 
mechanism which attempts to utilise the available carbohydrate, by increasing PDC 
flux (Mandarino et al., 1993). Conversely PDK4 expression was significantly 
upregulated at 24 hours which indicates that, a switch in fuel substrate had occurred 
or at least dependence on glucose was reduced.   Mechanisms for this induction of 
PDK4 could be via FOXO, but since there was a lack of insulin signalling in all 
treatments, under that hypothesis its expression would be expected to rise in each 
group. TherefRUH33$5ĮLQGXFWLRQRI3'.DVDQLQGLUHFWUHVXOWRILQFUHDVHGOLJDQG-
binding through lipid accumulation, is an alternative regulatory pathway. This would 
DFWDVDEUDNHRQWKHDFFXPXODWLRQRI,07*DQGLQFUHDVHGȕ-oxidation of fatty acids - 
possibly constituting a semi-IXWLOH F\FOH RI ,07* V\QWKHVLV IROORZHG E\ ȕ-oxidation, 
preventing lipotoxicity. IRS2 is involved the control of peripheral insulin sensitivity 
(Withers et al., 1998; Previs et al., 2000)DQGLW¶VXSUHgulation in high-glucose treated 
myotubes, between 4 and 24 hours, are potentially also a compensatory pathway for 
the development of insulin-resistance in high-glucose treated cells - its expression 
EHLQJUHJXODWHGE\33$5Ȗ(Smith et al., 2001). 
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Figure 5.4.1 Hypothesised routes via which prolonged excess glucose availability may cause 
insulin resistance and lipotoxicity in skeletal muscle. Excess glucose or supply, leads to 
increased production of acetyl-CoA, which is then converted into free-fatty acids by ACC. Under 
these conditions, malonyl-CoA inhibition of CPT- ZRXOG SUHYHQW ȕ-oxidation, leading to an 
expansion of the FA-CoA, triacylglycerol and diacylglycerol pool. Malonyl-CoA could also serve 
as a substrate for fatty acid synthesis worsening this problem. Two potential mechanisms to 
prevent lipotoxicity during hyperglycaemia were revealed in this study; i) sequestering DG 
through coating lipid droplets using ADFP for storage, or ii) deplete DG through DGDK activity. 
Ǻ-oxidation may also be increased latterly, but the rate of this would be balanced against the 
concentrations of malonyl-CoA.  
 
Future work should examine the global expression profiles, in vivo, to 
determine whether this hypothesis can be sustained when looking more generally at 
the networks involved, and also whether these situations can be maintained over 
longer-durations. Prospective studies, should examine IMTG synthesis directly, and 
also use a comparative approach with myotubes grown from diabetic subjects ± with 
measurements of fat oxidation and glucose uptake to establish any changes in these 
SDWKZD\V ,W¶V SRVVLEOH WKDW GLVUXSWLRQ WR WKLV SURWective system during prolonged 
hyperglycaemia could play a role in the development or maintenance of local insulin 
resistance in skeletal muscle, during T2DM. 
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In conclusion, the present study shows that 24 hours high-glucose treatment 
of primary myotubes, leads to changes in the expression of metabolic gene 
expression, associated with lipogenesis, in particular the transcription factor ChREBP. 
These changes may reflect a mechanism which promotes increasing accumulation of 
IMTG during hyperglycaemia in-vivo. However, high-glucose treatment also elicits 
responses in myotubes which may be capable of mitigating the effects of lipotoxicity, 
WKURXJK GHSOHWLRQ RI GLDF\OJO\FHURO OLSLG VWRUDJH DQG LQFUHDVHG ȕ-oxidation. 
Understanding how these pathways might be altered in obese insulin-resistant muscle 
could explain the link between IMTG and insulin resistance. 
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Chapter 6 
 
Skeletal muscle metabolic gene 
expression is not affected by 
dichloroacetate mediated modulation of 
substrate utilisation 
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6.0 Skeletal muscle metabolic gene expression is not affected by 
dichloroacetate mediated modulation of substrate utilisation 
6.1 Introduction 
The metabolic rate in human skeletal muscle is tightly regulated - with the 
control of flux through metabolic pathways being essential as cells adapt rapidly to 
fluctuations in energy intake and expenditure, and also to changes in substrate 
availability. These changes can be brought about through changes in enzyme activity, 
but often require stabilisation for longer periods. This can be accomplished through 
adaptive changes in the transcriptional activity of metabolic genes, due to interactions 
with transcription factors, which can elicit increased or decreased cellular responses to 
energetic demands.  
It has been well established that insulin regulates the activity of PDC 
(Mandarino et al., 1987) and recent studies have shown that this results from changes 
in the expression of pyruvate dehydrogenase kinase 4 (PDK4) mRNA, whereby it is 
upregulated during starvation (Pilegaard et al., 2003; Spriet et al., 2004) and 
suppressed with insulin infusion (Majer et al., 1998; Lee et al., 2004). Conversely, 
Hexokinase II (HKII) and its transcriptional regulator, Sterol-regulatory-element-
binding protein-1c (SREBP-1c), mRNA and protein expression are reduced during 
fasting (Bizeau et al., 2003; Gosmain et al., 2005) . 
Forty-eight hours starvation downregulates SREBP1c and HKII whilst PDK4 is 
upregulated ± a response which was not dependent on the phosphorylation status of 
Akt and Forkhead box 01 (FOXO1), or without changes in the expression of 
transcription factors or genes involved in fat metabolism (Tsintzas et al., 2006), which 
indicates that genes involved in carbohydrate oxidation respond rapidly and 
independently of those  in fat oxidation.  Further research indicates that elevating 
levels of circulating free fatty-acids, through infusion of intralipid and heparin, 
attenuates the insulin induced suppression of PDK4 (Tsintzas et al., 2007). These 
previous studies caused rapid alterations to metabolic gene expression; however they 
have all modified insulin signalling along with fuel availability. It has not yet been 
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assessed whether these changes to metabolic gene expression can be induced by 
simply increasing PDC flux and switching fuel use ± towards glucose oxidation ± 
without altering plasma substrate availability and insulin signalling. An improved 
understanding of how closely fuel use is coupled to the expression of metabolic 
genes; would provide a better model for many metabolic diseases, such as diabetes 
and obesity. 
DCA is an organohalide analogue of pyruvate which increases flux through 
the PDC via inhibition of PDK. Under normal conditions the PDC catalyzes the 
conversion of pyruvate to acetyl coenzyme A (CoA). PDC activity is modulated by 
reversible phosphorylation through PDK, which inactivates the PDC, and PDC 
phosphatase (PDP) which dephosphorylates PDC restoring catalytic activity 
(Stacpoole et al., 1998). PDK is activated by NADH and Acetyl CoA and inhibited by 
pyruvate and DCA. As an analogue of pyruvate, DCA binds to PDK and prevents it 
from phosphorylating PDC into its inactive form, this leaves the PDC in its switched 
µRQ¶FDWDO\WLFXQ-phosporylated active state. Administration of DCA in skeletal muscle 
at rest exhibits certain key features including; pyruvate dehydrogenase complex 
activation, increased carbohydrate oxidation, and elevation of 
acetylcarnitine.(Timmons et al., 1998; Constantin-Teodosiu et al., 1999; Knoechel et 
al., 2006). Constantin-Teodosiu et al have extensively researched the effect of DCA in 
human muscle during exercise (Constantin-Teodosiu et al., 1999) and concluded that 
the observed delay in accumulation of fatigue related metabolites, during exercise with 
DCA infusion, is due to increased availability of acetyl groups to the TCA cycle ±in the 
form of acetylcarnitine -, rather than through expansion of the Tri Carboxylic-Acid 
Cycle Intermediate (TCAI) pool itself. DCA was selected for use in this study because 
of its capacity to increase PDC flux and glucose oxidation without changing substrate 
availability and glycolytic flux. 
The aim of this study was to assess whether alterations in metabolic gene 
expression, in human skeletal muscle, could be produced by changes in fuel use and 
not plasma substrate availability. Through solely altering fuel selection, and increasing 
PDC flux, it was hypothesized that there would be no changes in metabolic gene 
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expression resulting from a short term (90 minutes - to limit the effects of fasting) DCA 
infusion.  
6.2 Materials and methods 
Subjects 
Ten healthy non-obese men were recruited. Mean age was 29.2 ± 1.56 years 
with a body mass index (BMI) of 24.7 ± 0.85kgm-2. They attended the laboratory on 
two occasions after a 12 hour overnight fast, having abstained from strenuous 
exercise and alcohol intake for the previous 24 hours. Subjects with any condition, 
disease or drug that would affect metabolic rates were excluded from these studies. 
All procedures carried out in this study were performed according to the Declaration of 
Helsinki and approved by the University of Nottingham Medical School Ethics 
Committee, with informed written consent obtained from all subjects. 
 
Study protocol 
Subjects attended the laboratory on 2 occasions for a 90 minute infusion, in 
random order, after a 12 hour overnight fast. After a 60 minute basal period an 
infusion of sodium dichloroacetate (DCA) was given at a rate of 50 mg kg-1 min-1 over 
90 minutes. The infusate was prepared by the sterile supplies unit at the University 
Hospital Nottingham Pharmacy. On a separate occasion, subjects received a 0.9% 
saline infusion which served a control (CON). Each study visit was at least two weeks 
apart. Studies took place in a temperature-controlled room (23°C) with subjects 
wearing a T-shirt and shorts only. On arrival, subjects rested supine for 30 minutes 
whilst two intravenous cannulae were inserted, the first into the antecubital vein for the 
infusion, the second retrogradely into a vein on the dorsal aspect of the hand for blood 
sampling. A slow running infusion of 0.9% saline was used to keep this patent. The 
hand was placed in a warm air box (50-55°C) to obtain arterialised blood samples 
(McGuire et al., 1976).  
 
Muscle biopsies 
                                                          The regulation of metabolic gene expression in Humans 
 
Paul Tisdale                                                                                                                                                  95 
 
 
Muscle biopsies were taken immediately before the start of the infusions, 30 
minutes into the infusion and 3 hours from the baseline (90 minutes post-infusion ± to 
allow for changes in transcription factor localisation to occur). Muscle samples were 
obtained from the vastus lateralis under local anaesthetic using percutaneous 
Bergstrom needles (Bergstrom, 1975). The samples were immediately frozen and 
stored in liquid nitrogen for subsequent analysis of gene expression. 
 
Indirect calorimetry 
Respiratory exchange was measured during the last 30 minutes of the basal 
period, the first 30 minutes of the infusion and the last 30 minutes of the study period. 
Continuous recordings of oxygen consumption and carbon dioxide production were 
made using a computerised flow-through canopy gas analyser system using either a 
SensorMedics 2900 metabolic cart (SensorMedics, CA) or Europa GEM (gas 
exchange monitor, Europa Scientific Ltd, UK) (Frayn, 1983; Nicholson et al., 1996). 
The same analyser was used for each subject. Calculation of resting energy 
expenditure (REE) and estimation of carbohydrate and lipid oxidation rates were made 
using indirect calorimetry (Frayn, 1983). 
 
Analytical procedures 
Blood samples were drawn during the baseline period and every 30 minutes 
during the study period (up to 3 hours) and used for the measurement of intermediary 
metabolites and hormones. Plasma and serum were separated using low-speed 
centrifugation (15 min at 3000 g). Plasma free fatty-acid (FFA) concentrations were 
measured by an enzymatic method (NEFA C, WAKO-Chemicals GmbH, Germany,). 
Serum insulin concentrations were measured using a radioimmunoassay (Coat-a 
Count; Diagnostic Products Corporation) and whole blood glucose and lactate 
concentrations were analysed using a Yellow Springs analyser (YSI 2300 Stat plus; 
Yellow Springs Industries, OH, USA). 
 
RNA preparation and quantification 
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Total RNA was isolated from muscle biopsies using Trizol (Invitrogen), and 
further purified using RNeasy RNA clean up columns (Qiagen). RNA concentration 
was determined using a Nanodrop ND-1000 (Thermo Fisher Scientific, Delaware, 
USA). 
RNA was reverse transcribed using Superscript III reverse transcriptase 
(Invitrogen). The mRNA levels were quantified using Real-time quantitative reverse 
transcriptase ± polymerase chain reaction (RT-qPCR), performed in an ABI Prism 
7000 sequence detection system. Primer and FAM/TAMRA labelled probes were 
designed using Primer Express® Software v2.0 (Applied Biosystems); sequences are 
shown in Supplemental Table 2.2.1. The standard curve method was used; with 
acceptable units for the slope, between -3.2 and -3.6 and R2 values of more than 90%. 
The probes and primers for the non-variant reference gene, Hydroxymethylbilane 
synthase (HMBS), were purchased from Applied Biosystems. All values were 
normalised by dividing the target gene by HMBS. 
 
Protein analysis by immunoblotting 
The protein lysates were extracted from the organic phase using Trizol 
(Invitrogen) and then the pellets were redissolved in 7M urea, 100mM DTT, 50mM Tris 
and 4%SDS. Protein was quantified using the BCA Protein Assay Kit (Pierce, 
Rockford, IL). Protein (50µg) was subjected to SDS-PAGE in a Bio-Rad (Hercules, 
CA) miniature slab gel apparatus (Mini-Protean). Electrotransfer of the proteins from 
gel to PVDF was performed for 120 minutes at 200 mA. Non-specific protein binding 
was reduced by blocking the PVDF in blocking buffer (5 % non-fat dry milk, 10 mmol 
L-1 Tris, 150 mmol L-1 NaCl, 0.02% Tween 20). The PVDF membrane was 
subsequently incubated with anti-phosphoAkt (Ser473) Mouse mAb (#4051, Cell 
Signalling Technology) antibody, in a 1:1000 dilution of 1% blocking buffer overnight at 
4°C. The blot was then incubated with an HRP conjugated secondary antibody 
(P0447, DAKO) in a 1:2000 dilution of 1% blocking buffer for 2 hours at room 
temperature. This procedure was repeated for total Akt (Ab #9272, Cell signalling) and 
the secondary Ab (P0217, DAK2Į-actin was used to normalise protein expression 
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OHYHOV XVLQJ DQ Į-actin primary (A2066, Sigma-Aldrich). The blots were developed 
using ECL reagents (GE Healthcare, Bucks, UK), and exposed to Amersham 
Hyperfilm ECL (GE Healthcare). Band intensities were quantified by optical 
densitometry, using Bio-rad, Quantity One software (Hercules, CA). 
 
Statistical analysis 
  Values are given as means ± SEM. Comparisons in; metabolite 
concentrations, substrate oxidation rates, gene expression and protein expression - 
both between and within treatments - were made by 2-way repeated measures 
ANOVA (applying a Bonferroni post-hoc test), using SPSS version 15.0 (SPSS Inc, 
Chicago IL). The threshold for significant change was P<0.05. 
 
6.3 Results 
Plasma hormones and metabolites 
Blood glucose levels were significantly reduced by 0.26 ± 0.07 mmol L-1 
(P<0.05) in DCA and by 0.14 ± 0.06 mmol L-1 (P<0.05) in the control infusion. At 3hrs 
after the start of the infusion, blood glucose in DCA was lower than CON by 0.16 ± 
0.05 mmol L-1 (P<0.05, Table 6.3.1). Blood lactate concentrations fell in both infusions; 
by 0.24 ± 0.05 mmol L-1 (P<0.05) in DCA, and 0.12 ±0.03 mmol L-1 in CON (P<0.05), 
with DCA decreasing significantly more than CON (P<0.001, Table 6.3.1). Serum 
insulin concentrations dropped significantly during the DCA infusion by 1.02 ± 0.29 
mmol L-1 (P<0.05). The CON infusion induced a trend for decreasing concentration but 
it was not significant (P=0.08), neither were the serum insulin concentrations 
significantly different at 3 hours post infusion (Table 6.3.1). FFA concentrations 
increased during the saline infusion by 0.07 ± 0.03 mmol L-1 (P<0.05). DCA was 
associated with a significant fall in FFA concentrations at 90 minutes, by 0.12 ±0.05 
mmol L-1 (P<0.05), followed by an increase at 3 hours, giving no significant overall 
change (P=0.76) (Table 6.3.1.)  
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Table 6.3.1 Blood and plasma metabolite concentrations at baseline and during the 
intervention.  
  
Baseline 1 hour 3 hours 
Blood glucose (mmol/L)    
DCA 4.56 ± 0.11 4.39 ± 0.10*  
CON 4.60 ± 0.07 4.43 ± 0.06* 4.46 ± 0.04* 
Blood lactate (mmol/L)    
DCA 0.46 ± 0.05 0.31 ± 0.01*  
CON 0.55 ± 0.04 0.52 ± 0.03 0.44 ± 0.03* 
Serum insulin (pmol/L)    
DCA 24.0 ± 3.0 19.8 ± 4.2 18.0 ± 2.4* 
CON 24.6 ± 3.0 21.0 ± 2.4 19.8 ± 2.4 
Plasma Free fatty-acids (mmol/L)    
DCA 0.76 ± 0.05 0.66  ± 0.04* 0.75 ± 0.04 
CON 0.70 ± 0.04 0.73 ± 0.03 0.77 ± 0.04* 
Data are means ± S.E., n=10, *PYV%DVHOLQHP<0.05 vs CON 
 
Whole body substrate metabolism 
Carbohydrate oxidation was increased by DCA (P<0.05) at 3 hours with no 
change in the CON infusion (Table 6.3.2). Lipid oxidation showed no change in either 
DCA or CON (Table 6.3.2). REE was significantly reduced in CON (0.38± 0.09 kJmin-
1; P<0.05), whereas the DCA infusion did not change the REE. The two groups were 
not significantly different at any time. (Figure 6.3.1) 
 
Table 6.3.2 Whole body substrate metabolism. CHO Oxn; Carbohydrate oxidation rate, FAT 
Oxn; Fat oxidation rate. 
  
Baseline 30 minutes 3 hours 
CHO Oxn (g min-1)    
DCA 0.16 ± 0.02 0.13 ± 0.02 0.19 ± 0.02* 
CON 0.16 ± 0.02 0.16 ± 0.02 0.15 ± 0.02 
FAT Oxn (g min-1)    
DCA 0.05 ± 0.01 0.06 ± 0.01 0.04 ± 0.01 
CON 0.05 ± 0.01 0.044 ± 0.01 0.05 ± 0.01 
Means ± S.E., n =10, *P<0.05 vs Baseline. No significant differences DCA vs CON 
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Figure 6.3.1 Resting Energy Expenditure (REE) at baseline and 30, 180 minutes post-infusion. 
 
Expression of metabolic genes in skeletal muscle 
PDK4 was unchanged in both CON and DCA, with no significant interaction 
between time and treatment. Uncoupling protein-3 (UCP3) showed no treatment 
effect, but it was significantly upregulated at 3 hours in the CON trial, and remained 
unchanged in DCA. A similar pattern was observed in peroxisome proliferator-
activated reFHSWRU Ȗ FR-activator-Į 3*&Į ZLWK QR GLIIHUHQFH EHWZHHQ WKH
treatments. All other transcripts were unchanged in both interventions. Baseline 
values for all genes were not significantly different (Table 6.3.3). 
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Table 6.3.3 mRNA expression (fold change from baseline) for CON and DCA infusions in 
skeletal muscle. 
 
Gene expression: fold change        Time (minutes) 
    30  180 
PDK4 
    
DCA  0.94 ± 0.23  1.24 ± 0.34 
CON  1.52 ± 0.22  2.66 ± 0.75 
PDK2 
    
DCA  1.11 ± 0.08  0.98 ± 0.08 
CON  0.98 ± 0.21 1.23 ±  0.42 
HKII 
    
DCA  1.02 ± 0.16  1.18 ± 0.19 
CON  1.11 ± 0.19  0.87 ± 0.13 
CPT1 
    
DCA  1.25 ± 0.21  1.00 ± 0.10 
CON  1.28 ± 0.25  1.37 ± 0.24 
UCP3 
    
DCA  1.24 ± 0.18  1.20 ±  0.15 
CON  1.42 ± 0.25  1.69 ± 0.22* 
SREBP1c 
    
DCA  1.01 ± 0.10  1.12 ± 0.21 
CON  1.14 ± 0.18  1.11 ± 0.22 
33$5Į 
    
DCA  0.94 ± 0.12  1.01 ± 0.13 
CON  1.12 ± 0.14  1.16 ± 0.17 
33$5į 
    
DCA  0.93 ± 0.06  0.94 ± 0.15 
CON  1.33 ± 0.17  1.393 ± 0.20 
3*&Į 
    
DCA  1.23 ± 0.21  1.08 ± 0.14 
CON   1.33 ± 0.12   1.84 ± 0.18* 
All values are reported as means ± S.E. n=10, *P<0.05 vs Baseline. No 
significant differences DCA vs CON 
 
 
 Protein expression 
There were no significant differences in total skeletal muscle protein Akt 
expression or Ser473 phosphorylation, either between treatments or during the 
infusions (Figure 6.3.2). 
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Figure 6.3.2 Akt phosphorylation. Data are means ± S.E. ratio of phosphorylated-Akt (Ser473) 
divided by total Akt for DCA and CON at baseline (0 minutes) and 30 and 180 minutes after the 
start of the infusion. One representative immunoblot showing phosphorylated-Akt and total-Akt. 
 
 
 
6.4 Discussion 
Studies have shown that the regulation of glucose and fatty-acid metabolism 
is a multi faceted and highly integrated process (Randle, 1998), requiring both 
changes in enzyme kinetics and gene expression. Skeletal muscle is the major site for 
insulin stimulated glucose disposal, and the pathways which regulate carbohydrate 
metabolism have been shown to respond to changes in substrate availability and 
hormonal signalling with secondary adaptations in gene expression (Arkinstall et al., 
2004).  There is no evidence that acute activation of the PDC can be accomplished 
without changing substrate availability or metabolic gene expression.  
The DCA infusion in this study showed an increase in carbohydrate utilisation 
and changes in blood metabolites which were consistent with previous studies 
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involving DCA (Timmons et al., 1998; Constantin-Teodosiu et al., 1999). There were 
sustained and significant decreases in blood lactate, probably due to increased 
conversion of pyruvate to acetyl-coA via the PDC (Stacpoole et al., 1998), 
accompanied by an increase in the whole body carbohydrate oxidation rate. In CON, 
the changes in blood glucose, serum insulin aQG))$¶VDUHVPDOOEXW LQDFFRUGDQFH
with continued fasting. The confirmation by immunoblotting (Figure 6.3.2) that there 
were no changes in insulin signalling, provides evidence that changes in  insulin 
stimulated glucose uptake via GLUT4, were not a factor in either infusion. The short 
duration of this study was intentional, to limit the effects of fasting on gene expression. 
Human intervention studies adopting a wide range of approaches including 
insulin & adrenaline infusions (Tsintzas et al., 2007), changes in dietary composition 
(Chokkalingam et al., 2007) and starvation (Tsintzas et al., 2006), have produced a 
wealth of data showing alterations in metabolic gene expression. Recent studies have 
shown that HKII is sensitive to alterations in substrate availability (Tsintzas et al., 
2007), and yet it was unchanged in this chapter, which suggests that changes in the 
expression of glycolytic genes are not required for short term increases in 
carbohydrate oxidation. The transcriptional activator of HKII, SREBP-1c was also 
unaffected. The expression of PDK2, the site where DCA is kinetically most effective, 
was also unchanged during both infusions, however, given that its basal level of 
expression and half-life are longer than that of PDK4, it might be sensible to expect a 
smaller role in the acute regulation of PDC flux (Huang et al., 2002). PDK4 is a gene 
which plays a significant role in cellular adaptation to alterations in carbohydrate 
availability and oxidation, and other studies have reported this (Huang et al., 2002), 
mainly through its close and inverse relationship with insulin (Lee et al., 2004). 
However, as anticipated, there were no large decreases in serum insulin 
concentrations during this study, or any changes in PDK4 expression. Despite the 
SRWHQWLDODFWLRQRI'&$RQ33$5Į- via changes in expression (Walgren et al., 2005) 
and trans-Activation (Maloney & Waxman, 1999) - there was no change in the mRNA 
content of the PPARĮ DQG į LQ '&$ RU &21 +RZHYHU WKH 33$5 FR-activator, 
3*&Į GLG LQFUHDVH VLJQLILFDQWO\ LQ &21 EXW QRW LQ '&$ WUHDWHG VXEMHFWV 3*&Į
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mRNA expression has previously been shown to increase during starvation (de Lange 
et al., 2006) , and with weight loss (Gastaldi et al., 2007). DCA may have had the 
HIIHFWRIEORFNLQJDQ\ IDVWLQJ LQGXFHG LQFUHDVH LQ3*&ĮP51$ WKURXJK LQFUHDVLQJ
carbohydrate utilisation, preventing the cell from sensing a physiological negative 
energy-balance normally associated with saline infusions following an overnight fast. 
:HQGHHWDOKDYHVKRZQWKDW3*&ĮVWLPXODWHV WKHH[SUHVVLRQRI3'. (Wende et 
al., 2005) and Zhang et al (Zhang et al., 2006) have proposed a mechanism involving 
the Estrogen-related receptor (ERR) for induction of PDK4. It is likely that there is a 
complex interplay between a number of transcription factors in the regulation of PDK4 
including PPARĮ 3*&D (55Į and Liver X receptor (LXR) (Sugden & Holness, 
2003; Wende et al., 2005). 
  Among the other potential targets for PPARs, CPT1 was unchanged in this 
study whilst UCP3 had contrasting results between the two treatments. An 
upregulation in UCP3 mRNA expression was seen in CON, which would be expected 
as a response to continued starvation. In contrast, in the DCA trial UCP3 expression 
was unaltered. One potential role of UCP3 that has been suggested is the export of 
fatty-acid anions out of the mitochondria (Nagy et al., 2004). With decreased reliance 
RQ IDW R[LGDWLRQ LQ '&$ FRPSDUHG WR &21 LW PD\ EH WKH FDVH WKDW 8&3¶V UROH LV
diminished (de Lange et al., 2006). DCA did not cause any changes in gene 
expression per se, but subtlety reduced the effects of fasting. This provides evidence 
for the concept that PDC flux can be independently altered in the short-term, without 
changing the expression of metabolic genes. 
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Chapter 7.0 General discussion and conclusions 
The human body is remarkable in its ability to adapt to changes in energy 
balance and substrate availability. It does this through multi-level regulatory 
processes; from the smallest scale of the genome, through the activity of enzymes, 
and the coordination of organ systems, right up to the behaviour of the individual. Part 
of this response involves control of the transcriptional activity of metabolic genes. 
Metabolic gene expression is altered in response to changes in the external and 
internal environment (Mutch et al., 2005), with the aim of maintaining the balance 
between energy intake and energy expenditure. Despite this simple goal, the systems 
which govern energy balance are highly complex, which confers both great resilience 
and flexibility. However, this same complexity makes understanding the process 
through which homeostasis is maintained, or how disease states arise, very difficult. 
Fortunately, the knowledge base surrounding metabolic networks has begun to grow, 
in parallel with improvements in technology which have made it possible to 
characterize and quantify the expression of metabolic genes. 
 Metabolic diseases have become more prevalent with the increasing energy 
intake and decreased energy expenditure associated with industrialisation, to the 
extent that it is now considered an international health crisis, the resolution of which is 
a priority (Popkin & Doak, 1998). This thesis has focussed on the problem of 
understanding how metabolic diseases arise, and also how metabolic gene 
expression changes in response to variations in nutrient supply. The studies in 
chapters 3 and 4 examined the role of postprandial fat oxidation in the adipose tissue 
of obese subjects, whilst chapters 5 and 6 are concerned with substrate utilisation in 
skeletal muscle. 
Chapter 3.0 in this thesis demonstrated that although changes in gene 
expression are different between dietary and fat-oxidising groups, during calorie 
restriction (CR), there is no fundamental difference in weight loss. This not only 
implies that caloric restriction is a greater driver of weight loss than dietary 
composition and postprandial fat oxidising capacity, but also that gene expression 
here is playing a secondary role to the environment. The observed adaptations in 
                                                          The regulation of metabolic gene expression in Humans 
 
Paul Tisdale                                                                                                                                                  106 
 
 
gene expression such as downregulation of HSL and ATGL, are ways of regulating or 
possibly adapting to changes in fuel use in response to weight loss, but are not in 
themselves driving weight loss. Further studies in this area, would benefit from the 
introduction of a post-diet postprandial fat oxidation test meal, to examine whether low 
±fat oxidisers on a high fat diet, and high-fat oxidisers on a low fat diet actually change 
their postprandial fat oxidising capacity after this period, since these two groups 
showed the largest changes in metabolic gene expression, despite having the same 
weight loss profiles. 
Chapter 4 provided a continuation of the theme of postprandial fat oxidation 
with the assessment of global gene expression profiles. The initial PCA analysis 
confirmed that there were differences between the high- and low-postprandial fat 
oxidising populations, and further statistical analysis and filtering provided a set of 
genes which offered a central role for GLUT4, fatty-acid synthase (FASN) and 
aquaporin (AQP7) in the maintenance of the phenotype in adipose tissue. The main 
WUDQVFULSWLRQDOIDFWRUVPHGLDWLQJWKLVZHUH5;5ĮDQG65(%)PRVWOLNHO\65(%3-1c) 
which may have been regulated by LXR. The results in chapters 3 & 4 offer 
confirmatory findings such as the suppression of SREBP-1c expression during calorie 
restricted diets, but also offer new insight in the arena of postprandial fat oxidation, 
showing for the first time that gene expression profiles adapt differently to calorie 
restricted diets or varying fat content and that there are important transcriptomic 
differences between the adipose tissue of individuals with altered postprandial fat-
oxidising capacity. This opens the door for future research to build upon by 
establishing, ideally via longitudinal studies, how such differences arise ± however, 
caution should be used when trying to attribute causality in these situations since 
although it may meet with success at the very smallest scale; at this level any 
biological meaning is lost. 
In the high-glucose study (chapter 5), ChREBP, which is a known activator of 
lipogenic gene expression, was upregulated along with its target FASN in high-
glucose treated myotubes. This demonstrated the ability of chronic glucose oversupply 
to alter gene expression, in contrast to the results of acute dichloroacetate treatment 
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(chapter 6), where no changes were observed in the absence of measurable changes 
in glucose availability, but there was a clear switch from fat to carbohydrate oxidation. 
Taken together these results are a clear example of the multi-level regulation of 
metabolism which has been a recurring theme throughout this thesis.  The high-
glucose study also exposes potential mechanisms which could be responsible for the 
protection of myocytes from excess lipid accumulation during prolonged 
hyperglycaemia. These pathways all involved methods of lipid clearance through; 
perilipin induced sequestration into lipid droplets, depletion into phosphatidic acid by 
diacylglycerol kinase, DQGLQFUHDVHGȕ-oxidation. 
The diverging regulation of lipogenic gene expression was demonstrated in 
both the fat-oxidation studies and the high-glucose treatments. With the transcriptional 
regulators SREBP-1c and ChREBP both appearing to induce the expression of FASN- 
this is a clear example of how the expression of a gene can be induced in quite 
different circumstances, depending on substrate supply, disease state and tissue type. 
)XUWKHUPRUH WKH FRQWULEXWLRQ RI 5;5Į GLVSOD\V WKH SRWHQWLDO IRU V\QHUJLVWLc 
LQWHUDFWLRQV ZKLFK PD\ DOVR DFW DV µIDLO-safes¶ IRU LPSRUWDQW ELRORJLFDO PHFKDQLVPV
should one pathway be compromised.  The high level of redundancy in biological 
systems, and the pleiotropic effects of many metabolic genes forms the basis of these 
activities (Tononi et al., 1999), which require researchers to must step back and 
suspend dualistic thinking when examining these problems (Van de Vijver, 2009).   
Early linkage studies proved to be very successful in describing causal 
relationships between the genome and monogenic disease states, however despite 
the promise of association studies, the understanding of how genes might be involved 
in the pathogenesis of complex disease states remains limited.  This could be the 
result of there being a vast number of rare polymorphisms, which are largely 
responsible for the development of a phenotype, or a small number of common 
polymorphisms, each of which make a small contribution towards a disease state or 
phenotype.  In reality it is likely a mixture of these two situations, and hence a greater 
number of genomes will need to be sequenced across many different haplogroups 
before this question can be appropriately answered. Furthermore, genomes do not 
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exist in splendid isolation, and as Denis Noble has argued, we should not award any 
biological level (i.e. the genome) a privileged status (Noble, 2008).  The work in this 
thesis has attempted to use this approach, by looking at how feed forward and 
feedback loops are integrated to maintain a dynamic equilibrium in the internal 
environment. eQTL analysis (chapter 4) integrated transcriptomic and genomic 
datasets and was successful in associating SNPs with gene expression, although 
interpretation of the data was complicated by the difficulty of resolving µELDVHG¶ lists of 
differentially expressed genes from the potential false positives, and there is 
insufficient knowledge as to the operation of the genome at this stage to form strong 
hypotheses for these associations or to discard them entirely. Instead genes which 
were differentially expressed were linked with metabolite concentrations, such as the 
FRUUHODWLRQEHWZHHQ5;5ĮH[SUHVVLRQDQGIDVWLQJEORRGJOXFRVHFRQFHQWUDWLRQV. This 
type of data place greater emphasis on the interaction between nutrients and genes 
through the action of transcription factors.  
The scientific community is increasingly aware of the contribution that 
methylation and gene imprinting has upon the phenotype; intergenerational 
environmental effects can now be observed that would have been dismissed as 
Lamarkian nonsense only 15 years ago. It is important not only to recognise that 
metabolic processes are regulated at multiple levels but that we should avoid being 
too hasty in trying to assign causality to very complex situations. One recent paper 
µFatness leads to inactivity, but inactivity does not lead to fatness: a longitudinal study 
in children (EarlyBird 45) (Metcalf et al., 2010) suggested that inactivity is the cause of 
increased adiposity and not vice-versa. However, whilst the findings of this 
investigation are robust, there is plenty of evidence that obesity can be caused by both 
decreased energy expenditure or increased calorific intake, and most commonly a 
combination of both, which has been observed in developed countries. The concept of 
the gene itself is becoming rather outmoded, in light of evidence showing that 
alternative splicing and miRNA regulate transcriptional activity to such an extent that 
the idea of a gene has become rather diffuse. Exomic sequencing would provide a 
clearer picture of what is actually being transcribed from the genome, and as shown in 
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chapter 4 alternative splicing in SREBF1 may partly account for differences in fat 
oxidising capacity. The relevance in this case being that SREBP-1c activates lipogenic 
genes with greater efficiency than -1a, potentially improving lipid storage capacity. 
An additional consideration for future work in modelling metabolic networks; is 
the importance of making sure that functional characterisation of transcripts is 
thoroughly carried out. When undertaking analysis of gene-expression data, it is 
necessary to use pathway analysis software to extract meaning from lists of 
transcripts, however it is vital that this should be used in conjunction with co-
expression and GSEA analysis as was carried out in chapter 4, to prevent researchers 
from overlooking the importance of genes which are yet to be characterised, but could 
play important roles in metabolic disease and other physiological systems. 
The development of obesity and diabetes will not have a clear step-by-step 
pathogenesis, since metabolic disease is distinct from monogenic diseases such as 
cystic fibrosis. Integration of multiple data sources will be required to model metabolic 
disorders properly, and also when applying this to diagnosis when the era of 
personalised medicine become practical (Mo & Palsson, 2009). 
The scientific community should be prepared to see various mechanisms such 
as ectopic fat accumulation and altered adipokine release both being part of these 
metabolic disease states, and not necessarily preceding one another but rather 
emerging simultaneously in response to changes in energy intake and expenditure. 
This offers the possibility of multiple targets where treatments can be developed to 
counteract metabolic disease, but likely also requires pharmaceutical agents which 
are able to work less specifically in order to have any useful effect. Side-effects from 
anti-obesity or anti- diabetic,  drugs will be hard to limit given the interdependence of 
nuclear receptor targets, and regulators should give serious consideration as to 
whether small but significant risks from a specific drug, really out-weigh the risks of 
prolonged metabolic disease. 
  The heterogeneity of disease states makes personalised medicine an 
attractive option, and the use of genotyping during treatment of patients is likely to 
become more common.  
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In summary this thesis shows that the human body is capable of adjusting 
metabolic gene expression quite considerably to counter or facilitate changes in 
substrate availability, but that it is also resilient in the short term to acute changes in 
flux through metabolic pathways. It also describes potentially important and novel 
mechanisms; the disruption of which could be linked to the progression of metabolic 
disease.  
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Appendix I 
Figure A: PPAR:RXR pathways. Unfiltered gene expression data (Chapter 4) 
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Figure B: LXR:RXR pathways. Unfiltered gene expression data (Chapter 4) 
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Table A. Differentially expressed genes. Fold-change>1.28 P<0.05 (Chapter 4) 
 
Genesymbol Fold change([HIGH] vs [LOW]) Regulation([HIGH] vs [LOW]) Genedescription Genbank
ABCA6 1.3571911 up ATP-binding cassette, sub-fami ly A (ABC1), mAY028898
ADCY6 1.3187706 down adenylate cyclase 6 BC064923
ADRA2A 1.3758698 down adrenergic, a lpha-2A-, receptor AF284095
ADRB1 1.3116388 down adrenergic, beta-1-, receptor J03019
AGPAT1 1.2800417 down 1-acylglycerol -3-phosphate O-acyl transferasBC090849
AKR1C3 1.5359242 up aldo-keto reductase fami ly 1, member C3 (3BC001479
ALDOC 1.3050004 down aldolase C, fructose-bisphosphate BC003613
AMAC1L2|AMAC1 1.3596889 down acyl -malonyl  condens ing enzyme 1-l ike 2 | BC131696
ANGPT1 1.3551071 up angiopoietin 1 BC152411
AOC3 1.2886319 down amine oxidase, copper conta ining 3 (vasculU39447
AQP7|AQP7P1|AQ 1.3710415 down aquaporin 7 | aquaporin 7 pseudogene 1 |BC119672|BC
ARHGEF15 1.2846545 down Rho guanine nucleotide exchange factor (GBC036749
ATL3 1.297632 up atlastin 3 AK090822
ATM|NPAT 1.3034247 up ataxia  telangiectas ia  mutated | nuclear proU33841|X911
ATP5L|ATP5L2 1.3342676 up ATP synthase, H+ transporting, mitochondriBC015128|BC
ATP5SL 1.3494071 down ATP5S-l ike BC013323|AK
AVPI1 1.3722355 down arginine vasopress in-induced 1 AF241786
BOK 1.3894626 down BCL2-related ovarian ki l ler BC006203
BTBD2 1.4143441 down BTB (POZ) domain conta ining 2 AF355797
BZW1 1.336499 up bas ic leucine zipper and W2 domains  1 AL833518
C10orf10 1.4220606 down chromosome 10 open reading frame 10 AB022718
C12orf35 1.4203917 up chromosome 12 open reading frame 35 AB046771
C17orf65 1.3175187 down chromosome 17 open reading frame 65 BC009448
C18orf32 1.4127433 up chromosome 18 open reading frame 32 BC093004|AB
C2orf40 1.3668827 down chromosome 2 open reading frame 40 AY358601
C3orf63 1.3651072 up chromosome 3 open reading frame 63 AF180425
C4orf18 1.295632 up chromosome 4 open reading frame 18 BC043193|AY
C6orf62 1.3063585 up chromosome 6 open reading frame 62 BC040260
C6orf72 1.2847519 up chromosome 6 open reading frame 72 AY358952
CACNA2D1 1.6213539 up calcium channel , vol tage-dependent, a lphaBC117468
CALD1 1.3185304 up caldesmon 1 M83216
CAPZA1 1.3126619 up capping protein (actin fi lament) muscle Z-lBX648738
CASP4|LOC643733 1.3266383 up caspase 4, apoptos is -related cysteine peptiAK057094|BC
CCDC80 1.2886823 up coi led-coi l  domain conta ining 80 AB266387
CD81 1.3852338 down AB209380
CDC27 1.3093524 up cel l  divis ion cycle 27 homolog (S. cerevis iaeBC011656
CHRM1 1.3090012 down chol inergic receptor, muscarinic 1 BC022984
CISH 1.2879168 down cytokine inducible SH2-conta ining protein AF035947
CKB 1.2964231 down creatine kinase, bra in AK290101
CLSTN2 1.3122133 down calsyntenin 2 AY753303
CNTFR 1.30802 down ci l iary neurotrophic factor receptor M73238
COPE 1.2884257 down coatomer protein complex, subunit eps i lonBC007250
COX7B 1.2965676 up cytochrome c oxidase subunit VIIb Z14244
CP 1.3387864 up ceruloplasmin (ferroxidase) BC146801
CRIP2 1.2949564 down cysteine-rich protein 2 AK091845
CSNK1A1 1.3429672 up casein kinase 1, a lpha 1 AF447582
CTDSP1 1.4229194 down CTD (carboxy-terminal  domain, RNA polymeAF229162
CTNNBIP1 1.3693366 down catenin, beta  interacting protein 1 AB021262
CYGB 1.3375119 down cytoglobin BC029798
CYP2F1 1.3748977 down cytochrome P450, fami ly 2, subfami ly F, polyJ02906
CYP7B1 1.3155025 up cytochrome P450, fami ly 7, subfami ly B, polyAF127090
DCUN1D1 1.423355 up DCN1, defective in cul l in neddylation 1, domAF292100
DSEL 1.2945799 up dermatan sul fate epimerase-l ike AF480435
DTX1|LOC1001294 1.329856 down deltex homolog 1 (Drosophi la) | hypotheticBC048216|AK
EEA1 1.3565503 up early endosome antigen 1 L40157
EPB41 1.4220278 up erythrocyte membrane protein band 4.1 (el lAF156225
ERAP1 1.28302 up endoplasmic reticulum aminopeptidase 1AF222340
ERV3|ZNF117 1.6929694 up endogenous  retrovira l  sequence 3 (includeM55422
ESAM|LOC100129 1.2865764 down endothel ia l  cel l  adhes ion molecule | hypoAY189281|AK
F13A1 1.4683992 up coagulation factor XIII , A1 polypeptide BC027963
FAM126A 1.3657682 up fami ly with sequence s imi lari ty 126, membAL833296
FAM38A 1.2944229 down fami ly with sequence s imi lari ty 38, membeD87071|BC00
FAM82B|NTAN1 1.2879077 up fami ly with sequence s imi lari ty 82, membeAF151848
FASN 1.567724 down fatty acid synthase U29344
FBXO34 1.3953445 down F-box protein 34 AF531436
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Genesymbol Fold change([HIGH] vs [LOW]) Regulation([HIGH] vs [LOW]) Genedescription Genbank
FSCN1 1.2861162 down fascin homolog 1, actin-bundl ing protein (SU03057
FXYD1|FXYD7 1.4315841 down FXYD domain conta ining ion transport reguAK289811
GDPD5 1.332104 down glycerophosphodiester phosphodiesteraseBC018771
GMFB 1.3870455 up gl ia  maturation factor, beta BX647679
GOLGA4 1.2939342 up golgi  autoantigen, golgin subfami ly a , 4 U41740
GPR124 1.2888402 down G protein-coupled receptor 124 AF378755
GPR146|LOC10013 1.3736134 down G protein-coupled receptor 146 | hypotheticBC014241|AK
GPSN2 1.2967759 down glycoprotein, synaptic 2 BC005384
GRINA 1.3535607 down glutamate receptor, ionotropic, N-methyl  D-AK127640
GRN 1.3576738 down granul in AF055008
GSPT1 1.2975861 up G1 to S phase trans i tion 1 BC009503
HIST1H2BC|HIST1 1.4504973 up his tone cluster 1, H2bc | his tone cluster 1, HBC105595
HIST1H2BK|H2BF 1.325995 up his tone cluster 1, H2bk | H2B his tone fami lAK292062|BC
HIST1H3C|HIST1H 1.4559077 up his tone cluster 1, H3c | his tone cluster 1, HBC127610
HIST1H4C|HIST4H 1.3686852 up his tone cluster 1, H4c | his tone cluster 4, HBC130558
HP|HPR 1.4728715 up haptoglobin | haptoglobin-related proteinAK055872
HSPG2 1.346241 down heparan sul fate proteoglycan 2 M85289
HSPH1 1.3341 up heat shock 105kDa/110kDa protein 1 BX648125
IBTK 1.3036625 up inhibi tor of Bruton agammaglobul inemia  tyDQ005633
IFI16 1.3356922 up interferon, gamma-inducible protein 16 AF208043
IFIT2 1.3295484 up interferon-induced protein with tetratricopBC032839
IFNAR1 1.2957867 up interferon (a lpha, beta  and omega) receptoJ03171
IFRD1 1.3281156 up interferon-related developmental  regulatoBC001272
ITGA7 1.3042641 down integrin, a lpha 7 BC050280
JUP 1.3093927 down junction plakoglobin M23410
KIAA0195 1.3117917 down BC042942
KIAA0515|SNORD 1.3229375 down KIAA0515 | smal l  nucleolar RNA, C/D box 62BC012289
KIAA1033 1.2932938 up BC104992
KLHL30 1.3587592 down kelch-l ike 30 (Drosophi la)
KRTAP5-1 1.3639313 down keratin associated protein 5-1 AB126070
KRTAP5-3|KRTAP5 1.3152089 down keratin associated protein 5-3 | keratin assAB126072|AB
KTN1 1.2927551 up kinectin 1 (kines in receptor) AY264265
LDOC1 1.3327429 down leucine zipper, down-regulated in cancer 1AB019527
LMF2 1.35955 down l ipase maturation factor 2 BC014652
LOC401152 1.5641345 up HCV F-transactivated protein 1 BC017399
LRP3 1.3533 down low dens i ty l ipoprotein receptor-related prAB009462
LRP5 1.2942703 down low dens i ty l ipoprotein receptor-related prAF077820
LTBP3|LOC100128 1.3342304 down latent transforming growth factor beta  bindAK024477|AK
LUM 1.4693182 up lumican BC007038
LYRM5 1.3147453 up LYR moti f conta ining 5 AK095164
MAN1A2 1.3279696 up mannos idase, a lpha, class  1A, member 2 BC052954
MAP1LC3B|LOC64 1.2982559 up microtubule-associated protein 1 l ight chaiBC041874
MAP3K2 1.3152387 up mitogen-activated protein kinase kinase kiAF111105
MAZ 1.2877185 down MYC-associated zinc finger protein (purine-AB209061
MCL1|C1orf138 1.3145552 up myeloid cel l  leukemia  sequence 1 (BCL2-reBC017197|AK
MGC34829 1.2804462 down Simi lar to hypothetica l  gene supported by ABC030200
MME 1.2809939 up membrane metal lo-endopeptidase J03779
MRGPRF 1.3357364 down MAS-related GPR, member F BC016964
MRPL42 1.2813953 up mitochondria l  ribosomal  protein L42 BC040240
MRPL47 1.3140916 up mitochondria l  ribosomal  protein L47 BC032522
MYADM 1.3140979 down myeloid-associated di fferentiation markerBC095412
NAP1L1 1.2867484 up nucleosome assembly protein 1-l ike 1 BC002387
NAT8L 1.7762655 down N-acetyl transferase 8-l ike BC103748
NBEAL1 1.3779292 up neurobeachin-l ike 1 AY172970
NMT2 1.287753 up N-myris toyl transferase 2 AF043325
NPHS1|PRODH2 1.2847013 down nephros is  1, congenita l , Finnish type (nephAF035835
NPR1 1.3369122 down natriuretic peptide receptor A/guanylate cyBC063304
NUCB2 1.2917719 up nucleobindin 2 AK097398
OBFC2B 1.290334 down ol igonucleotide/ol igosaccharide-binding foBC006171
OBSL1 1.2971791 down obscurin-l ike 1 EF063638
OMD 1.3109467 up osteomodul in AB000114
OR10G4|OR10G8| 1.2836123 down olfactory receptor, fami ly 10, subfami ly G, member 4 | o
OR3A2|OR3A3 1.3429304 down olfactory receptor, fami ly 3, subfami ly A, meBC108921|BC
OR4D1 1.3194876 down olfactory receptor, fami ly 4, subfami ly D, member 1
OR52W1 1.348034 down olfactory receptor, fami ly 52, subfami ly W, member 1
PA2G4 1.2947758 down prol i feration-associated 2G4, 38kDa BC001951
PALLD 1.2804977 up pal ladin, cytoskeleta l  associated protein AF464873
                                                          The regulation of metabolic gene expression in Humans 
 
Paul Tisdale                                                                                                                                                  136 
 
 
 
Genesymbol Fold change([HIGH] vs [LOW]) Regulation([HIGH] vs [LOW]) Genedescription Genbank
PARVB 1.2815949 down parvin, beta AF303887
PCNP 1.2885157 up PEST proteolytic s ignal  conta ining nuclear pBC022001
PDK2 1.2969232 down pyruvate dehydrogenase kinase, i sozyme 2AK055119
PHGDH 1.3558596 down phosphoglycerate dehydrogenase AK093306
PICALM 1.3215449 up phosphatidyl inos i tol  binding clathrin asseBC048259
PIK3C2A 1.291929 up phosphoinos i tide-3-kinase, class  2, a lpha BC113658
PIK3CA 1.3282412 up phosphoinos i tide-3-kinase, cata lytic, a lphaBC113601
PKN1 1.3285573 down protein kinase N1 BC094766
PLD3 1.3544598 down phosphol ipase D fami ly, member 3 BC096820
PLS3 1.3176662 up plastin 3 (T i soform) BC056898
PLSCR3 1.3523171 down phosphol ipid scramblase 3 AK124006
PNPLA2 1.3410758 down patatin-l ike phosphol ipase domain conta iBC017280
PNPLA3 1.3764329 down patatin-l ike phosphol ipase domain conta iBC065195
PPP2R1A 1.3007822 down protein phosphatase 2 (formerly 2A), regulaAK290593
PRKCD 1.2924075 down protein kinase C, del ta BC043350
PRPF40A 1.3220056 up PRP40 pre-mRNA process ing factor 40 homoAK024810
PTMS 1.3291321 down parathymos in BC017025
PTPN12 1.332375 up protein tyros ine phosphatase, non-receptoBC050008
RAB8B 1.325626 up AB038995
RANBP3L 1.3320328 up RAN binding protein 3-l ike BC047660
RHBDD2 1.2872766 down rhomboid domain conta ining 2 AF226732
RNPEPL1 1.3314698 down arginyl  aminopeptidase (aminopeptidase BC082975
ROBO4 1.2838385 down roundabout homolog 4, magic roundabout (AK074163
ROCK2 1.3039379 up Rho-associated, coi led-coi l  conta ining proteAB014519
RPE 1.2972766 up ribulose-5-phosphate-3-epimerase BC005148
RXRA 1.2920302 down retinoid X receptor, a lpha BC063827
S1PR2 1.2911686 down sphingos ine-1-phosphate receptor 2 BC069598
SCCPDH 1.297631 up saccharopine dehydrogenase (putative) AF151807
SCFD1 1.3204099 up sec1 fami ly domain conta ining 1 AK290410
SCYL2 1.3025248 up SCY1-l ike 2 (S. cerevis iae) AK292980
SEC62 1.2813747 up D87127
SEMA3C 1.2857058 up sema domain, immunoglobul in domain (IgAB000220
SEPP1 1.2980919 up selenoprotein P, plasma, 1 BC015875
SEPT7. 1.3668896 up septin 7 AB209677
SERBP1 1.2809391 up SERPINE1 mRNA binding protein 1 BC002488
SGCB 1.3348573 up sarcoglycan, beta  (43kDa dystrophin-associU31116
SLC22A17 1.2876432 down solute carrier fami ly 22, member 17 BC020565
SLC25A1 1.4673209 down solute carrier fami ly 25 (mitochondria l  carriL75823
SLC29A4 1.4261646 down solute carrier fami ly 29 (nucleos ide transpoAY485959
SLC2A4 1.5324149 down solute carrier fami ly 2 (faci l i tated glucose trBC034387
SLC39A13 1.3727272 down solute carrier fami ly 39 (zinc transporter), mBX647491
SLC5A3 1.4402211 up solute carrier fami ly 5 (inos i tol  transporters ), member 
SLC5A6 1.2811979 down solute carrier fami ly 5 (sodium-dependent AK027855
SLC7A10 1.3367475 down solute carrier fami ly 7, (neutra l  amino acidAB037670
SLC9A3R2 1.3403714 down solute carrier fami ly 9 (sodium/hydrogen exBC014513
SMCHD1 1.4377396 up structura l  maintenance of chromosomes  fleBC035774
SNX2 1.2851511 up sorting nexin 2 BC003382
SNX6|RPS19 1.3398315 up sorting nexin 6 | ribosomal  protein S19 BC001798|M8
SON 1.2821213 up AF380183
SREBF1 1.4806234 down sterol  regulatory element binding transcripBC057388
ST6GALNAC6|LOC 1.3010876 down ST6 (a lpha-N-acetyl -neuraminyl -2,3-beta-gaAK057100|AK
STK17B 1.4810407 up serine/threonine kinase 17b BC016040
STX8 1.3753562 up syntaxin 8 AF062077
TBL1XR1 1.2845194 up transducin (beta)-l ike 1 X-l inked receptor 1BX648935
TENC1 1.3654742 down tens in l ike C1 domain conta ining phosphataBC150259
TM7SF2 1.2912121 down transmembrane 7 superfami ly member 2 AF023676
TMEM109 1.3384503 down transmembrane protein 109 BC001309
TMEM115 1.3936688 down transmembrane protein 115 BC017367
TMEM126A 1.3360947 up transmembrane protein 126A BC007875
TMEM185B|LOC15 1.3674604 down transmembrane protein 185B (pseudogeneBC080607|AK
TMEM204 1.3196149 down transmembrane protein 204 AY676494
TMEM88|JMJD3 1.3173466 down transmembrane protein 88 | jumonji  domaiBC057812
TMEM92 1.2842566 down transmembrane protein 92 AY358204
TOM1L2 1.3289075 down target of myb1-l ike 2 (chicken) AY358769
TPPP3 1.3578701 down tubul in polymerization-promoting protein fBC037798
TSKU 1.4549828 down tsukushin AY358317|BT
TXNRD1 1.3127711 up thioredoxin reductase 1 AK128515
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Table B: eQTL analysis results. (Chapter 4) 
GENE, eQTL; CHR, Chromosome; SNP, SNP identifier; UNADJ, Unadjusted asymptotic 
significance value; GC, Genomic control adjusted significance value. This is based on a simple 
estimation of the inflation factor based on median chi-square statistic. These values do not 
control for multiple testing therefore; BONF, Bonferroni adjusted significance value; HOLM, 
Holm step-down adjusted significance value; SIDAK_SS, Sidak single-step adjusted 
significance value; SIDAK_SD, Sidak step-down adjusted significance value; FDR_BH, 
Benjamini & Hochberg (1995) step-up FDR control; BY, Benjamini & Yekutieli (2001) step-up 
FDR control  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genesymbol Fold change([HIGH] vs [LOW]) Regulation([HIGH] vs [LOW]) Genedescription Genbank
USP53 1.3232888 up ubiquitin speci fic peptidase 53 AK025301
VAMP2 1.2904371 down ves icle-associated membrane protein 2 (syAK021522
VCAM1 1.3510455 up vascular cel l  adhes ion molecule 1 BC068490
VEGFB 1.479503 down vascular endothel ia l  growth factor B BC008818
VIPR1 1.2872312 down vasoactive intestina l  peptide receptor 1 AK056819
VPS13C 1.2848843 up vacuolar protein sorting 13 homolog C (S. ceAK001243
WDR13 1.378264 down WD repeat domain 13 AF158978
WDR57 1.3082151 up WD repeat domain 57 (U5 snRNP speci fic) EF011621
XPOT 1.2979851 up exportin, tRNA (nuclear export receptor for tRBC020569
YIPF3 1.3230605 down Yip1 domain fami ly, member 3 BC019297
ZC3H11A 1.3522984 up zinc finger CCCH-type containing 11A BC038513
ZDHHC20 1.2838407 up zinc finger, DHHC-type containing 20 AK098818|AL8
ZFP36L2 1.3408856 down zinc finger protein 36, C3H type-l ike 2 BC005010
ZNF385A 1.301093 down zinc finger protein 385A AF304052
ZNF429 1.3314047 up zinc finger protein 429 AY269786
ZNF460 1.2801796 up zinc finger protein 460 AY329492
ZNF706 1.2991164 up zinc finger protein 706 AF275802|BC
ZNF91 1.3351623 up zinc finger protein 91 AK291256
GENE CHR     SNP               UNADJ                  GC            BONF          HOLM     SIDAK_SS   SIDAK_SD     FDR_BH     FDR_BY MATCH CHR?CODING
HECTD3 15   rs1158683      7.982e-009      1.201e-008    0.002447    0.002447    0.002444     0.002444     0.002447     0.03233 N s lco3a1/ptprd
UGCGL1 2     rs7563853      3.324e-008      4.351e-008    0.01019      0.01019      0.01014       0.01014       0.01019       0.1346 Y
AZI2 9     rs7856797      3.009e-008      3.853e-008    0.009225    0.009225    0.009183     0.009183     0.009225     0.1219 N ptprd
CP 3     rs10511083    7.82e-008        9.761e-008    0.02398      0.02398      0.02369       0.02369       0.02398       0.3167 Y cadm2
GZMK 4     rs6835588      2.234e-008      2.666e-008    0.006849    0.006849    0.006826     0.006826     0.0026         0.03434 N fam190a
LY6G5B 6     rs9398869      3.348e-008      4.701e-008    0.01026      0.01026      0.01021       0.01021       0.01026       0.1356 Y ptprk
AMD1 19   rs2287851      2.906e-008      3.822e-008    0.008912    0.008912    0.008872     0.008872     0.008912     0.1177 N unc13a
FAM92A1 17   rs1345451      3.89e-009        5.602e-009    0.001193    0.001193    0.001192     0.001192     0.001193     0.01576 N ccdc46
17   rs997651        1.829e-008      2.613e-008    0.005606    0.005606    0.005591     0.005591     0.002771     0.0366 N ccdc46
17   rs3744318      2.711e-008      3.831e-008    0.008312    0.008312    0.008277     0.008277     0.002771     0.0366 N ccdc46
SPAG11B 18   rs470563        2.069e-008      2.678e-008    0.006345    0.006345    0.006325     0.006325     0.006345     0.08382 N znf236
FAM69B 2     rs6546473      5.188e-008      6.531e-008    0.01591      0.01591      0.01578       0.01578       0.01591       0.2101 N antxr1
EEA1 22   rs861826        2.253e-008      3.117e-008    0.006908    0.006908    0.006885     0.006885     0.006908    0.09126 N ppi l2 
DICER1 12   rs7956904      2.646e-010      5.068e-010    8.112e-005 8.112e-005 8.111e-005 8.111e-005 8.112e-005   0.001072 N kcna6
TOM1L2 17   rs9303380      2.272e-009      3.569e-009    0.0006966  0.0006966  0.0006963   0.0006963   0.0006966   0.009202 Y n/a
11   rs4910365      9.121e-009      1.41e-008      0.002797    0.002797    0.002793     0.002793     0.001398    0.01847 N galntl4
NUFIP2 12   rs7956904      1.669e-008      2.504e-008    0.005116    0.005116    0.005103     0.005103     0.005116    0.06759 N kcna6
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Figure C: rs861826 in LD with splice/non-synonymous coding SNP. PPIL2-EEA1 (Chapter 4) 
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Figure D: SREBP-1a mRNA expression (Chapter 4) 
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